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General introduction
Food products fermented by lactic acid bacteria (LAB) have long been used for their
proposed health promoting properties. At the beginning of the 20th century, Elie Metchnikoff
(1907) advocated the consumption of large quantities of cultured foods containing LAB, such
as sour milk and yoghurt, for good health and long life and by doing so, the Russian scientist
gave birth to the concept of ‘probiotics’ “avant la lettre”. At present, the growing awareness
that a well-balanced and healthy diet contributes to a good physical condition has marked an
era of strong expansion of the functional food market, including probiotic products. As a
result, the modern consumer has adopted a general desire of self-treatment and managing a
specific health condition or illness using probiotic foods and dietary supplements. In the
development of human probiotics, strains belonging to the bacterial genera Lactobacillus
and Bifidobacterium are amongst the most commonly used primarily because these organisms
have a long history of safe use commonly referred to as the GRAS (Generally Recognized As
Safe) status. Despite their widespread use, however, not all of the available probiotic strains
currently on the market have adequate scientific documentation. It is important that new and
existing potentially probiotic strains are subjected to profound analyses addressing safety and
functionality before conducting clinical trials and before entering a marketing strategy. In this
way, successful probiotic products can be delivered with long-term marketing potential.
In general, it cannot be assumed that the properties concerning safety and functionality
of any given strain will be shared by strains of the same genus or species. The strain-specificity
of these properties thus justifies efforts to correctly identify a probiotic strain. Furthermore, a
correct identification is crucial to link a strain to a specific health effect as well as to enable
accurate surveillance and epidemiological studies (Reid et al., 2002). In addition, it is incumbent
upon the producer to provide full information as to strain designation on the product label to
enable the consumer to select a product whose component bacteria have been shown to
possess useful properties.
There is a large collection of historical data indicating that lactobacilli and bifidobacteria
are safe for human use (Adams and Marteau, 1995; Naidu et al., 1999). In addition, if a
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probiotic strain is of human origin and thus a member of the normal commensal flora, the
organism can generally be considered safe for use. However, due to the indiscriminate use of
antibiotics in human and veterinary medicine and as animal growth promoters, acquired antibiotic
resistance has become an increasingly common characteristic in microorganisms, sometimes
leading to serious problems in the treatment of microbial infections. Expert panels have indicated
that strains harbouring transferable antibiotic resistance genes are not suitable for use as
probiotics (Salminen et al., 2001). In this context, the specific risks related to each probiotic
strain must be carefully identified.
Regarding functionality aspects of a probiotic strain, the screening process of candidate
strains should involve determination of their survival capacity during gastro-intestinal (GI)
transit, which has been considered as an important prerequisite for probiotic action (Saarela
et al., 2000). Many probiotic effects are mediated by immune regulation, particularly through
a balanced control of pro-and anti-inflammatory cytokines (Isolauri et al., 2001).
Consequently, probiotics may be used as innovative tools to alleviate intestinal inflammation,
normalize gut mucosal dysfunction, and down-regulate hypersensitivity reactions. However,
recent data evidence that differences exist in the immunomodulatory effects of candidate
probiotic bacteria (Mercenier et al., 2004), hence necessitating the characterization of these
properties before developing clinical applications for extended target populations.
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Objectives of this work
Some general aspects related to probiotics were investigated during this Ph.D. study,
which was focussed on the genus Bifidobacterium. In comparison to the large variety of
probiotic products claiming to contain bifidobacteria, the diversity of marketed probiotic
Bifidobacterium strains appears to be relatively low (Grand et al., 2003). In order to
successfully commercialise probiotic products containing Bifidobacterium strains, research
towards the correct identification as well as the safety and functionality properties of the
included Bifidobacterium strains has to be conducted. These three aspects constituted the
starting point of the research described in this Ph.D. thesis.
The first goal of this work was to establish a taxonomical framework of validly described
Bifidobacterium species using a genotypic fingerprinting technique, which allows the
unambiguous identification of unknown bifidobacteria. Consequently, using both culture-
dependent and culture-independent methodologies including Denaturing Gradient Gel
Electrophoresis (DGGE) and real-time PCR, the qualitative as well as quantitative
microbial aspects of probiotic products claiming to contain bifidobacteria were investigated.
Additionally, the work aimed to provide scientific documentation related to safety and
functionality on commercially applied Bifidobacterium strains as well as on human reference
strains.
- The use of the genomic fingerprinting technique repetitive DNA sequence-based
polymerase chain reaction (rep-PCR), was evaluated for the taxonomic discrimination
among the majority of validly described species within the genus Bifidobacterium.
- A set of commercially available, worldwide collected probiotic products claiming to
contain bifidobacteria was subjected to culture-dependent microbial analysis using
rep-PCR fingerprinting for identification of the bifidobacterial isolates.
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- As an alternative/complement for culture-dependent qualitative analysis, Denaturing
Gradient Gel Electrophoresis (DGGE) was used for the culture-independent detection
of bifidobacteria present in probiotic products.
- To complete microbial analysis of probiotic products, real-time PCR was optimised
for the culture-independent quantification of bifidobacteria in probiotic products.
- Finally, a selected subset of probiotic product isolates and human reference strains of
Bifidobacterium were screened for the presence of antibiotic resistance, for GI transit
survival capacity and for immunomodulatory properties in order to generate basic
information documenting the safety and functionality of the strains.
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Short overview of this thesis
Part 2 presents an overview of the literature relating to the content of this work. Firstly, a
concise discussion on the probiotic concept is provided, including the technological, functional
and safety aspects of probiotics. The second part presents an extensive description of the
genus Bifidobacterium, including an overview of currently available culture-dependent and
culture-independent methods for identification, typing, detection and quantification.
Part 3 presents the experimental work performed in the framework of this Ph.D. study.
- The first chapter describes the evaluation and use of rep-PCR fingerprinting as an
identification tool for a broad range of Bifidobacterium species. Subsequently, the taxonomical
standing of the closely related species B. animalis and B. lactis is further investigated using a
polyphasic approach.
- The second chapter includes the culture-dependent and culture-independent microbial
analysis of a range of worldwide collected probiotic products claiming to contain bifidobacteria.
Culture-dependent analysis involved the isolation and subsequent identification of bifidobacteria
using rep-PCR fingerprinting. Subsequently, the results are compared with Denaturing Gradient
Gel Electrophoresis, which was chosen for the culture-independent qualitative detection of
bifidobacteria. Finally, to complete the culture-independent microbial analysis, real-time PCR
is evaluated for the quantification of bifidobacteria in probiotic products.
- In the third chapter, the antibiotic susceptibility of human reference strains and probiotic
isolates of Bifidobacterium is investigated as part of the safety assessment of new potential
probiotic Bifidobacterium strains.
- Finally, the last chapter includes trials addressing some aspects of functionality, such
as the effect of bifidobacteria on the cytokine production by human peripheral blood
mononuclear cells and the ability of bifidobacteria to survive transit through the GI-tract.
Part 4 comprises the general conclusions, future perspectives and a summary of this work.

Part 2
Overview of the literature
Calvin’s thoughts on “Writing a doctoral dissertation”
SOURCE: http://wwwiaim.ira.uka.de/

27
Chapter 1
Probiotics
Chapter 1 provides a concise overview of the definition and the selection criteria of probiotics.
Several aspects will be discussed with specific reference to the target group of microorganisms
investigated during this Ph.D., i.e. the bifidobacteria. Specific information on the genus
Bifidobacterium will be presented in the following chapter.
1.1. Definition
Although the ‘probiotic concept’ was already established at the turn of the 19th century
(Metchnikoff, 1907), it wasn’t until the mid-1960s that the term ‘probiotic’ as such was
defined (Lilley and Stillwell, 1965). Following its first citation, numerous definitions have been
proposed in an attempt to address several key points of discussion regarding the site of
activity, the need for viability of the strain, the concentration of cells required to obtain the
claimed beneficial effect, etc... This resulted in the formulation of several excessively long
definitions, of which none so far received universal acceptance. Recently, the Food and
Agriculture Organization of the United Nations (FAO) and the World Health Organization
(WHO) have proposed the following concise definition of a probiotic: “a live microorganism
which when administered in adequate amounts confers a health benefit on the host”
(http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf). This definition
is confined to effects exerted by viable microorganisms without explicit reference to the site of
action (upper and lower gastro-intestinal (GI) tract, oral cavity, vagina,...), the route of
administration or the clinical status of the host. On the other hand, it clearly indicates that the
probiotic is a health-promoting microorganism and addresses the requirement of sufficient
microbial numbers to exert those health effects. Although this definition has attempted to
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harmonize the understanding of the term ‘probiotic’ with consideration of the current state of
science, it clearly does not exclude further discussion.
Positive health effects have also been ascribed to “prebiotics”, defined by Gibson and
Roberfroid (1995) as “non-digestible food ingredients that beneficially affect the host by
selectively stimulating the growth and/or activity of one or a limited number of bacteria
already resident in the colon”. The combined use of pro- and prebiotics, commonly referred
to as ‘synbiotics’, falls into the functional foods category, which is an expanding sector of the
food industry (Stanton et al., 2001). Although no clear delineation of the definition for functional
food has been developed so far (Menrad et al., 2002), these compounds can be described
as “modified food or food-ingredients conferring a beneficial effect on health beyond or
additional to the effects of the traditional nutrients present in the food” (ONFS Committee,
1994).
According to the current definition of a probiotic, a large variety of microbial species
and genera are considered to have probiotic potential, most of which belong to the lactic acid
bacteria (LAB). In the development of human probiotics, strains belonging to the genera
Lactobacillus and Bifidobacterium have been most commonly used, even though some
probiotic preparations are based on other LAB or even non-LAB species and yeasts (Table
1).
Lactobacillus Bifidobacterium Other LAB Non-LAB
L. acidophilus B. adolescentis Enterococcus faecium Escherichia coli
L. casei B. animalis subsp. lactis Lactococcus lactis Saccharomyces cerevisiae('boulardii')
L. crispatus B. bifidum Leuconostoc mesenteroides
L. delbrueckii subsp. bulgaricus B. breve Pediococcus acidilactici
L. fermentum B. longum biotype infantis Streptococcus thermophilus
L. helveticus B. longum biotype longum
L. gasseri
L. johnsonii
L. paracasei
L. plantarum
L. reuteri
L. rhamnosus
L. salivarius
Table 1. List of species used in the development of probiotic products for human consumption
(based on Holzapfel et al ., 1998 and Mercenier et al ., 2003)
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1.2. Probiotic bifidobacteria
Essentially, fundamental and applied research on probiotic bifidobacteria started in
the 1950s in Japan. In 1971, the Morinaga Milk Industry Company developed the first ‘bifidus’
product – a fermented milk containing Bifidobacterium longum and Streptococcus
thermophilus (Ishibashi and Shimamura, 1993; Hughes and Hoover, 1991). Throughout the
1970s, advanced technologies triggered the delivery of products containing viable bifidobacteria
on a commercial basis of which some were shown to have the potential to improve the health
of the general public (Hughes and Hoover, 1991). Subsequently, the Morinaga Milk Industry
Company launched a ‘bifidus’ milk (1977) as well as a ‘bifidus’ yoghurt (1979). At the same
time (1978), Yakult introduced a fermented milk named MilMil in Japan that contained
strains of Bifidobacterium breve, Bifidobacterium bifidum and Lactobacillus acidophilus
(Ishibashi and Shimamura, 1993). Today, the market of probiotic preparations claimed to
contain bifidobacteria has extended from milk-based products to powders and tablets and
are partly responsible for a market value of approximately $1,3 billion in Europe alone
(Leatherhead Food Research Association, Functional Food Markets, Innovation and
Prospects, 2002). In present-day commercial probiotic products, bifidobacteria are used
singly or in combination with other lactic acid bacteria such as lactobacilli and Streptococcus
thermophilus.
Within the genus Bifidobacterium, the following (sub)species have been used as
potential probiotics: B. adolescentis, B. animalis subsp. lactis, B. bifidum, B. breve and B.
longum biotypes infantis and longum (Table 1). However, since many probiotic characteristics
are strain-specific, it is clear that these attributes have to be investigated on an individual strain
basis rather than designating an entire species as probiotic. Potential probiotic strains need to
be selected with respect to their safety, functionality, technological properties and health benefits,
before they can be included into a commercial probiotic product. A list of well-documented
probiotic Bifidobacterium strains is given in Table 2.
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1.3. Proposed guidelines for the selection of probiotics
The guidelines discussed below constitute a set of parameters that have been proposed
for a strain, and hence the product containing the strain, to be considered and/or named
‘probiotic’. Besides the availability of evidence supporting specific health promoting properties,
these selection parameters include safety, basic functionality and technological properties
(Figure 1).
1.3.1. Health benefit assessment
Essentially, two research tasks need to be performed in order to document the potential
health promoting activity of a promising probiotic strain. First, clinical trials are needed to
analyze the beneficial effects of administering a probiotic to a subject group. Secondly, if such
an effect has been reported, the underlying microbial, biochemical and molecular mechanisms
need to be unraveled. The limited correlation between in vitro observations and prediction of
functionality of probiotic microorganisms in the human body has necessitated further
substantiation of efficacy with human trials (Reid, 2005). It is generally recommended that
such evidence result from randomised, double-blind, placebo-controlled (DBPC) or so-called
phase II studies in which a test group, containing a sufficient number of subjects, is placed
under complete dietary supervision (Marteau et al., 2002). The strength of these studies is
Strain Source
B. breve strain Yakult Yakult (Japan)
B. lactis Bb-12 Chr. Hansen, Inc. (Denmark)
B. lactis FK120 Fukuchan milk (Japan)
B. lactis HN019 (DR10) New Zealand Dairy Board (N.-Z.)
B. lactis LKM512 Fukuchan milk (Japan)
B. longum BB536 Morinaga Milk Industry Co., Ltd. (Japan)
B. longum SBT-2928 Snow Brand Milk Products Co., Ltd. (Japan)
Bifidobacterium species 420 Danlac (Canada)
the true taxonomic position of these strains
Table 2. List of well-documented probiotic Bifidobacterium strains (based on Mercenier et al ., 2003)
Species names are those reported by the manufacturer, but do not necessarily reflect
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that results from the test group can be compared to those of a placebo-controlled group.
When testing probiotic foods, the placebo should consist of the food carrier devoid of the
probiotic compound. The principle outcome of these efficacy studies should be proven benefits
such as (i) statistically and biologically significant improvement in condition, symptoms, signs,
well-being or quality of life; (ii) prevention, reduced risk or longer period to next occurrence
of disease and (iii) faster recovery from illness. Probiotics delivered in a food matrix are
generally not tested in phase III studies, which concern parallel comparisons with a standard
therapy. However, once reference is made to curing or treating a disease, most governmental
regulatory agencies would regard this as drug therapy and will demand extensive testing
including a phase III study. These randomised blinded designs are necessary to determine
whether a probiotic therapy is as effective as or better than a standard treatment for a particular
clinical condition. At present, no phase III studies have been reported on probiotics (Reid,
2005).
Figure 1. Proposed guidelines for the selection of potential probiotic strains for food use (based on Reid
et al., 2002 and Reid, 2005)
Safety
- Strain identification
- Human origin
- History of safe use
- Antibiotic resistance
Functionality
- Gastric survival
- Resistance to bile acids
- Adhesion properties
Technological properties
- Survival potential during processing
- Shelf-life stability
- Organoleptic properties
Health benefits (DBPC studies)
Double blind, randomized, placebo-controlled phase II human studies
PROBIOTIC PRODUCT
Effectiveness trial (phase III)
- Compare probiotics with standard treatment of a specific condition
- Verify possible side-effects
Labeling
- Contents - genus, species, strain designation
- Minimum numbers of viable bacteria at end of shelf life
- Proper storage conditions
- Corporate contact details for consumer information
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Finally, no adverse effects should be observed when the probiotic is administered via
a food product. Adverse effects should be monitored and incidents reported. Furthermore, it
is generally recommended that human clinical trials are performed by independent institutions
and that the results are published in peer-reviewed scientific or medical journals (Reid et al.,
2002), thereby also including publications on negative results as these also contribute to the
totality of the evidence supporting probiotic efficacy.
Although the list of potential probiotic health claims mainly attributed to lactic acid
bacteria is still growing, most of these effects remain to be substantiated by human randomised
DBPC clinical studies (for review see Ouwehand et al., 2002; Stanton et al., 2003; Mercenier
et al., 2003). So far, the use of probiotics as biotherapeutics has been proven in cases of
gastro-intestinal disturbances (Marteau et al., 2001), management of allergic diseases
(Majamaa and Isolauri, 1997) and treatment and prevention of inflammatory bowel diseases
(Marteau et al., 2001; Hanauer and Dassopoulos, 2001). A list of beneficial health effects
evidenced by clinical studies or human intervention trials, resembling the traditional
pharmacological DBPC approach is given in Table 3.
Table 3. Therapeutic use of probiotics (based on Mercenier et al ., 2003)
Therapeutic use considered successful:
Alleviation of lactose intolerance
Prevention of antibiotic associated diarrhoea
Prevention of gastro-enteritis caused by:
* Rotavirus in children
* Clostridium difficile after antibiotic treatment
Treatment of bacterial overgrowth
Effect on Inflammatory Bowel Diseases (IBD)
* Ulcerative colitis
* Crohn's disease
* Pouchitis
Reduction of allergy such as atopic dermatitis
Positive indications for therapeutic use:
Prevention and improvement of symptoms associated with Irritable Bowel Syndrome (IBS)
Suppression of colon cancer
Prevention or treatment of Traveler's diarrhoea
Inhibitory effects of Helicobacter pylori
Insufficient proof for therapeutic use:
Effect on viral infections
Cholesterol lowering effects
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As mentioned earlier, it is important to bear in mind that not all strains within one
species will be able to mediate comparable ‘probiotic’ effects. Conversely, it is also unlikely
that a single strain will produce a multitude of potential benefits. Hence, each specific type of
disorder requires careful selection of the most suitable probiotic strain in order to achieve the
optimal health benefit. However, prior to submitting potential probiotic candidates to extensive
human efficacy trials, more detailed knowledge is required regarding their safety, functionality
and technological aspects.
1.3.2. Safety aspects
Despite the fact that most probiotics belong to bacterial taxa that have a very good
safety record, it has been recommended that new and existing probiotic strains including
genetically modified organisms (GMOs) need to be characterized with respect to the following
safety aspects (for reviews, see Salminen et al., 1998; Reid et al., 2002 and Ouwehand et
al., in press):
- As a first safety criterion, the taxonomic identity of the probiotic strain should be
determined using validated and reproducible methodologies preferably by combining phenotypic
and genotypic methods (see Chapter 2). This also implies the correct use of valid taxonomic
names and the adequate designation of particular strains. The current state of evidence suggests
that different strains can possess different features related to different safety risks, implying
that it is not possible to identify the specific safety risks associated with a probiotic strain
without proper identification. Proper identification is also necessary to avoid the inclusion of
pathogenic microorganisms in probiotic products.
- Although a matter of debate, it has been suggested that probiotic strains should originate
from the species of intended use. One can argue that a probiotic strain originating from a
healthy human GI-tract can function better in a similar environment from where it was
originally isolated. Although this point of view has been supported by the fact that most of the
currently used strains are of human origin, some animal derived strains have also shown positive
effects on humans. Perhaps the importance of this criterion is one of consumer perception, in
that humans may not wish to consume strains that originated from pigs, rats or mice.
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- In general, the microorganisms used in the production of fermented foods have a long
history of safe use, and are often referred to as ‘food grade’ or GRAS organisms (Holzapfel
et al., 1998). On the other hand, it should be kept in mind that any microorganism may cause
unwanted side effects when administered in sufficiently high doses. The most immediate risk
associated with the consumption of microorganisms is infection (e.g. meningitis, endocarditis),
especially in immunocompromised individuals. In the particular case of bifidobacteria, reports
on infections are very rare (Hata et al., 1988; Nakazawa et al., 1996; Ha et al., 1999) and
such infections are most likely caused by bifidobacteria that are part of the patients’ own
microbiota (Wang et al., 1996; MacFie et al., 1999). Thus, despite the fact that bifidobacteria
are present at high levels in the intestine, they appear to be among the least infectious organisms.
However, also other risks such as administration toxicity, deleterious metabolic activities and
excessive immune stimulation in susceptible individuals need to be taken into consideration
(Table 4). The median lethal dose of orally administered B. longum BB536 and B. lactis
HN019 in mice was shown to be > 50 g/kg/day (Momose et al., 1979; Zhou et al., 2000).
No toxicity was reported after repeated oral administration of the former strain (Momose et
al., 1979). Recently, Ouwehand and co-workers (2004) investigated the presence of known
virulence factors in clinical blood isolates and dairy and faecal isolates of bifidobacteria. No
significant differences with respect to these virulence factors could be observed between
clinical and faecal isolates supporting the general opinion that bifidobacteria are safe for food
and probiotic use.
- Due to the indiscriminate use of antibiotics in human and veterinary medicine and as
animal growth promoters, antibiotic resistance has become an increasingly common
characteristic in (food-borne) microorganisms (Threlfall et al., 2000) causing serious problems
in treatment of microbial infections. Antibiotic resistance in bacteria may be intrinsic or acquired.
Intrinsic resistance is a naturally occurring trait considered to be a species-specific characteristic,
whereas acquired resistance stems from genetic mutations or from the acquisition of foreign
DNA from other bacteria. Probiotic strains with non-transmissible antibiotic resistances do
not usually confer a safety concern. To some extent, non-transmissible antibiotic resistance
might even be a useful property if the probiotic strain is to be used as a prophylactic agent in
the treatment of antibiotic associated diarrhoea (Charteris et al., 1998a). However, antibiotic
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resistance linked to transferable mobile genetic elements such as plasmids and transposons is
another matter because of the possibility of resistance spreading to other, more harmful bacteria.
Expert panels have indicated that strains harbouring transferable antibiotic resistance genes
are not suitable for use as probiotics (Salminen et al., 2001). In this context, the specific risks
related to each probiotic strain must be carefully considered.  Although several studies have
documented the presence of antibiotic resistances in bifidobacteria (Matteuzi et al., 1983;
Lim et al., 1993; Charteris et al., 1998b; Yazid et al., 2000; Moubareck et al., 2005), none
of these were able to detect conjugative plasmids or transposons carrying resistance
determinants.
- Finally, it is important not only to evaluate the risks directly associated with the probiotic
strain itself, also the risks associated with the target population as well as possible microbe-
host interactions must be taken into consideration. Likewise, the pharmacokinetics of the
specific probiotics such as survival within the gastro-intestinal tract, colonization and
translocation properties, as well as the fate of their metabolic products, need to be determined
to predict the potential safety risks associated with a probiotic strain.
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Chapter 1 - Probiotics
1.3.3. Functional aspects
Undoubtedly, one of the most important aspects reflecting the functionality of a probiotic
culture concerns its ability to promote human health at the site of action (see § 1.3.1). However,
prior to achieving this, probiotic cultures must survive the transit through the gastro-intestinal
tract after oral consumption. Although dead bacteria have been shown to mediate a number
of beneficial effects, the majority of the health promoting benefits associated with probiotics
require viable microorganisms (Ouwehand et al., 1998). Consequently, resistance to gastric
acidity and bile toxicity is a first major functional requirement.
- The pH in the stomach may be as low as 1.5 (Waterman and Small, 1998), and one
of the first challenges encountered by probiotics following ingestion is the ability to survive in
highly acidic conditions. Resistance to these adverse conditions has been investigated in
several studies, indicating large variation between strains and species. In general,
Bifidobacterium cultures are less acid tolerant than Lactobacillus cultures, particularly when
exposed to human gastric juice (Dunne et al., 2001).
- When selecting a probiotic candidate, the ability of bacteria to resist the effects of
bile is generally considered an important property for survival in the small intestine. Following
synthesis from cholesterol and secretion into the duodenum, conjugated bile salts undergo
extensive chemical modifications in the colon due to microbial activity. Conjugated bile salt
hydrolysis is an important bile salt modification liberating the amino acid moiety from the
deconjugated bile acid. Although both forms exhibit anti-bacterial activity, deconjugated bile
salts are more inhibitory to anaerobes (Grill et al., 1995). Accordingly, most Bifidobacterium
strains have shown to be bile-sensitive (Kociubinski et al., 1999). However, since bile salt
resistance can differ considerably among strains of a certain species (Gilliland, 2002), a profound
selection of the most resistant strain is necessary.
Following survival of the gastro-intestinal transit, adhesion of probiotic strains to the
intestinal surface and temporary colonization of the human GI-tract have been suggested as
important prerequisites for probiotic action. Although several probiotic strains have been noted
to temporarily persist in the human GI-tract (Fukushima et al., 1998; Johansson et al., 1998;
Alander et al., 1999; Donnet-Hughes et al., 1999), adherent strains are likely to persist
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longer in the intestinal tract than non-adherent strains and may therefore enhance their health-
promoting potential in the GI-tract. Conversely, adhesion to the intestinal mucosa can also be
the first step in bacterial pathogenesis (Finlay and Falkow, 1997). However, this concern has
recently been shown to be unwarranted as far as bifidobacteria are concerned (Ouwehand et
al., 2004) (see § 1.3.2).
1.3.4. Technological aspects
Whereas there is little doubt that safety and functional criteria are of paramount
importance in the probiotic selection process, it is less well emphasized that also the
technological suitability of probiotic cultures is critical to their exploitation (for reviews, see
Mattila-Sandholm et al., 2002 and Ross et al., 2005).
The viability and stability of probiotics has been both a marketing and technological challenge
for industrial producers. For successful delivery in foods, probiotics must survive food
processing and maintain a suitable level of viable cells during product maturation
and shelf life. Although adequate strain selection may provide strains with good manufacturing
and food technology characteristics, even the physiologically most robust strains are currently
limited in the range of food applications to which they can be applied. Additionally, bacteria
with exceptional functional health properties are often ruled out due to technological limitations.
Intensive research has therefore focussed on protecting the viability of probiotic cultures both
during product manufacture and storage (Table 5).
Table 5. Overcoming the technological hurdles in the development of probiotic foods (based on Ross et al., 2005)
Selection of probiotic strains for technological properties
The use of protectants
* thermoprotectants during spray-drying
* cryoprotectants during freeze-drying
Micro-encapsulation in carriers
* milk proteins
* complex (prebiotic) carbohydrates (e.g. resistant starch)
Induction of cellular stress responses
* acid tolerance (e.g. F 1 F 0 -ATPase )
* oxygen tolerance (e.g. Osp)
* thermotolerance
Genetic manipulation
e.g. enhanced thermal tolerance due to overexpression of heat shock protein chaperones GroEL and GroES
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To maintain confidence in probiotic products it is not only important to demonstrate
good survival of the bacteria in consumer products during shelf life, but also to guarantee that
the probiotic culture contributes to the good sensory properties of the final product. Because
the environment within the GI-tract and in a food matrix are quite different, the probiotic is
often not suitable as a starter organism (German et al., 1999). Therefore, it is common practice
to use probiotics together with other bacteria, e.g. Lactobacillus delbrueckii subsp.
bulgaricus and Streptococcus thermophilus, in order to obtain the appropriate taste and
texture. By selecting an optimal support culture, it is possible to produce fermented probiotic
products with excellent sensory properties and good survival of the bacteria (Fondén et al.,
2000). A recent study by Roy (2005) has elaborated on the technological aspects related to
the use of bifidobacteria in dairy products.
1.4. Legislation aspects
Once a probiotic candidate has been carefully selected based on the criteria outlined in
§ 1.3.2 – 1.3.4 and specific health benefits (see § 1.3.1) have been identified, regulatory and
product labelling issues remain to be addressed prior to marketing (Sanders and Huis in ‘t
Veld, 1999). These issues are a complicated matter because they differ for each country, but
are likewise critical because they provide the means of communication of the product benefits
to the consumer. Accurate information on the content and counts of bacteria in commercial
products is one aspect of communication on probiotics. However, the main emphasis of the
message addressed to the consumer lies at the level of the health claims. In Europe,
commercialisation of probiotics is regulated by the normal legislation on foods, provided that
no claims are made related to health, prevention and curing. In Japan, a specific ‘FOSHU
label’ can be requested that grants the producer the permission to put a health claim on a food
label, which has been substantiated by scientific evidence. Although regulations are far from
unanimous worldwide, efforts are presently being made for the implementation of standards in
terms of labelling and use of health claims in United Nations member countries, which are
intended to provide the consumer with more useful and precise information (Reid, 2005).
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Likewise, the European Food Safety Authority (EFSA) has attempted to develop a qualified
generic approval system based on the concept of “qualified presumption of safety” (QPS),
defined as the assumption based on reasonable evidence and qualified to allow certain
restrictions to apply. Such a system would improve the consistency of safety assessment and
at the same time make better use of assessment resources by not requiring a full and arguably
unnecessary safety review of organisms with a long history of safe use. Case-by-case safety
assessments could be eliminated or restricted to only those aspects that are relevant for the
organism in question (i.e. the presence of transmissible antibiotic resistance markers or known
virulence factors in a species known to have pathogenic strains) (http://europa.eu.int/comm/
food/fs/sc/scf/out178_en.pdf).
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The genus Bifidobacterium
The first published reference to the name ‘bifidus’ dates from 1900, when Tissier
isolated an anaerobic bacterium with bifid morphology from the faeces of breast-fed infants,
which he named Bacillus bifidus. In 1924, Orla-Jensen recognized the existence of the genus
Bifidobacterium as a separate taxon, explaining that various species of bifidobacteria
“doubtless constitute a separate genus, possibly forming a connective link between the lactic
acid bacteria and the propionic acid bacteria”. However, given their similarities to the genus
Lactobacillus, bifidobacteria remained included in this genus. Studies on this bacterial group
gradually declined thereafter, until in 1957 a separation of bifidobacteria from lactobacilli was
accomplished, and the existence of multiple biotypes of Bifidobacterium was recognized
based on their carbohydrate fermentation patterns (Dehnert, 1957). This was the beginning of
an era of taxonomic evolution and knowledge acquisition on the genus Bifidobacterium,
starting from its initial listing as Lactobacillus bifidus in the seventh edition of Bergey’s Manual
of Determinative Bacteriology (Breed et al., 1957) to the 32 current validly described
(sub)species.
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2.1. Morphology, physiology and metabolism
The genus Bifidobacterium consists of Gram-positive, non-spore forming, non-motile
anaerobes (some species can tolerate oxygen only in presence of CO2) that are catalase-
negative (except for B. indicum and B. coryneforme when grown in presence of air). They
are pleomorphic, exhibiting a bifid-shaped or multiple-branched cellular morphology, and
occur singly or in chains or aggregates (Figure 2). Bifidobacteria isolated from humans have
been demonstrated to grow optimally at temperatures ranging from 36°C to 38°C.
Bifidobacterium species isolated from animals, on the other hand, have been shown to grow
at higher temperatures (41°C to 43°C), with B. thermacidophilum exhibiting a maximum
growth temperature of 49.5°C (Dong et al., 2000a). The minimum growth temperature for
bifidobacteria is generally not below 20°C with the notable exception of B. psychraerophilum,
which has been shown to grow at 4°C (Simpson et al., 2004). The optimum pH at the
beginning of growth is between 6.5 and 7.0. No growth has been recorded at pH lower than
4.5 or higher than 8.5 with the exception of B. thermacidophilum, which is able to grow at
pH 4.0 (Dong et al., 2000a).
Figure 2. Typical morphology of bifidobacteria
Hexose metabolism of bifidobacteria follows the “fructose-6-phosphate shunt” or
“bifidus shunt” (Scardovi and Trovatelli, 1965). The key enzyme of this pathway is fructose-
6-phosphate phosphoketolase (F6PPK), which cleaves hexose phosphate into erythrose-4-
phosphate and acetyl phosphate. From tetrose and hexose phosphates, through the successive
action of transaldolase and transketolase, pentose phosphates are formed which give rise to
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lactic acid and acetic acid in the theoretical ratio 1.0:1.5. However, this ratio is scarcely ever
found in growing cultures of bifidobacteria. Cleavage of pyruvate to formic acid and acetyl
phosphate, and the reduction of acetyl phosphate to ethanol can often alter the fermentation
balance to a highly variable extent (Lauer and Kandler, 1976). Different bifidobacterial species
produce different amounts of acetic, lactic and formic acid and ethanol under the same
conditions. Furthermore, variations of growth conditions, such as type and quantity of the
carbon source, may result in the production of varying amounts of fermentation products.
During metabolism of hexose, no CO2 is produced, except during degradation of gluconate.
In order to adapt and compete in an environment with changing nutritional conditions,
bifidobacteria possess an array of enzymes that allow them to utilize a great variety of mono-
and disaccharides as well as to metabolise complex carbohydrates that are normally not
digested in the small intestine. This latter feature should give an ecological advantage to
bifidobacterial colonizers of the intestinal environment where complex carbohydrates are present
either because of production by the host epithelium or introduction through the diet, which
forms the basis of the prebiotic concept.
2.2. Environmental distribution and ecology
The Bifidobacterium species described to date can be grouped according to their
respective ecological niches: the human intestine, vagina and oral cavity, the animal intestine,
the insect intestine and sewage (Table 6).
The presence of bifidobacteria in the human gut has stimulated much interest among
microbiologists and nutritionists. Many factors, including host development, age, health condition,
diet and the adaptability of each bacterial species influences the number and overall composition
of microbial populations in different parts of the gastrointestinal tract (Fuller, 1989). In the first
few days of life, the gastrointestinal tract of newborns is colonized by coliforms and streptococci,
which create a reducing environment favourable to the settlement of anaerobic bacteria such
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as Bacteroides, Bifidobacterium, Clostridium and Lactobacillus. After 5-7 days,
bifidobacteria become the predominant intestinal bacteria in breast-fed infants (Biavati et al.,
1984), whereas no such predominance has ever been noted in bottle-fed infants. This
compositional diversity of the microflora in infants nourished with mothers’ or artificial milk is
due to the fact that the former contains specific growth factors, the so called ‘bifidogenic
factors’, that stimulate the development of bifidobacteria. After solid food introduction and
weaning, the composition of the intestinal microbiota of breast-fed infants evolves to become
similar to that of bottle-fed infants. Around the second year of life an adult-like intestinal
microbial composition is established in which bifidobacteria are no longer dominant (Conway,
1997), but constitute the third most abundant bacterial group following the genera Bacteroides
and Eubacterium (Finegold et al., 1983) reaching numbers of approximately 109 CFU per
g of faeces (Matsuki et al., 2004; Gueimonde et al., 2004). Recent studies by Matsuki and
co-workers (1999, 2004) using species-specific PCR primers show that B. catenulatum
and B. pseudocatenulatum (i.e. the B. catenulatum group) are the most common of the
adult intestinal bifidobacterial flora (detected in 44 of 48 samples [92%]), followed by B.
longum and B. adolescentis and that B. breve, B. infantis and B. longum are the predominate
bifidobacterial species in the intestinal tracts of infants.
Bifidobacteria have also been located in the human oral cavity. The most common species in
this site is B. dentium (Scardovi and Crociani, 1974), which seems to be involved in dental
plaque formation. In the human vagina, bifidobacteria are considered to play a role in maintaining
homeostasis by producing organic acids and bacteriocins antagonistic towards pathogens. It
has been estimated that bifidobacteria are present in 22–26% of all healthy women (Werner
and Seeliger, 1963; Crociani et al., 1973). The species B. breve and B. adolescentis have
been most frequently isolated from the human vagina, whereas B. longum and B. bifidum
appear to be present to a smaller extent (Korschunov et al., 1999). Finally, B. scardovii is
the only species from human origin that has so far only been isolated from clinical sources, i.e.
blood, urine and the hip of a female patient. However, its original habitat is not known and the
underlying infections, which have lead to the isolation of these organisms, were not discussed
in the original description of the species.
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A large variety of bifidobacterial species have been isolated from animal faeces.
The composition of the bifidobacterial microflora in animals varies with the age, species and
diet of the host. Most species are host-specific, and are typical for a given animal habitat,
e.g. B. cuniculi, B. magnum and B. saeculare were only isolated from rabbit faeces, B.
gallinarum and B. pullorum were only found in the intestine of chicken, and B. merycicum
and B. ruminantium in cattle rumen. In general, Bifidobacterium species are specific
either for humans or for animals, with exception of the intestinal microflora of suckling calves
and breast-fed infants in which the same Bifidobacterium species have been found.
Three Bifidobacterium species, namely B. asteroides, B. coryneforme and B.
indicum, have been isolated from the hindgut of the honeybee, all of which possess a subtle
host dependency. However, the significance of bifidobacteria in the honeybee gut is at present
unknown.
Next to human and animal sources, 12 Bifidobacterium species have also been
isolated from sewage; six are from humans and four from animals, in which case faecal
contamination may have been the cause. However, two species, namely B. subtile and B.
minimum have not been found elsewhere, which raises the question of the possible
development of bifidobacteria in extra-enteral ecological niches. Similarly, B. animalis subsp.
lactis, formerly classified as B. lactis, was originally isolated from fermented milk but was
most likely a contamination from another source. B. thermacidophilum is one of the more
recently described species (Dong et al., 2000a) and has been isolated from an anaerobic
digester used to treat wastewater from a bean-curd farm.
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2.3. Clinical relevance
In general, bifidobacteria are not clinically relevant. They are rarely associated with
infections (Hata et al., 1988; Nakazawa et al., 1996; Ha et al., 1999), which most likely
have an opportunistic nature and are caused by bifidobacteria from the patient’s own
microbiota (Wang et al., 1996; MacFie et al., 1999) or by contact with contaminated
material (Ha et al., 1999). Only B. dentium, isolated from dental caries and plaques, appears
to have pathogenic potential in cariogenic processes. However, the role played by
bifidobacteria in this pathology is still unclear. Furthermore, the isolation of B. scardovii
from human sterile sites, including blood, urine and a female hip (Hoyles et al., 2002), may
imply that this species has clinical relevance. However, since its description, no additional
evidence for this assumption has been reported.
2.4. Phylogeny and taxonomic composition of the genus Bifidobacterium
Based on their high DNA G+C content (55-67 mol%) and 16S rDNA sequence
data, bifidobacteria constitute a phylogenetically coherent unit within the family
Bifidobacteriaceae, exhibiting over 93% 16S rDNA sequence similarity, as part of the
Actinobacteria branch of Gram-positive bacteria. Although generally considered as lactic
acid bacteria (LAB) based on a number of common metabolic features and because of their
widespread use in the food industry, typical LAB (e.g. Lactobacillus, Lactococcus and
Pediococcus) are characterised by a DNA G+C content of less than 50 mol% and belong to
the Clostridium branch of the Gram-positive bacteria. Phylogenetically, these typical LAB
genera are thus only distantly related to members of the genus Bifidobacterium (Figure 3).
Within the phylogenetic family of Bifidobacteriaceae, there also reside the species
Parascardovia denticolens, Scardovia inopinata, Aeriscardovia aeriphila and Gardnerella
vaginalis, which are also known to exhibit F6PPK activity. Although it is reported that the
G+C content of G. vaginalis (i.e. 42 mol%) is significantly lower than that of Bifidobacterium,
it is difficult to differentiate Gardnerella from Bifidobacterium based on 16 rRNA gene
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sequences. In contrast, when performing phylogenetic analysis based on partial gene sequences
of the 60 kDa heat-shock protein (HSP60), G. vaginalis constitutes a well-separated branch
within the HSP60 tree (Jian et al., 2001). At present, the phylogenetic position of G. vaginalis
is still under discussion and awaits further studies.
Although 16S rRNA gene sequence similarity analysis is demonstrated to be a valuable
tool in bacterial phylogeny (Stackebrandt and Goebel, 1994), its value to discriminate species
within the genus Bifidobacterium is fairly limited. Several closely related species groups are
known within which no differentiation is possible even when based on the complete sequence
of the 16S rRNA gene. These groups include the B. catenulatum/B. pseudocatenulatum
group (similarity 99.5%), the B. indicum/B. coryneforme group (similarity 99.1%), the B.
longum/B. infantis/B. suis group (similarity 99.1-99.2%), the B. gallinarum/B. pullorum/
B. saeculare group (similarity 99.3-99.9%) and the B. animalis/B. lactis group (similarity
98.9%) (Miyake et al., 1998) (Figure 4). In recent years, several protein-encoding genes
have been proposed as alternative phylogenetic markers for the 16S rRNA gene in
Bifidobacterium, such as recA (Kullen et al., 1997), the HSP60 gene (Jian et al., 2001) and
tuf gene (Ventura et al., 2003a) (see § 2.5.2.1., Table 7). All these genes encode housekeeping
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Bacillus subtilis
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Figure 3. Phylogenetic tree of Gram-positive bacteria
(Schleifer and Ludwig, 1995)
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functions and are common for all bifidobacteria and thus fulfil the prerequisites for suitable
phylogenetic markers. Although some discrepancies have been reported, the use of one or
more protein-encoding gene sequences in bifidobacterial phylogeny is considered to be a
valuable alternative or complementary approach to the 16S rRNA gene sequencing to unravel
the phylogenetic relationships in Bifidobacterium. In addition, some of these markers display
higher divergence rates and consequently have more discriminatory power than 16 rDNA to
differentiate closely related Bifidobacterium species (see § 2.5.2.1.).
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Figure 4. Tree showing the phylogenetic relationship of members of the genus Bifidobacterium
and some related species. The tree was constructed using the neighbour-joining method.
Bootstrap values, expressed as a percentage of 1000 replications, are given at branching
points.
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Based on polyphasic taxonomic studies, the classification and nomenclature of the B.
longum/B. infantis/B. suis group (Sakata et al., 2002) and the B. animalis/B. lactis group
(Masco et al., 2004) have been recently updated. The species B. longum and B. infantis are
known to belong to one single DNA hybridisation group together with B. suis (Lauer and
Kandler, 1983). Substantiated by new taxonomic evidence from carbohydrate fermentation
patterning, ribotyping, RAPD-PCR and additional DNA-DNA hybridisation experiments,
Sakata and co-workers (2002) proposed to unify B. longum, B. infantis and B. suis into the
single species B. longum in which three biotypes are delineated, i.e. biotypes longum, infantis
and suis, respectively. A similar situation of taxonomic confusion has existed for many years,
concerning the taxonomic affiliation between the probiotic species B. lactis (Meile et al.,
1997) and B. animalis (Scardovi and Trovatelli, 1974). Many probiotic strains in
Bifidobacterium have been taxonomically labelled as B. lactis although there were several
indications that the majority of them actually belonged to the closely related species B. animalis.
Based on phenotypic characteristics, 16S rRNA gene sequencing, and DNA-DNA
hybridisation, Cai and co-workers (2000) proposed to consider B. lactis as a junior synonym
of B. animalis.  In contrast, other workers (Ventura and Zink, 2002, Ventura and Zink, 2003;
Zhu et al., 2003) suggested on the basis of molecular evidence that these two taxa should
remain two separate taxonomic entities not at the species level but at the subspecies level.
Further work to substantiate the latter proposal was performed in the framework of this
Ph.D. study and is reported in Chapter 3.2. of this thesis.
2.5. Identification, typing, detection and quantification of bifidobacteria
At present, members of the genus Bifidobacterium are assigned to 32 validly
described (sub)species. Although the identification of most of these taxa is relatively
straightforward, the taxonomic recognition of closely related species remains problematic
(see § 2.4.). The development and evaluation of methods to speciate and type bifidobacteria
has mainly focussed on those species that are predominating the human gastro-intestinal tract
(GIT). Special attention has also been concentrated on those species that have been claimed
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to possess health-promoting properties and of which some have been incorporated in
commercial probiotic products. Clearly, the correct identification of bifidobacterial strains
that have already been extensively characterized with respect to their probiotic potential is of
paramount importance in the functional food industry. As a consequence, a broad range of
techniques has been evaluated for the identification of bifidobacteria for human consumption,
all displaying differences in discriminatory power, reproducibility and workload.
This part of the chapter provides an overview of the most frequently used culture-dependent
and culture-independent methods for the identification, typing, detection and/or quantification
of bifidobacteria. It should be noted that the methods discussed below are categorized
according to their most straightforward application although several of these techniques can
serve multiple purposes. A table summarizing the most important techniques and their possible
applications is given at the end of this chapter (Table 8).
Note: Despite recently described taxonomic rearrangements (see § 2.4.), the original species
names B. longum, B. infantis and B. suis, now classified as B. longum biotype longum,
biotype infantis and biotype suis, respectively, as well as B. animalis and B. lactis, now
classified as B. animalis subsp. animalis and subsp. lactis, respectively, are still used in the
discussion below according to their original citation. Unless specified otherwise, the term
‘identification’ refers to the classification of isolates at the genus and/or (sub)species level
while ‘typing’ refers to the differentiation of isolates at the strain level .
2.5.1. Culture-dependent methods
Despite their limited taxonomic resolution and high labour intensity, methods based
on phenotypic characteristics are still frequently used to identify bifidobacteria. In addition,
phenotypic characterization is still indispensable to screen bifidobacterial isolates for interesting
probiotic and technological indicators such as inhibitory capacity, resistance to bile and low
pH, etc. Nevertheless, the past two decades have witnessed the development of a large
series of DNA-based identification and detection methods. Undoubtedly, one of the main
advantages of these methods is their independence of variation in growth conditions of the
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microorganisms. However, also genotypic characterization techniques are not without limitation
(cost, equipment, databases). Therefore, in order to obtain a robust classification and
differentiation, a polyphasic or combined approach is usually recommended.
2.5.1.1. Phenotypic methods
In most laboratories involved in industrial and applied microbiology, phenotypic
tests are still the principle tools for the identification of (food-associated) bacteria. The most
direct and reliable assignment of a bacterial strain to the genus Bifidobacterium is based on
the presence of F6PPK, the key enzyme of bifidobacterial hexose metabolism. However,
this approach does not allow identification at the species level. One of the very first
identification schemes developed for Bifidobacterium species was based on a simple
carbohydrate fermentation pattern (Mitsuoka, 1969). This method is still in use, but data
obtained from fermentation tests cannot be considered conclusive. Next to carbohydrate
fermentation patterning, identification of bifidobacterial isolates has also been based on cell
wall analysis. Extensive studies of peptidoglycan types in bifidobacterial cell walls conducted
by Kandler and Lauer (1974) and Lauer and Kandler (1983) revealed a considerable
variety of peptidoglycan types within the genus Bifidobacterium and was therefore proposed
as a taxonomic marker. In general, the use of biochemical and physiological tests for
identification of bifidobacterial species is limited because of relative poor reproducibility
and a low taxonomic resolution. In this respect, chemotaxonomic methods analysing one
specific cellular compound have proven to be much more powerful. Sodiumdodecylsulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) of whole-cell proteins, i.e. protein profiling,
has been successfully applied for the discrimination of B. adolescentis, B. bifidum, B.
breve, B. dentium and B. longum isolated from adult faeces, and for the identification of
Bifidobacterium isolates (mainly B. lactis) from European probiotic products (Reuter et
al., 2002; Temmerman et al., 2003a). Furthermore, protein profiling has shown good
correspondence with the classification of bifidobacteria based on DNA-DNA hybridisations
(Biavati et al., 1982) as well as with results obtained from 16S rRNA gene sequence
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analysis (Kim et al., 2005). Within species, strains that have 80% or greater DNA homology
have identical or nearly identical protein profiles, with B. animalis being the only exception;
within this species, protein patterns of strains isolated from rats appear to differ from those
of strains isolated from sewage, rabbits and chickens (Biavati et al., 1982), which is in
accordance with the recent separation of these strains at the subspecies level (Masco et al.,
2004). Provided that highly standardized conditions of cultivation and electrophoresis are
used throughout the procedure, computer-assisted numerical comparisons of protein patterns
is possible, and a database can be created for identification purposes. This allows large
numbers of strains to be compared and grouped in clusters of closely related homology.
Among the most recently developed physicochemical identification methods, Fourier transform
infrared (FT-IR) spectroscopy has been used for the speciation of bifidobacterial isolates
from foods and human faeces (Mayer et al., 2003). However, differentiation between B.
infantis and B. longum and between B. animalis and B. lactis remained difficult.
2.5.1.2. Genotypic methods
In contrast to phenotypic methods, genotypic identification is based on primary
information obtained from the genome or from specific genes rather than on the products of
their expression. DNA-DNA hybridisation, ribotyping, southern hybridisation and sequence
analysis of the 16S rRNA gene are amongst the first genotypic methods used to identify
bifidobacteria isolated from commercial products and gastro-intestinal tract (GIT) samples.
Later, a new generation of genotypic methods emerged that allowed the identification of
bifidobacteria up to the genus, species and strain level.
Molecular studies were initiated by Scardovi and co-workers (1971). Methodologies
of DNA-DNA hybridisation and the value of mol% G+C reconfirmed species that had
initially been described only on the basis of phenotypic characteristics. Although DNA-DNA
hybridisation is regarded as the ‘golden standard’ for the description of Bifidobacterium
species, it cannot be routinely carried out in most laboratories. A few studies have used
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(microscale) DNA-DNA hybridisations to assess the taxonomic identity of bifidobacteria,
usually in combination with other techniques. Herreman and colleagues (1994) verified the
identity of three industrial starter strains of Bifidobacterium by DNA-DNA hybridisation
with type strains of commercially used Bifidobacterium species.  In another study (Yaeshima
et al., 1996), a collection of Bifidobacterium strains isolated from dairy products such as
yoghurt, cultured milk, butter and cheese were characterized on the basis of phenotypic
characteristics followed by determination of DNA similarities with a microplate hybridisation
method. The same approach was used by Gavini and Beerens (1999) in order to identify 47
strains of bifidobacteria previously isolated from meat and meat products.
Many genotypic methods are based on the principle of Polymerase Chain Reaction
(PCR), which enables the selective amplification of specifically targeted DNA fragments through
the use of oligonucleotide primers. Detailed analysis of the 16S rRNA region as well as the
16S-23S internally transcribed spacer (ITS) region has revealed several nucleotide signatures
with specificity at different taxonomic levels. This has been employed to generate oligonucleotide
primers as well as nucleic acid probes for detection and identification of bifidobacteria to the
genus, species or strain level. Although the majority of these primers were evaluated for their
ability to identify pure cultures, they can also be used in the culture-independent detection of
bifidobacteria in food and faecal samples (see § 2.5.2). Genus-specific primers targeting
sequences of the 16S rRNA gene have been elaborated for bifidobacteria (Kaufmann et al.,
1997), which enables their detection within the complex microflora of the human gut as well
as in a food matrix. Recently, an additional set of Bifidobacterium genus-specific primers has
been designed that do not cross react with Propionibacterium, but then again these primers
produced amplicons with Gardnerella vaginalis (Matsuki et al., 2002). Beyond genus level,
16S rRNA based species- and group-specific primers have been designed for species
commonly found in the human gastrointestinal tract, i.e. B. adolescentis, B. angulatum, B.
bifidum, B. breve, B. dentium, B. gallicum, the B. catenulatum group (B. catenulatum
and B. pseudocatenulatum) and the B. longum group (B. longum/B. infantis) (Matsuki et
al., 1998; Matsuki et al., 1999; Dong et al., 2000b). One limitation of species-specific
primers is that in large-scale studies, the analysis of the species composition requires multiple
PCR rounds with different sets of primers. To avoid this inconvenience, multiplex PCR
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strategies have been developed. By combining species-specific PCR primers that target different
sites of the 16S rRNA gene with a genus-specific reversed primer (Kaufmann et al., 1997),
B. bifidum, B. adolescentis, B. infantis, B. longum and B. breve can be simultaneously
identified (Dong et al., 2000b). Mullié and co-workers (2003) focussed on the simultaneous
detection of B. bifidum, B. breve and B. infantis, B. angulatum, B. catenulatum/B.
pseudocatenulatum continuum, B. dentium and B. longum, and B. adolescentis, B.
scardovii and B. gallicum. However, cross-reaction of B. suis with both B. infantis and B.
longum primers as well as amplification of B. catenulatum with B. angulatum primers was
witnessed under multiplex conditions. Although most PCR primers based on bifidobacterial
16S rRNA genes are developed mainly for the identification and detection of specific
Bifidobacterium taxa, some workers have also attempted to design primers that target
individual strains. For instance, Kok and colleagues (1996) reported the use of three strain-
specific 16 rRNA gene-targeted primers for the detection of the probiotic Bifidobacterium
strain LW420 in infant faeces and for rapid quality control of this strain in culture.
Next to its value in studies on bifidobacterial phylogeny, the 16S-23S internally
transcribed spacer (ITS) sequence has also proven useful for the determination of
intraspecific relationships (LeblondBourget et al., 1996). Based on ITS sequences, strain-
specific primers were designed to trace Bifidobacterium strains, incorporated in a
pharmaceutical probiotic product (VSL-3), in faecal specimens of patients that were taking
VSL-3 (Brigidi et al., 2000). The 16S-23S spacer sequences can also be used for the
differentiation of closely related bifidobacterial taxa. As such, ITS sequences of the closely
related taxa B. animalis and B. lactis allowed a clear separation of these taxa in two distinct
clusters (Ventura and Zink, 2002). Notably, two large insertions in the ITS sequence were
identified in B. animalis but not in B. lactis, which provided a suitable PCR target for reliable
separation of these taxa.
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The limited resolution of bifidobacterial 16S rRNA gene sequences to distinguish
between certain pairs of taxa, e.g. B. animalis and B. lactis, has initiated the search for
alternative universal taxonomic markers with higher divergence rates and thus a more
pronounced discriminatory power (Table 7).
Genes encoding transaldolases were shown to be a suitable target for bifidobacterial
detection and differentiation (Requena et al., 2002). PCR amplification of a 301 bp
transaldolase gene sequence and subsequent comparison of the relative migration of the resulting
amplicons in Denaturing Gradient Gel Electrophoresis (DGGE) allowed the differentiation of
all human Bifidobacterium species tested, except for B. catenulatum and B. angulatum of
which transaldolase amplicons co-migrated in the DGGE gel. Sequence analysis of the conserved
ldh gene encoding the L-lactate dehydrogenase makes it possible to distinguish between B.
infantis and B. longum (Roy and Sirois, 2000) but not between B. animalis and B. lactis.
Kullen and co-workers (1997) described a PCR-based method targeting a 300 bp fragment
of the recA gene for the identification of six intestinal Bifidobacterium species. For the
separation of B. longum and B. infantis, the recA-based method allowed a more reliable
differentiation (96.9% sequence similarity) compared to assays based on the 16S rRNA gene
(>98.5% sequence similarity). Later, Ventura and Zink (2003) demonstrated that the recA
gene sequence also allows to disciminate between B. animalis and B. lactis. Other genes that
have proven to be promising taxonomic markers for investigating evolutionary distances and
Molecular marker Reference
16S-23S Internally Transcribed Spacer (ITS) sequence LeblondBourget et al ., 1996
transaldolase gene encoding transaldolase Requena et al ., 2002
ldh encoding L-lactate dehydrogenase Roy and Sirois, 2000
rec A encoding a protein for DNA strand exchange and renaturation Kullen et al ., 1997
tuf encoding elongation factor Tu Ventura et al ., 2003
grp E encoding GrpE chaperone Ventura et al ., 2005
dna K encoding DnaK chaperone Ventura et al ., 2005
atp D encoding the -subunit of F1F0-ATPase Ventura et al. , 2004a
gro EL encoding GroEL chaperone Ventura et al ., 2004b
pyruvate kinase gene encoding pyruvate kinase Vaugien et al ., 2002
HSP60 gene encoding 60kDa Heat Shock Protein Jian et al ., 2001
xfp encoding xylulose-5-phosphate/fructose-6-phosphate phosphoketolase Berthoud et al ., 2005
Table 7. Alternative molecular markers for 16S rDNA in Bifidobacterium
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to discriminate between closely related bifidobacteria include the gene encoding for the
elongation factor Tu (Ventura et al, 2003; Ventura and Zink, 2003), the dnaK and grpE
genes (Ventura et al., 2005), the atpD (Ventura et al., 2004a), groEL (Ventura et al., 2004b)
and pyruvate kinase gene (Vaugien et al., 2002). Also, the analysis of partial HSP60 gene
sequences has proven to be very useful for the differentiation of Bifidobacterium species
(Jian et al., 2001; Zhu et al., 2003). The sequence similarities of the HSP60 gene have been
determined at various taxonomic levels: 99.4-100% at the intraspecific level, 96% at the
subspecific level, and 73-96% (mean 85%) at the interspecific level. Sequence similarities
ranged from 91-93% between B. catenulatum and B. pseudocatenulatum, from 98-100%
between B. longum, B. infantis and B. suis and from 98.9-100% between B. animalis and
B. lactis. In contrast, the 16S rRNA sequence similarities of all these species are above
98,5%. In a recent study conducted by Berthoud and co-workers (2005), a new identification
method for Bifidobacterium species based on partial sequencing of the xylulose-5-phosphate/
fructose-6-phosphate phosphoketolase gene (xfp) was evaluated. Using sequences of
approximately 500 bp from 68 different strains including 34 type strains, all bifidobacterial
species could be discriminated with an accuracy higher than that of 16S rDNA sequence
analysis. Interestingly, xfp sequence analysis even allowed to distinguish B. longum biotype
infantis from B. longum biotype longum and B. longum biotype suis, as well as B. animalis
from B. lactis.
In addition to taxon-specific PCR primers, also short oligonucleotide probes have
been developed that are directed to rRNA regions known to be genus- (Langendijk et al.,
1995; Kaufmann et al., 1997) or species-specific (Yamamoto et al., 1992; Mangin et al.,
1995). These probes can be used to screen presumptive bifidobacterial colonies for the
presence of a specific DNA sequence using a labeled probe (see § 2.5.2).
Triggered by the growing insights in the taxonomic divergence of ribosomal RNA
gene sequences in Bifidobacterium, ribotyping was one of the first DNA fingerprinting
techniques to be used for the speciation of bifidobacteria. Starting from conventional restriction
fragment length polymorphism (RFLP) analysis of genomic DNA, a subset of the restriction
fragments are selected and visualized after electrophoresis by southern hybridisation with an
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rDNA probe in order to obtain a less complex pattern that is easier to interpret. To a large
extend, the discriminatory power of ribotyping depends on the size and specificity of the
probe as well as on the restriction enzyme used. By using probes derived from 16S or 23S
rDNA sequences, this method has been applied for the intra- and interspecies differentiation
of industrial and culture collection strains as well as of human faecal isolates of Bifidobacterium
(Mangin et al., 1994, 1996, 1999; McCartney and Tannock, 1995; Mättö et al., 2004). In
corroboration with Randomly Amplified Polymorphic DNA (RAPD), this approach also
allowed the recognition of three biotypes (i.e. longum, infantis and suis) in the species B.
longum (Sakata et al., 2002).
The concept of another ribosomal fingerprinting technique, i.e. Amplified Ribosomal
DNA Restriction Analysis (ARDRA) essentially relies on the restriction enzyme analysis
of 16S rDNA PCR amplicons. Although less discriminatory than ribotyping, ARDRA has
shown significant potential to identify Bifidobacterium strains at the species level. A first
study by Roy and Sirois (2000) demonstrated the differentiation of B. breve, B. bifidum and
B. adolescentis and confirmed the close relatedness between B. longum and B. infantis.
However, the restriction patterns of B. lactis and B. animalis were identical. Later, the ARDRA
identification scheme described by Ventura and co-workers (2001) allowed the species-
specific detection of a number of ecologically diverse species including B. catenulatum and
B. pseudocatenulatum. However, the closely related taxa B. animalis and B. lactis and B.
longum and B. suis could not be distinguished with this method. A study by Venema and
Maathuis (2003) described the use of ARDRA to differentiate between all Bifidobacterium
species found in the human alimentary tract as well as B. animalis and B. lactis. Although this
technique is labour-intensive and time-consuming, it is generally regarded as a robust and
reproducible molecular identification tool for human Bifidobacterium species. Provided that
more than one restriction profile is analysed and compared, this method allows the differentiation
of B. longum and B. infantis, B. catenulatum and B. pseudocatenulatum, and B. animalis
and B. lactis.
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Of all conventional fingerprinting techniques, Pulsed Field Gel Electrophoresis
(PFGE) is generally considered to afford the greatest differentiation, primarily because the
PFGE profile generated represents the whole genome. PFGE employs an alternating field of
electrophoresis to allow separation of the large DNA fragments obtained from restriction
digests with rare-cutting enzymes. A number of studies have demonstrated the usefulness of
PFGE to monitor changes in the predominant bifidobacterial populations in humans, both
within individuals over time and between individuals (McCartney et al., 1996; Kimura et al.,
1997). Other workers have shown the ability of PFGE to characterize and differentiate
commercial and faecal Bifidobacterium strains (Roy et al., 1996; Engel et al., 2003; Mättö
et al., 2004). Although PFGE is generally not considered for identification purposes, Grand
and co-workers (2003) used this method to verify the identity of bifidobacterial isolates from
probiotic milk products by comparison of their macro-restriction profiles with those of reference
strains from producer companies.
DNA fingerprinting techniques that solely rely on PCR include Randomly Amplified
Polymorphic DNA (RAPD) and repetitive sequence based (rep)-PCR. Both techniques
encompass the whole genome and thus exhibit a higher discriminatory power than techniques
based on highly conserved rRNA genes. RAPD analysis makes use of short arbitrary primers
and low-stringency conditions to randomly amplify DNA fragments, which are then separated
electrophoretically to produce a fingerprint. The flexibility in primer choice and PCR conditions
allows its application for the differentiation of bifidobacteria at different taxonomic levels,
although it also makes this technique prone to poor reproducibility. RAPD analysis has been
used for differentiation (Vincent et al., 1998; Fanedl et al., 1998; Sakata et al., 2002; Mättö
et al., 2004) and monitoring purposes (Fujiwara et al., 2001; Alander et al., 2001). Superior
to the reproducibility of RAPD, fingerprinting methods based on the PCR amplification of
repetitive elements (rep-PCR) targeting ERIC (enterobacterial repetitive intergenic consensus)
(Shuhaimi et al., 2001; Ventura et al., 2003b) or BOX (Zavaglia et al., 2000) elements are
reported to be suitable for both the speciation and the intra-specific differentiation (subtyping)
of bifidobacteria.
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2.5.2. Culture-independent methods
Traditionally, analysis of bifidobacterial communities (e.g. faeces or food) has been
achieved by combining a conventional isolation strategy with culture-dependent identification.
However, besides being time-consuming, this approach has been impaired by the lack of
suitable media for the selective isolation of bifidobacteria (Roy, 2001). In addition, results
may also be biased by a poor viability or low concentration present of the target organism,
resulting in an inaccurate reflection of the bifidobacterial composition of the sample. As a
result, culture-independent techniques have been promoted as alternative and/or complementary
approaches to study the microbial ecology of the GIT and to trace bifidobacterial strains in
probiotic products and environmental samples.
The fastest culture-independent approach for the genus, species or strain specific
analysis of bifidobacterial populations is based on the use of specific primers (§ 2.5.1.2.) for
the PCR-based detection of bifidobacteria in bacterial community DNA extracted from a
sample. However, one of the major drawbacks of this approach is the prerequisite for prior
knowledge of the bacterial content of the sample, making such PCR assays of limited value in
the analysis of highly complex ecosystems or samples showing variable or unknown species
composition. In these cases, community fingerprinting techniques, such as DGGE and T-
RFLP provide worthy alternatives. Denaturing Gradient Gel Electrophoresis (DGGE)
is a PCR-based technique that allows the sequence-dependent separation of a mixture of
amplified DNA fragments, all identical in size, on an acrylamide gel containing a well-defined
gradient of denaturing components. By combining genus- or group-specific PCR with DGGE,
a fingerprint can be obtained from the bifidobacterial community, which allows to monitor its
taxonomic complexity as well as its temporal and spatial changes. Furthermore, individual
members of the community can be identified either by cloning and sequencing of the PCR
fragments or by comparing the obtained DGGE band positions with an identification database.
The nested-PCR DGGE methodology developed by Temmerman and colleagues (2003b)
allowed the reliable taxonomic characterization of 32 (sub)species of Bifidobacterium,
including B. longum, B. infantis and B. suis, and representatives of B. animalis and B.
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lactis. Only B. indicum and B. coryneforme could not be distinguished. Several applications
of DGGE analysis of 16S rDNA (Satokari et al., 2001a and b; Fasoli et al., 2003; Favier et
al., 2003; Temmerman et al., 2003b; Burton et al., 2003) or transaldolase gene (Requena et
al., 2002) amplicons have been reported for the identification, detection and monitoring of
Bifidobacterium species prominent in probiotic products and human faecal and vaginal flora.
Another community fingerprinting method, i.e. terminal restriction fragment length
polymorphism (T-RFLP), has been used to assess the diversity of the human faecal
bifidobacteria and rapid comparison of the bifidobacterial community structure among human
individuals (Sakamoto et al., 2003; Hayashi et al., 2004; Sakata et al., 2005).
Although highly valuable for qualitative detection purposes, community fingerprinting
methods generally do not yield quantitative information and need to be combined with culture-
based techniques to obtain total bifidobacterial counts. Real-time PCR (or quantitative PCR)
enables the simultaneous detection and quantification of microorganisms by measuring the
relative amount of amplicon generated throughout the PCR reaction using a combination of
specific primers and intercalating dyes or specific fluorescently labeled probes. Several real-
time PCR approaches targeting either the 16S rRNA gene (Vitali et al., 2003; Matsuki et al.,
2004; Penders et al., 2005; Bartosch et al., 2005), 16S-23S ITS sequence (Haarman and
Knol, 2005) or transaldolase gene (Requena et al., 2002) have been used for the detection
and enumeration of bifidobacteria in faecal samples as well as for strain-specific detection in
probiotic products. The application of a real-time PCR based method for the qualitative
analysis of bifidobacterial populations implies that each species requires a separate probe or
primer set, which may result in an enormous increase of cost and workload. For such purposes,
the combined use of real-time PCR and DGGE analysis can provide quantitative as well as
qualitative data (Requena et al., 2002).
Unlike conventional PCR primers, hybridisation probes are linked to a radioactive or
fluorescent label enabling the visual detection of the target after hybridisation under controlled
conditions. Labelled oligonucleotide probes can be employed in a variety of assays including
colony, dot blot and in situ hybridisations. Colony hybridisation involves probing of bacterial
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colonies that have been transferred onto membranes (e.g. nitrocellulose membranes). This
technique has proven successful in tracking down bifidobacterial indicators of human faecal
pollution (Lynch et al., 2002; Nebra et al., 2003), in detecting specific probiotic
Bifidobacterium strains (Su et al., 2005) and in analysing human faecal samples (Kaufmann
et al., 1997; Kaneko and Kurihara, 1997). Dot blot assays involve probing DNA extracts
from samples and have been used to study the binding of Bifidobacterium strains to amylomaize
starch granules (O’Riordan et al., 2001).
The most frequently applied method that makes use of oligonucleotide probes is Fluorescent
In Situ Hybridisation (FISH), which enables the direct enumeration of whole bacterial cells
in samples using either fluorescence microscopy or flow cytometry. Probes targeting 16S
ribosomal RNA sequences specific for Bifidobacterium have been applied for microscopic
analysis of bifidobacteria in human faecal samples (Langendijk et al., 1995; Welling et al.,
1997). Recently, Takada and colleagues (2004) used a multi-color FISH method to detect
seven Bifidobacterium species predominant in human faeces in one single assay. Flow
cytometry is a rapid and sensitive technique that can determine cell numbers and measure
various physiological characteristics of each individual cell using appropriate fluorescent dyes
(e.g. SYTO9 and propidium iodide for LIVE/DEAD analysis) (Bunthof and Abee, 2002).
Flow cytometry has been applied to evaluate the effect of bile salt on the viability of
bifidobacteria (Ben Amor et al., 2002) as well as for the analysis of the composition of
microbial communities, including bifidobacteria, in human faeces (Rigottier-Gois et al., 2003).
One of the most recent technological developments is the integration of a multiple oligonucleotide
probe approach in an ELISA-based system. This approach has been used to monitor the
fluctuation of nine bifidobacterial species in faecal samples during and after a human feeding
trial (Malinen et al., 2002).
Miniaturization of DNA hybridisation techniques has led to the development of DNA chips or
DNA microarrays. With these tools, an array of probes can be immobilized on a small glass
slide in such a way that one sample can be tested simultaneously against a large number of
probes. This miniaturized approach overcomes one of the major limitations associated with
probe-based methods, namely the restricted number of bacteria that can be targeted in a
single analysis. Recently, DNA microarrays containing 20 16S rDNA probes of the predominant
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intestinal bacterial species, including bifidobacteria, have been developed to monitor the
populations of anaerobic bacteria in human faecal samples (Wang et al., 2002). Although
probe-based techniques are reliable and relatively easy to use, probe design and detection
limit remain the major bottlenecks in the construction of a microarray.
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Method
Culture-dependent
Phenotypic characterization X
SDS-PAGE X X
DNA-DNA hybridisation X X
16S rRNA gene:
Sequence analysis X X x
Specific primers X X X X
16S-23S ITS:
Sequence analysis X X X
Specific primers X X X X
Housekeeping genes:
Sequence analysis X X x
Specific primers X X X X
RFLP X X
Ribotyping X X
ARDRA X x
PFGE X
RAPD X X
rep-PCR X X
Culture-independent
DGGE X X X
Real-Time PCR X X
Hybridisation probes X X X X
FISH X X
x: Applicable under certain circumstances
Table 8. Overview of the most frequently used
techniques for the identification, typing, detection
and/or quantification of bifidobacteria
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2.6. Genomics of bifidobacteria
Genomic work on bifidobacteria has only started relatively recent. The early work
of Sgorbati and coworkers (1982) demonstrated the presence of plasmids in several members
of the genus Bifidobacterium including B. longum, B. pseudolongum subsp. globosum,
B. asteroides and B. indicum. The investigated strains of B. infantis, which is most closely
related to B. longum, did not carry plasmids. Later studies also reported the presence of
plasmids in B. breve (Iwata and Morishita, 1989; Bourget et al., 1993). Recently, the first
genome sequence of a Bifidobacterium strain, i.e. B. longum NCC2705, has become
publicly available (Schell et al., 2002). This strain has a genome of 2,256,646 bp with a
G+C content of 60,1% and contains four nearly identical rrn operons. Complete pathways
for the biosynthesis of the majority of amino acids, all nucleotides and some vitamins (folic
acid, thiamine, and nicotinate) have been identified. Furthermore, sequence analysis revealed
the capacity of B. longum NCC2705 to encode a rich arsenal of proteins (more than 8% of
the total predicted proteins) that are probably involved in the catabolism of a variety of
oligosaccharides. This finding might be reflected by the ability of this microorganism to grow
and persist in the colon. Genome analysis not only enhances our understanding of
bifidobacterial physiology, it also provides useful information in understanding the processes
underlying speciation and evolution. By comparing genome sequences (i.e. comparative
genomics), patterns of similarity or variability are obtained indicating physiological plasticity
and various evolutionary processes. Unfortunately, to date, only the B. longum genome
sequence is publicly available. However, in this respect, the DNA microarray technology
allows a global comparative analysis of gene content between different bifidobacterial isolates
of a given species without the necessity of sequencing many strains (i.e. genomotyping).
Recently, a B. longum NCC2705-based DNA microarray has been developed to compare
the genomes of a number of bifidobacterial strains in order to evaluate the genetic variability
at intra-specific and inter-specific level (Rezzonico et al., 2003). However, genomic
comparison with microarrays does not respect the syntheny of the bacterial genome. The
genomic comparison of two genomes that have very similar gene contents but that are
organized differently will not reveal genetic differences in microarray analysis. Nevertheless,
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while awaiting additional bifidobacterial genome sequence data, microarrays provide a highly
powerful, high-throughput means to characterize strains and are expected to complement
other techniques in a polyphasic taxonomic approach.
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Chapter 3: Classification and identification of Bifidobacterium species
1.1. Identification of Bifidobacterium species using rep-PCR fingerprinting
Rep-PCR fingerprinting was evaluated for the differentiation of a broad
taxonomical range of bifidobacteria and subsequently used for the
establishment of an identification framework using Bifidobacterium type and
reference strains.
1.2. Polyphasic taxonomic analysis of Bifidobacterium animalis and
Bifidobacterium lactis reveals relatedness at the subspecies level:
reclassification of Bifidobacterium animalis as Bifidobacterium animalis
subsp. animalis subsp. nov. and Bifidobacterium lactis as Bifidobacterium
animalis subsp. lactis subsp. nov.
In this study, the taxonomic position of the species B. lactis and B. animalis
was investigated using a polyphasic approach which resulted in a proposal to
unify both taxa at the species level but to differentiate them at the subspecies
level.
Chapter 4: Culture-dependent and culture-independent microbial analysis
                  of probiotic products claiming to contain bifidobacteria
4.1. Culture-dependent and culture-independent qualitative analysis of probiotic
products claiming to contain bifidobacteria
This study describes the isolation of bifidobacteria from 58 worldwide
collected probiotic products, followed by their identification using BOX-
PCR fingerprinting and strain typing using PFGE. In parallel, DGGE was
used for the culture-independent detection of Bifidobacterium species in
these products.
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Table A of the addendum compiles the data obtained in the studies described in §3.1-4.1
and gives an overview of the origin and taxonomic diversity of Bifidobacterium strains
studied in this work.
4.2. Evaluation of real-time PCR targeting the 16S rRNA and recA genes for the
enumeration of bifidobacteria in probiotic products
For a subset of 29 probiotic products, real-time PCR targeting the multicopy
16S rRNA gene and the single copy recA gene was evaluated for the culture-
independent enumeration of bifidobacteria.
Chapter 5: Safety assessment of product isolates and reference strains
of Bifidobacterium
5.1. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and
probiotic products
The research in this section investigates the phenotypic susceptibility of
Bifidobacterium strains to 15 antimicrobial agents. For a subset of strains, the
genotypic basis of tetracycline resistance was further characterized.
Table B of the addendum summarizes the tetracycline resistance properties of Bifidobacterium
strains tested in this study.
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Chapter 6: Functionality assessment of product isolates and
       reference strains of Bifidobacterium
6.1. Bifidobacterium strains induce in vitro cytokine production by human peripheral
blood mononuclear cells in a strain-specific way
This study describes the use of an in vitro method to study the effect of
human and probiotic Bifidobacterium strains on cytokine production by human
peripheral blood mononuclear cells.
6.2. In vitro assessment of the gastrointestinal transit tolerance of human reference
strains and probiotic isolates of Bifidobacterium
A selection of human and probiotic Bifidobacterium isolates, representing 9
species was evaluated towards GI-tract survival capacity using a microplate
scale fluorochrome assay.
Table C of the addendum provides an overview of the immunological and survival properties
of Bifidobacterium strains tested in this study.

Chapter 3
Classification and identification of Bifidobacterium species
3.1. Identification of Bifidobacterium species
using  rep-PCR fingerprinting
Masco L., Huys G., Gevers D., Verbrugghen L. and
Swings J. (2003). Systematic and Applied Microbiology 26:
557-563.
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Summary
The aim of the present study was to evaluate the use of repetitive sequence-based
PCR fingerprinting (rep-PCR) for the taxonomic discrimination among the currently described
species within the genus Bifidobacterium. After evaluating several primer sets targeting the
repetitive DNA elements BOX, ERIC, (GTG)5 and REP, the BOXA1R primer was found to
be the most optimal choice for the establishment of a taxonomic framework of 80
Bifidobacterium type and reference strains. Subsequently, the BOX-PCR protocol was tested
for the identification of 48 unknown bifidobacterial isolates originating from human faecal
samples and probiotic products. In conclusion, rep-PCR fingerprinting using the BOXA1R
primer can be considered as a promising genotypic tool for the identification of a wide range
of bifidobacteria at the species, subspecies and potentially up to the strain level.
Keywords: Bifidobacterium, Identification, BOX, ERIC, (GTG)5, REP, faecal isolates,
probiotic products
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Introduction
Bifidobacteria are Gram-positive, non-spore forming, non-motile rod-shaped
anaerobes. Although most bifidobacteria are known to reside within the animal intestine
(Matteuzi et al., 1971; Scardovi and Zani, 1974; Biavati and Mattarelli, 1991) or in the oral
cavity, intestine and vagina of humans (Reuter, 1963; Scardovi and Crociani, 1974; Lauer,
1990), they have also been isolated from various other environments such as wastewater
(Scardovi and Trovatelli, 1974), anaerobic digesters (Dong et al., 2000) and fermented milk
(Meile et al., 1997). Members of the genus Bifidobacterium dominate the indigenous
microflora of infants and as humans age bifidobacteria become the third most abundant bacterial
group following the genera Bacteroides and Eubacterium (Holzapfel et al., 1998). Based
on suggested probiotic functions, Bifidobacterium strains from a number of species are added
as living cultures to milk products, pharmaceutical preparations and animal feed.
Currently, over 30 species are recognised within the genus Bifidobacterium and the
taxonomic position of several of these species has been controversial for many years.
Bifidobacteria belong to the class of the Actinobacteria (Stackebrandt et al., 1997),
characterised by a high guanine plus cytosine (G+C) content, i.e. 55 to 67 mol%. Bifidobacteria
have been identified by physiological and biochemical methods, which are often time-consuming,
laborious and do not always allow the differentiation of closely related species. Consequently,
molecular techniques based on restriction fragment analysis (Ventura et al., 2001) and/or the
polymerase chain reaction (PCR) (Matsuki et al., 1999) have recently been evaluated for the
identification of bifidobacteria.
Repetitive sequence-based polymerase chain reaction (rep-PCR) fingerprinting is a
genotypic technique using outwardly facing oligonucleotide PCR primers complementary to
interspersed repetitive sequences, which enable the amplification of differently sized DNA
fragments lying between these elements. Examples of evolutionarily conserved repetitive
sequences are BOX, ERIC, REP and (GTG)5. Rep-PCR fingerprinting is considered to be a
valuable tool for classifying and typing of a wide range of Gram-negative and several Gram-
positive genera (Versalovic et al., 1994). To our knowledge, the use of the rep-PCR
fingerprinting technique for the identification or typing of bifidobacteria has not been fully
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evaluated. Shuhaimi and co-workers (2001) conducted a study to determine whether ERIC-
like sequences were present in the genomes of bifidobacteria, whereas Gómez Zavaglia and
colleagues (2000) evaluated rep-PCR fingerprinting using the BOXA1R primer for the
identification of Bifidobacterium isolates from newborns’ faeces.
The aim of the present study was to assess the applicability of rep-PCR fingerprinting
for the differentiation of a broad range of bifidobacteria. For this purpose, several primer sets
targeting different repetitive DNA elements were evaluated on a subset of reference strains.
The most suitable primer set was used to establish a taxonomic framework of type and reference
strains representing all of the currently described Bifidobacterium species. This framework
was subsequently tested for the identification of bifidobacterial isolates from different
environments.
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Materials and methods
Bacterial strains and cultivation
Type and reference strains were obtained from the BCCM™/LMG Bacteria Collection, Ghent
University, Belgium (http://www.belspo.be/bccm/lmg.htm) (Figure 1). Faecal bifidobacterial isolates
(CFPL) were kindly provided by M.-B. Romond and C. Mullié, Université de Lille 2 (Lille, France).
Bifidobacterial isolates R-3933 ® R-3940 are from faecal origin whereas probiotic isolates are numbered
R-20204 ® R-20229. All bifidobacterial strains as well as the strains belonging to the genus
Propionibacterium were grown overnight at 37°C under anaerobic conditions (84% N
2
, 8% H
2
, 8% CO
2
)
on modified Columbia agar comprising 23 g special peptone (L72, Oxoid, Drongen, Belgium), 1 g soluble
starch, 5 g NaCl, 0.3 g cystein-HCl-H
2
O (C-4820, Sigma, Bornem, Belgium), 5 g glucose and 15 g agar
dissolved in 1 litre of distilled water (BCCM™/LMG, Medium 144). Gardnerella vaginalis strains were
grown on Columbia Agar Base (211124, BD, Erembodegem, Belgium) supplemented with 5% defibrinated
horse blood (355-6642, Bio-Rad, Nazareth-Eke, Belgium), and were incubated aerobically at 37°C with 5%
CO
2
 enrichment.
Total DNA extraction
Extraction of total bacterial DNA was based on the method of Pitcher and co-workers (1989)
with slight modifications regarding the concentration of lysozyme and an additional step involving
RNase at the end of the procedure. Cells grown overnight were harvested and washed in 500 µl TE-buffer
(1 mM EDTA pH 8.0; 10 mM Tris-HCl pH 8.0) after which the cell suspension was centrifuged for 2 min
at 13000rpm. Following the removal of the supernatant, the resulting pellet was frozen at –20°C for at
least one hour to facilitate the rupture of the Gram-positive cell wall. The thawed pellet was then
resuspended in 150 µl lysozyme-solution [5 mg lysozyme (28262, Serva, Zandhoven, Belgium) in 150 µl
of TE buffer] followed by an incubation step at 37°C during 40 min. The remaining steps of the procedure
were performed according to Pitcher and co-workers (1989). Finally, the resulting DNA pellet was dissolved
in 200 µl TE-buffer and kept overnight at 4°C. An RNA digesting step was then performed by adding 2 µl
of an RNase solution [10 mg RNase (R6513, Sigma) dissolved in 1 ml MQ water] followed by an incubation
step of 90 min. at 37°C. Quality of the DNA samples was verified by spectrophotometric measurements
at 260/280/234 nm. The DNA was then diluted to a working concentration of 50 ng/µl. The integrity of the
DNA was checked by gel electrophoresis in 1% agarose in 1x TAE (0.04 M Tris-acetate, 0.001 M EDTA)
buffer. The gel was visualised after staining with ethidium bromide under ultraviolet light.
Rep-PCR fingerprinting
The repetitive sequence-based oligonucleotide primers (Sigma-Genosys, Cambridge, UK) that
have been evaluated in this study are ERIC (ERIC1R: 5’-ATGTAAGCTCCTGGGGATTCAC-3’, ERIC2: 5’-
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AAGTAAGTGACTGGGGTGAGCG-3’), BOX (BOXA1R: 5’-CTACGGCAAGGCGACGCTGACG-3’), GTG
5
(GTG
5
: 5’-GTGGTGGTGGTGGTG-3’)
 
and REP (REP1R: 5’-IIIICGICGICATCIGGC-3’, REP2I: 5’-
ICGICTTATCIGGCCTAC-3’) each with their specific annealing temperature (Versalovic et al., 1994). A
universal PCR reaction mix was used for all rep-PCR assays in which only the primer was changed. Each
25 µl PCR reaction contained 5 µl 5x Gitschier buffer (83 mM (NH
4
)
2
SO
4
, 335 mM Tris-HCl (pH 8.8), 33.5
mM MgCl
2
, 32.5 µM EDTA (pH 8.8) and 150 mM ˜ -mercapto-ethanol), 160 µg/ml BSA, 10% DMSO, 1.25
mM of each of 4 dNTPs (dATP, dCTP, dGTP and dTTP), 0.3 µg/µl oligonucleotide primer, 2 units of Red
Goldstar DNA polymerase (Eurogentec, Seraing,  Belgium) in MQ water containing 50 ng of template
DNA. PCR amplifications were performed in a DNA thermal cycler (Perkin Elmer 9600) with an initial
denaturation step (95°C, 7 min), followed by 30 cycles of denaturation (94°C, 1 min), annealing (variable
temperature, 1 min) and extension (65°C, 8 min), and a single final extension step (65°C, 16 min). The
amplified fragments were fractionated on a 1.5% agarose gel during 16 h at a constant voltage of 55 V in
1x TAE at 4°C. The rep-PCR genomic fragments were visualised after staining with ethidium bromide
under ultraviolet light, followed by digital capturing of the image using a CCD camera and storage as a
tiff file. The resulting fingerprints were analysed using the BioNumerics V2.5 software package (Applied
Maths, Kortrijk, Belgium).
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Results
Evaluation of the different primer sets
Two single oligonucleotide primers, BOXA1R and (GTG)5, and two oligonucleotide
primer pairs, REP1R-I/REP2-I and ERIC1R/ERIC2, were tested for their ability to differentiate
a subset of 35 strains belonging to 7 Bifidobacterium species, namely B. adolescentis, B.
animalis, B. bifidum, B. breve, B. infantis, B. lactis and B. longum, previously identified by
protein profiling (data not shown). Fingerprints generated with the ERIC and REP primers
contained less than 20 bands, with an average of 19.8 and 14.8, respectively. The use of
BOX and (GTG)5 resulted in banding patterns containing more than 20 bands, with an average
of 25.5 and 29.9 bands, respectively. The highest discriminatory power was obtained using
the BOXA1R primer, which generated banding patterns that displayed a much higher inter-
strain heterogeneity compared to (GTG)5-generated banding patterns, which were too complex.
The size of the amplicons generated with the BOXA1R primer ranged from 250bp to 6000bp,
the broadest range witnessed after amplification with each of the 4 primer sets. For these
reasons, we decided that rep-PCR fingerprinting using the BOXA1R primer (BOX-PCR)
was the method of choice for the further construction of a taxonomic framework for identification
of bifidobacteria.
Identification of bifidobacteria using BOX-PCR
A total of 80 type and reference strains, belonging to 32 Bifidobacterium (sub)species,
were subjected to BOX-PCR fingerprinting for the establishment of a taxonomic framework.
The results of the numerical analysis of the generated BOX-PCR banding patterns are shown
in a dendrogram (Figure 1). Three strains of the closely related species Gardnerella vaginalis
that were subjected to BOX-PCR fingerprinting produced banding patterns containing less
than 7 bands (Figure 1). Three strains belonging to the genus Propionibacterium, another
member of the Actinobacteria branch of the Gram-positive bacteria, were also included.
The resulting amplification profiles grouped into a single BOX-PCR cluster within the framework
of bifidobacteria (Figure 1). When clusters were delineated at a correlation level of 50%,
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type and reference strains of Bifidobacterium taxa that were represented by two or more
strains usually grouped in clusters according to their taxonomic designation. In fact, only the
representatives of B. pseudolongum subsp. pseudolongum and B. asteroides did not group
in a single BOX-PCR cluster, respectively.
In order to evaluate the applicability of BOX-PCR for the identification of unknown
Bifidobacterium isolates, three different sets of isolates were subjected to BOX-PCR
fingerprinting (Figure 2). A first set comprised 14 bifidobacterial isolates from faecal origin,
previously identified by means of Multiplex PCR including different species-specific primers
(C. Mullié, personal communication). The results of numerical analysis of the generated BOX-
PCR banding patterns confirmed the identification results obtained with Multiplex PCR, except
for one. The isolates could be identified as B. adolescentis, B. bifidum, B. breve and B.
longum. A second set consisted of 26 new bifidobacterial isolates originating from different
kinds of probiotic products. These were subjected to BOX-PCR and the resulting banding
patterns were clustered together with the reference framework. The newly isolated
bifidobacteria were assigned to the species B. lactis, B. longum and B. bifidum. A third set
comprising 8 strains from faecal origin, previously identified by means of protein profiling
(data not shown), were also added to our reference frame. The strains could be assigned to
the species B. adolescentis, B. catenulatum and B. pseudolcatenulatum. No pronounced
effect was observed from the addition of these isolates on the stability of the cluster analysis
based on the BOX-PCR banding patterns of the reference strains.
The reproducibility of each PCR run was evaluated by the inclusion of reference
strain LMG 10733. All runs were performed with the same thermal cycler. Throughout this
study, a similarity range from 92.5% to 97% was found for repeated BOX-PCR banding
patterns of strain LMG 10733 (data not shown). These variations were mainly due to changes
in band intensity rather than to qualitative differences, i.e. the presence or absence of a band.
Overall, these variations did not significantly affect the stability of the cluster analysis.
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Figure 1. Dendrogram generated after cluster analysis of digitized BOX-PCR fingerprints
of type and reference strains. The dendrogram was constructed using the unweighted pair -
group method using arithmetic averages with correlation levels expressed as percentage
values of the Pearson correlation coefficiënt.
a
LMG: BCCM
TM
/LMG Bacteria Collection; T: type strain; t1: type of colony 1
b
B.: Bifidobacterium; P.: Propionibacterium; G.: Gardnerella
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Discussion
Based on the discriminatory power, complexity of the patterns and the taxonomic
correlation, the BOXA1R primer was found to be the most suitable rep-PCR primer for the
identification of bifidobacteria. Furthermore, the resulting BOX-PCR patterns were sufficiently
complex to allow discrimination at the subspecies level whilst the absence or presence of one
or more bands within a cluster resulted in a heterogeneity among strains which was far more
pronounced than with any other primer set. Consequently, BOX-PCR fingerprinting is not
only suitable for identification purposes but can also be used for the pre-grouping of isolates.
In this way, only those isolates that display highly similar if not identical BOX-PCR banding
patterns may need further typing.
For many years, members of the genus Bifidobacterium were considered as lactic
acid bacteria (LAB) based on some common metabolic features and because of their
widespread use in the food industry. However, based on their high DNA G+C content and
from 16S rDNA sequence data, bifidobacteria appear to constitute a phylogenetically coherent
unit, i.e. the family Bifidobacteriaceae within the Actinobacteria class which also comprises
the genus Propionibacterium. Within this taxonomic unit, there resides only one other organism,
namely Gardnerella vaginalis. The typical LAB, such as Lactobacillus, Lactococcus and
Pediococcus are characterised by a DNA G+C content of less than 50 mol% and therefore
belong to the Clostridium branch of the Gram-positive bacteria. Because of this phylogenetic
position, LAB are only distantly related to members of the genus Bifidobacterium. Accordingly,
BOX-PCR profiles of LAB typically contain merely up to 6 bands (Gevers et al., 2001)
whereas Bifidobacterium profiles usually comprise more than 20 bands. Due to its close
relatedness to the genus Bifidobacterium we also included 3 strains of the species Gardnerella
vaginalis in this BOX-PCR fingerprinting study. Representatives of G. vaginalis are known
to exhibit fructose-6-phosphate phosphoketolase activity and display a 16S rDNA sequence
similarity of 93.1% with the type species Bifidobacterium bifidum (Van Esbroeck et al.,
1996). Nevertheless, the BOX-PCR banding patterns of the three G. vaginalis strains
contained as little as 7 bands and could therefore be clearly differentiated from those of
bifidobacteria. The Propionibacterium strains included in this study grouped in a separate
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cluster within the Bifidobacterium reference framework (Figure 1). Unlike the Gardnerella
strains, however, the BOX-PCR profiles of the Propionibacterium strains displayed a similar
number and distribution range of bands compared to typical Bifidobacterium banding patterns.
In cluster analysis, Bifidobacterium type and reference strains grouped according to
their taxonomic designation except for representatives of B. pseudolongum subsp.
pseudolongum and B. asteroides.  In the former case, the 2 reference strains LMG 11594
(28T) and LMG 11595 (29 Sr-T) and the type strain LMG 11571T (PNC-2-9G) did not
group in a single cluster (Figure 1). Interestingly, previous taxonomic studies have indicated
that the species B. pseudolongum is phenotypically and genomically heterogeneous. Mitsuoka
(1969) proposed four biotypes (a, b, c and d) in B. pseudolongum on the basis of differences
in the fermentation of four sugars. Later, in the proposal of Yaeshima and co-workers (1992)
on the unification of B. pseudolongum and B. globosum, four groups of strains were
distinguished based on G+C content and DNA-DNA hybridisation values. The authors
assembled strains similar to the type strain of B. pseudolongum and strains similar to the type
strain of B. globosum in two new subspecies of B. pseudolongum, while the remaining strains
were divided in 2 intermediate groups (I and II), which were more closely related to B.
globosum than to B. pseudolongum. Furthermore, it was shown that strains belonging to
biotype a, consist of B. pseudolongum and B. globosum, whereas strains belonging to biotype
b and c consist of intermediate group II and biotype d consists of intermediate group I (Yaeshima
et al., 1992). Correspondingly, the reference strains LMG 11594 and LMG 11595, both
belonging to intermediate group II (biotype b and c) display banding patterns that are distinct
from the banding pattern of the type strain LMG 11571T, which belongs to biotype a, and that
are more similar to the banding patterns of the B. pseudolongum subsp. globosum strains.
Collectively, our BOX-PCR data confirm previous observations that strains belonging to
intermediate group I and II (represented here by LMG 11594 and LMG 11595) are distinct
from the type strains of both subspecies of B. pseudolongum. Further studies including more
isolates affiliated to these intermediate groups should be conducted in order to determine their
taxonomic position.
The two strains of B. asteroides included in this study, LMG 10735T and LMG
11581, also did not group in the same BOX-PCR cluster (Figure 1). In a previous study,
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Lauer and Kandler (1983) performed DNA-DNA hybridisations between representatives of
the B. indicum/B. coryneforme/B. asteroides group, all inhabitants of the intestine of the
honeybee. The type strains of B. indicum and B. coryneforme showed 100% DNA-DNA
homology to each other. The type strain (C51T = LMG 10735T) and one reference strain (C3
= LMG 11581) of B. asteroides showed only about 65% DNA-DNA homology to each
other and were only moderately related to B. indicum and B. coryneforme at a level of 35%
DNA-DNA homology. Also from BOX-PCR fingerprinting, the profiles of type strains of B.
indicum and B. coryneforme were relatively closely related at a similarity level of 75.5%. In
contrast, the banding patterns of the two representatives of B. asteroides were quite different
from each other and from those of B. indicum and B. coryneforme. Possibly, our BOX-
PCR results corroborate with the phenotypic heterogeneity in B. asteroides, reflected by the
high number of different isoenzymes of transaldolase (Scardovi et al., 1979) and carbohydrate
fermentation patterns (Scardovi and Trovatelli, 1969). However, the study of Lauer and
Kandler (1983) seems to indicate that the type strain of B. asteroides does not fit the original
description, in contrast to the reference strain LMG 11581. Therefore, as mentioned in the
minutes of the meetings of the International Committee on Systematic Bacteriology (Biavati,
2001), our BOX-PCR results support the proposal that the original species description of B.
asteroides has to be emended because of a lack of accordance with the type strain LMG
10735T.
The taxonomic standing of B. lactis has been much debated since its description by
Meile and co-workers (1997). In fact, there has been a proposal from Cai and colleagues
(2000) to consider B. lactis as a subjective synonym of the earlier described B. animalis
(Mitsuoka, 1969; Scardovi and Trovatelli, 1974) as well as to reclassify B. lactis as a
subspecies of B. animalis, namely B. animalis subsp. lactis and B. animalis subsp. animalis
(Ventura and Zink, 2002). As shown in Figure 1, reference strains of B. lactis and B. animalis
grouped in two separate clusters. These results suggest that future taxonomic proposals on
the unification of these two species should take into account their pronounced genotypic
heterogeneity displayed by BOX-PCR fingerprinting. Likewise, Sakata and co-workers (2002)
recently suggested to unify the species B. longum, B. infantis and B. suis, whereas in our
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study strains belonging to each of these three species could be easily differentiated with BOX-
PCR fingerprinting.
A good correlation was obtained when comparing the BOX-PCR identification results
of faecal isolates with protein profiling and Multiplex-PCR, respectively. As an exception, one
isolate identified by Multiplex-PCR as B. infantis clustered together with representatives of
B. longum within the BOX-PCR reference frame, which may be a reflection of the phylogenetic
relatedness of these 2 species (Sakata et al., 2002). Overall, no pronounced effect was
observed from the addition of unknown isolates on the stability of the cluster analysis based
on the BOX-PCR banding patterns of the reference strains. However, it is important to realise
that the continuous addition of new isolates encompassing a large taxonomical and/or
geographical diversity may lead to a minor shift of the reference framework.
In conclusion, rep-PCR fingerprinting using the BOXA1R primer is a rapid, easy to
perform and reproducible method that is suitable for a high throughput of Bifidobacterium
strains. It is a highly discriminatory technique that permits differentiation at the species, subspecies
and potentially up to the strain level. In our opinion, this technique is a promising tool for the
identification of bifidobacteria originating from all kinds of environments.
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Figure 2. Dendrogram generated after the cluster analysis of digitized BOX-PCR fingerprints of the 80
Bifidobacterium type and reference strains and 48 bifidobacterial isolates. The dendrogram was
constructed using the unweighted pair-group method using arethmetic averages with correlation levels
expressed as a percentage values of the Pearson correlation coefficient.
CFPL: Collection de la Faculté de Pharmacie de Lille
R: Research collection, Laboratory of Microbiology, Ghent University
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Summary
The taxonomic standing of Bifidobacterium lactis and Bifidobacterium animalis
was investigated using a polyphasic approach. Sixteen representatives of both taxa were
found to be phenotypically similar and shared more than 70 % DNA-DNA relatedness (76-
100 %), which reinforces the conclusions of previous studies in which B. lactis and B. animalis
were considered as one single species. However, the results of protein profiling, BOX-PCR
fingerprinting, Fluorescent Amplified Fragment Length Polymorphism (FAFLP) and atpD
and groEL gene sequence analysis demonstrate that representatives of B. animalis and B.
lactis constitute two clearly separated subgroups. This subdivision was also phenotypically
supported based on the ability to grow in milk. Given the fact that B. lactis Meile et al. 1997
has to be considered as a junior synonym of B. animalis (Mitsuoka, 1969) Scardovi and
Trovatelli 1974, our data indicate that the latter species should be split up in two new subspecies,
i.e. Bifidobacterium animalis subsp. animalis subsp. nov. (type strain R101-8T = LMG
10508T = ATCC 25527T = DSM 20104T = JCM 1190T) and Bifidobacterium animalis
subsp. lactis subsp. nov. (type strain UR1T = LMG 18314T = DSM 10140T = JCM 10602T).
Keywords: Bifidobacterium animalis, Bifidobacterium lactis, polyphasic taxonomy,
reclassification
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Introduction
The taxonomic standing of the species Bifidobacterium lactis has been much debated
since its description by Meile et al. (1997), and several studies have investigated its affiliation
with the closely related but earlier described Bifidobacterium animalis (Scardovi and
Trovatelli, 1974). Based on phenotypic characteristics, 16S rDNA sequence analysis and
DNA-DNA hybridisation, Cai et al. (2000) proposed that B. lactis should be considered as
a junior synonym of B. animalis. However, new genotypic evidence, recently reported by
Ventura and Zink (2002, 2003) and Zhu et al. (2003), suggested that B. lactis and B. animalis
should still be considered as two separate taxonomic entities, not at the species level but at the
subspecies level.
Compared to B. animalis, strains of B. lactis exhibit an elevated oxygen tolerance,
which is a remarkable trait within the bifidobacteria that allows organisms to reach high numbers
in commercial products under non-anaerobic conditions. Because of this, B. lactis strains are
frequently applied in probiotic dairy products, food supplements and pharmaceutical
preparations (Prasad et al., 1998). In order to guarantee the quality and the label correctness
of such products, it is thus very important that the taxonomic position of this industrially applied
microorganism is well clarified.
The aim of this polyphasic study was to investigate the taxonomic relationship between
B. animalis and B. lactis on the basis of DNA-DNA hybridisation, mol% G+C determination,
sugar fermentation patterns, the ability to grow in milk, protein profiling, BOX-PCR and
Fluorescent Amplified Fragment Length Polymorphism (FAFLP) fingerprinting and atpD and
groEL gene sequence analysis.
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Materials and methods
Bacterial strains and cultivation
The 16 Bifidobacterium strains used in this study, namely B. animalis LMG 10508T, LMG 18900
and NCC 273 and B. lactis LMG 18314T, LMG 11615, LMG 18906, LMG 11580, NCC 239, NCC 282, NCC
311, NCC 330, NCC 362 (= Bb12, Chr. Hansen, Denmark), NCC 363, NCC 383, NCC 387 and NCC 402 were
obtained from the BCCM/LMG Bacteria Collection, Ghent University, Belgium (http://www.belspo.be/
bccm/lmg.htm) or from the Nestlé Culture Collection (NCC), Nestlé Research Centre, Lausanne, Switzerland
(additional descriptive data are available as supplementary Table 1). All strains were grown overnight at
37 °C under anaerobic conditions (84 % N
2
, 8 % H
2
, 8 % CO
2
) on modified Columbia agar comprising 23
g special peptone (Oxoid), 1 g soluble starch, 5 g NaCl, 0.3 g cystein-HCl-H
2
O (Sigma), 5 g glucose and
15 g agar dissolved in 1 litre of distilled water (BCCM/LMG, Medium 144).
Phenotypic characterization
Strains were phenotypically characterized using the AN MicroPlate system (Biolog) according
to the instructions of the manufacturer. Cells were subcultured twice on modified Columbia agar, after
which the MicroPlates were incubated under a hydrogen-free anaerobic atmosphere (100 % CO
2
) during
24 h. The MicroPlates were spectrophotometrically read using the Biolog Micro Station-reader. The
ability to ferment starch was tested separately by inoculation of the strains on modified Columbia agar
depleted of the usual carbon sources and subsequently supplemented with an equal amount (w/v) of
soluble starch. After incubation under anaerobic conditions at 37 °C during 72 h, a lugol solution (0.5 %
I
2
 + 1 % KI in distilled water) was poured on the growth zone and visually checked for a hydrolysis halo.
DNA-DNA hybridisation and mol% G+C determination
High molecular weight-DNA for DNA-DNA hybridisations and mol% G+C determination was
prepared using a combination of the protocols of Marmur (1961) and Pitcher et al. (1989), as described by
Goris et al. (1998). DNA base compositions were determined by the method of Mesbah et al. (1989). DNA
was enzymatically digested into deoxyribonucleosides and separated by HPLC using a Waters Symmetry
Shield C8 column thermostatted at 37 °C. The solvent used was 0.02 M NH
4
H
2
PO
4
 pH 4.0 with 1.5 %
acetonitrile. Unmethylated lambda phage DNA (Sigma) was used as the calibration reference. DNA-
DNA hybridisations were performed with biotin-labelled probes in microplate wells (Ezaki et al. 1989),
using a HTS7000 Bio Assay Reader (Perkin Elmer) for the fluorescence measurements. The hybridisation
temperature was 45 °C in the presence of 50 % formamide. Reciprocal experiments were performed for
every pair of strains.
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Fingerprinting techniques
Sodium Dodecyl Sulphate-Polyacrylamide Gelelectrophoresis (SDS-PAGE) analysis of whole-
cell proteins, using standardized conditions for comparison with the laboratory-based protein pattern
database, was performed according to Pot et al. (1994).
Microscale DNA extraction was based on the method of Pitcher et al. (1989) with slight modifications as
described earlier (Masco et al., 2003). Microscale DNA extracts were used for BOX-PCR and FAFLP
fingerprinting. Repetitive sequence-based (rep-) PCR fingerprinting using the BOXA1R primer was
carried out as described previously (Masco et al., 2003). FAFLP template preparation was carried out
essentially as described by Thompson et al. (2001) with slight modifications. High-molecular DNA was
digested with TaqI (Westburg) and EcoRI (Amersham Pharmacia Biotech). For the pre-selective PCR the
E00 primer (5’-GACTGCGTACCAATTC-3’, 1 µM) and T00 primer (5’-CGATGAGTCCTGACCGA-3’, 5
µM) (Sigma-Genosys) were used. The initial denaturation step was performed at 94 °C. In the selective
PCR, the E01-6FAM primer (5’-6FAM-GACTGCGTACCAATTCA-3’, 1 µM) and T01 primer (5’-
CGATGAGTCCTGACCGAA-3’, 5 µM) (Sigma-Genosys) were used. The selective PCR products were
separated on a denaturing polyacrylamide gel (10.6 % v/v acrylamide, 36 % w/v urea, 1 % w/v resine and
10 % v/v 1x TBE in HPLC water) in 1x TBE buffer. Numerical analysis was performed with BioNumerics
V2.5 software (Applied Maths).
Sequencing of the atpD and groEL genes
For sequencing of the atpD and groEL genes, DNA was prepared as previously described
(Ventura et al., 2001). An 1133 bp fragment of atpD and an 1158 bp fragment of groEL were amplified
using oligonucleotide primers atp-1 (5’-CACCCTCGAGGTCGAAC-3’, position 180 of B. longum NCC
2705) and atp-2 (5’-CTGCATCTTGTGCCACTTC-3’, position 1313 of B. longum NCC 2705), and gro-1
(5’-GACCATCACCAACGATG-3’, position 138 of B. longum NCC 2705) and gro-2 (5’-
GCTCCGGCTTGTTGGC-3’, position 1296 of B. longum NCC 2705), respectively. Each PCR mixture (50
˜l) contained 20 mM Tris-HCl, 50 mM KCl, 200 ˜ M of each deoxynucleoside triphosphate, 50 pmol of
each primer, 1.5 mM of MgCl
2
 and 1 U of Taq DNA polymerase (Gibco BRL). The PCR cycling profile
consisted of an initial denaturation step of 3 min at 95 °C, followed by amplification for 30 cycles as
follows: denaturation (30 sec at 95 °C), annealing (30 sec at 50 °C) and extension (2 min at 72 °C), and
completed with an elongation phase (10 min at 72 °C). The resulting amplicons were separated on a 1 %
agarose gel followed by ethidium bromide staining. PCR fragments were purified using the PCR purification
kit (Qiagen) and were subsequently cloned in the pGEM-T Easy plasmid vector (Promega) following
supplier’s instructions. Nucleotide sequencing of both strands from cloned DNA was performed using
the fluorescent-labelled primer cycle-sequencing kit (Amersham Buchler) following supplier’s instructions.
The primers used were: atp-1, atp-2 and gro-1, gro-2 labelled with IRD800 (MWG Biotech). Sequence
alignment was done using the MultiAlign program and the Clustal W program. Dendrograms from gene
116
Part 3 - Experimental work
sequences were drawn using the Clustal X program. All atpD and groEL gene sequences reported in this
study have been deposited at Genbank and their accession numbers are indicated in Figure 3.
Growth performance in milk
The ability to grow in milk was checked by measuring changes in the impedance of the milk
medium using the Rapid Automated Bacterial Impedance Technique (Don Whitley System). This system
measures the transformation of polar uncharged lactose into charged lactic acid via changes in the
electric conductivity. The changes vs incubation time curve is proportional to the acidification of the
medium that was measured with a pH electrode. The bacterial growth was measured as cfu ml-1. To
determine the cell yield, fermentations were performed using Skim milk (Difco) medium. Anaerobic
fermentations were conducted in duplicate and samples were taken periodically during fermentation and
analysed for viable counts using duplicate MRS-cysteine agar plates.
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Results and Discussion
According to the DSMZ Bacterial Nomenclature Up-to-date site (http:// http://
www.dsmz.de/bactnom/bactname.htm), B. lactis is considered as a heterotypic synonym of
B. animalis based on the proposal of Cai et al. (2000). In spite of this proposal, both names
are still regularly used. In the period from January 2001-August 2003 following the proposal
of Cai et al. (2000) to unify B. lactis and B. animalis, the species name B. lactis has been
cited in at least 37 papers. A recent genotypic study of Ventura and Zink (2002) supported
this unification, but also concluded from their Enterobacterial Repetitive Intergenic Consensus
(ERIC)-PCR fingerprinting and 16S–23S Internally Transcribed Spacer (ITS) analysis that
strains formerly classified as B. lactis should be allocated in a subspecies of B. animalis.
The current study was initiated to collect more polyphasic evidence in support of the
subdivision of B. animalis at the subspecies level. DNA base compositions were determined
which ranged from 60.3 mol% to 61.4 mol%, with averages of 61.3 mol% and 61.0 mol%
for representatives of B. animalis and B. lactis, respectively (additional data are available as
supplementary Table 2). DNA-DNA hybridisations were performed using seven strains of
which some were also included in the study of Cai et al. (2000).  Consistent with their findings,
all DNA-DNA reassociation values were above 70 % ranging from 76 to 100 % and the type
strains of B. lactis and B. animalis displayed at least 90 % DNA relatedness. This is in
contrast with the findings of Meile et al. (1997) who found only 27 % DNA homology between
the type strain of B. lactis and B. animalis using a rather unusual technique based on
hybridization of uniformly labeled EcoRI-restricted chromosomal DNA of the B. lactis type
strain followed by southern hybridization with the same amounts of EcoRI-restricted DNA of
other Bifidobacterium strains. Based on the narrow % G+C range and the high DNA
reassociation values, our data reinforce the proposal of Cai et al. (2000) to join B. lactis and
B. animalis in one single species for which the name of the oldest description, i.e. B. animalis,
should be maintained according to Rule 42 of the Bacterial Code (1990 Revision) (Lapage et
al., 1992).
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Following a polyphasic approach, all B. animalis and B. lactis strains were subjected
to a number of techniques that have the potential to unravel relationships at the subspecific
level which included protein and DNA (BOX-PCR and FAFLP) fingerprinting as well as
atpD and groEL gene sequence typing. Furthermore, the ability of some strains to grow in
milk was determined. As further discussed below, the overall result of this approach showed
that each of these methods allowed the unambiguous separation of B. animalis from B. lactis.
In case of SDS-PAGE protein profiling, BOX-PCR and FAFLP, the resulting B. lactis and
B. animalis clusters exhibited similarity levels that were comparable to those between clusters
of other Bifidobacterium species (data not shown). The results of the numerical analysis of
the SDS-PAGE protein patterns are shown in Figure 1. After numerical comparison of the
digitized protein electrophoretic fingerprints, two well-delineated clusters were observed which
corresponded to strains previously assigned to B. animalis and B. lactis, respectively. Given
the fact that protein profiling displays a lower taxonomic resolution compared to genotypic
techniques such as rep-PCR and FAFLP, these findings indicate that both species are distinct
from each other on a phenotypic basis. As shown previously by BOX-PCR fingerprinting
(Masco et al., 2003), reference strains of B. lactis and B. animalis group in two separate
clusters indicating their pronounced genotypic heterogeneity. In the present study, BOX-PCR
was performed on additional strains from the NCC, which demonstrated the robustness of
these genotypic subgroups (data not shown). Recently, Ventura and Zink (2002) reported
that rep-PCR targeting the ERIC element also allowed to differentiate between type and
reference strains of B. animalis and B. lactis, respectively. FAFLP exhibits a slightly higher
resolution than BOX-PCR fingerprinting and is considered, along with Pulsed-Field Gel
Electrophoresis (PFGE), as the most discriminating genotypic technique. Clustering of the
FAFLP banding patterns of 14 strains studied, resulted in two clusters representing B. animalis
and B. lactis at a cut-off level of 59 % (Figure 2).
The partial nucleotide sequences of the atpD and groEL genes from Bifidobacterium
strains belonging to B. lactis and B. animalis species were determined and phylogenetic
trees based on these data were constructed. The topology of the atpD and groEL-based
trees was highly comparable (Figure 3). In these trees, Bifidobacterium strains were grouped
into two clusters. Cluster I contained only the type strain of B. animalis and the reference
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Figure 1. Dendrogram of protein profiles calculated by the unweighted pair-group method using arithmetic
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strain ATCC 27672, whereas cluster II contained six representatives of B. lactis including its
type strain. Twenty-eight nucleotide substitutions were observed between the atpD gene
sequences of B. lactis DSM 10140T and B. animalis ATCC 25527T. Likewise, 31
synonymous nucleotide substitutions were noticed between the groEL gene sequences of the
two type strains. The phylogenetic distances calculated from the nucleotide substitution ratios
at synonymous positions in the atpD and groEL genes were examined for all possible
combinations of these Bifidobacterium genes. A significant correlation between the
phylogenetic distances in the atpD genes and those in the groEL genes was observed. This
result was not unexpected, because it has been demonstrated that a synonymous substitution
rate is constant for many chromosomal genes in many organisms, and can thus serve as a
molecular clock of their evolution (Lawrence et al., 1991). Noteworthy, a clear separation of
B. animalis ATCC 25527T and B. lactis DSM 10140T was not possible based on 16S
rDNA sequence analysis since their sequences displayed at least 98.8 % homology (Cai et
al., 2000).
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B. lactis NCC 402 (AY488177)
B. lactis ATCC 27674 (AY488179)
B. lactis DSM 10140T (AY488180)
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Figure 3. Phylogenetic trees of B. animalis and B. lactis strains drawn using the Clustal X program. (a)
Tree based on partial groEL sequences (1158 base positions). (b) Tree based on partial atpD sequences
(1133 base positions). Accession numbers are given in parentheses. Bars indicate evolutionary distance.
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Twelve B. lactis and B. animalis strains used in this work were tested for their ability
to grow on a milk based medium during which growth was monitored by measuring changes
in conductance. When the milk medium was inoculated with 106 cfu ml-1, only B. lactis strains
DSM 10140T, NCC 363, NCC 383, NCC 311, NCC 387, NCC 402, NCC 239, ATCC
27673, ATCC 27674, and ATCC 27536 showed an increase in conductivity whereas B.
animalis ATCC 25527T and ATCC 27672 did not reveal any changes in the impedance
values of the milk medium. All B. lactis strains maintained viable counts greater than 2x 108
cfu ml-1 throughout the 24 h of fermentation and displayed differences in growth of 1.5 log
(Figure 4a). On the other hand, B. animalis ATCC 25527T and ATCC 27672 did not reveal
any significant growth and their viable counts dropped steadily to below the value of 5x 107
cfu ml-1 with small differences (below 0.5 log) in relative growth (Figure 4b). Collectively,
these findings indicate that only B. lactis has the potential to grow in milk or milk-based
media.
As could be expected from the results of Cai et al. (2000), the carbohydrate-
fermentation patterns of B. animalis and B. lactis were very similar based on the examination
of 95 different carbon sources. As some characters varied from strain to strain, it was not
possible to define a species-specific pattern for representatives of B. animalis and B. lactis.
This is clearly illustrated by the fact that, of all tested carbon sources, only dextrin, α-D-
glucose, maltose, maltotriose, D-raffinose and sucrose were fermented by all tested strains.
At the individual strain level, only strains NCC 311 and NCC 362 displayed an identical
fermentation behavior. In addition to the AN MicroPlate characterization, the ability to
ferment starch was verified based on the formation of a hydrolysis halo on M144-medium
depleted of the usual sugars and supplemented with 0.6 % soluble starch. Meile et al. (1997)
asserted that the non-utilisation of starch by B. lactis was a major difference between both
species. However, consistent with the findings of Cai et al. (2000) and Lauer and Kandler
(1983), we observed that both species were unable to use this carbon source.
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In support of the proposal of Cai et al. (2000), the DNA-DNA hybridisation data
and phenotypic results reported in this study evidence that B. animalis and B. lactis belong to
one single species. However, results of protein profiling, genotypic analyses and growth
evaluation in milk indicate that both these taxa are clearly different. Based on the fact that
members of both species share more than 70 % DNA-DNA relatedness, B. lactis should be
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Figure 4. (a) Bar diagram representing viable counts at t = 0 and t = 24 h; (b) Bar diagram
reflecting the difference in viable counts after 24 h of incubation.
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reclassified as B. animalis, as required by Rule 42 of the Bacterial Code (1990 Revision)
(Lapage et al., 1992). Taking into account that strains formerly assigned to B. animalis and
B. lactis can be clearly distinguished at the intraspecific level, we propose to create two
subspecies in B. animalis, for which the names B. animalis subsp. animalis and B. animalis
subsp. lactis are suggested, respectively.
The following descriptions are based on data obtained from the present study and on
previously reported data (Scardovi and Trovatelli, 1974; Meile et al., 1997).
Description of B. animalis
Strains display the following characteristics typical for the genus Bifidobacterium: Gram-
positive, non-motile, non-spore forming, irregular rod-shaped anaerobes. Glucose is fermented
using the characteristic enzyme fructose-6-phosphate phosphoketolase in the so-called Bifidus-
shunt. Dextrin, α-D-glucose, maltose, maltotriose, D-raffinose and sucrose are fermented,
starch is not fermented.
Description of B. animalis subsp. animalis subsp. nov.
Strains display characteristics typical for the species B. animalis as reported above. The
optimum growth temperature is 39 to 41 °C. No growth occurs in slants incubated in air or in
air enriched with carbon dioxide. No growth occurs in milk or milk-based media. Lactate and
acetate are produced in a molar ratio of 1:3.6 ± 0.3. Strains originate from the faeces of rats.
The G+C content of the DNA is 61.3 ± 0.0 %.
Type strain: Bifidobacterium animalis subsp. animalis R101-8 (LMG 10508T = ATCC
25527T = DSM 20104T = JCM 1190T).
Description of B. animalis subsp. lactis subsp. nov.
Strains display characteristics typical for the species B. animalis as reported above. The
optimum growth temperature is 39 to 42 °C. No growth occurs on agar-plates exposed to
air, but B. animalis subsp. lactis tolerates 10 % of oxygen in the headspace atmosphere
above liquid media. Growth occurs in milk or milk-based media. The molar ratio of acetate to
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lactate from glucose metabolism is about 10 to 1 under anaerobic conditions, e.g. lactate
production is replaced by formate production. Strains have been isolated from fermented
milk samples, human and infant faeces, rabbit and chicken faeces and from sewage. The G+C
content of the DNA is 61.0 ± 0.5 %.
Type strain: Bifidobacterium animalis subsp. lactis UR1 (LMG 18314T = DSM 10140T =
JCM 10602T).
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Supplementary data
Species Strain designation* Biological PFGE Reference
origin fingerprint type
B. animalis LMG 10508
T
= ATCC 25527
T
= Rat feces I Scardovi and Trovatelli, 1974
DSM 20104
T
= JCM 1190
T
B. animalis LMG 18900 Unknown I Masco et al. , 2003
B. animalis NCC 273 = ATCC 27672 Rat feces II Scardovi and Trovatelli, 1974
B. lactis LMG 18314
T
= DSM 10140
T
= JCM 10602
T Yoghurt III Meile et al. , 1997
B. lactis LMG 11615 Unknown V Masco et al. , 2003
B. lactis LMG 18906 = ATCC 27674 = JCM 7117 Rabbit feces III Scardovi and Trovatelli, 1974
B. lactis LMG 11580 = ATCC 27536 = DSM 20105 Chicken feces III Scardovi and Trovatelli, 1974
= JCM 1253
B. lactis NCC 239 Human feces III Ventura and Zink, 2002
B. lactis NCC 282 = ATCC 27673 Sewage VI Scardovi and Trovatelli, 1974
B. lactis NCC 311 Human feces IV Ventura and Zink, 2002
B. lactis NCC 330 Unknown III This study
B. lactis NCC 362 = Bb12 Yoghurt III Cai et al ., 2000
B. lactis NCC 363 Human feces III Ventura and Zink, 2002
B. lactis NCC 383 Yoghurt III Ventura and Zink, 2002
B. lactis NCC 387 Infant feces III Ventura and Zink, 2002
B. lactis NCC 402 Yoghurt III Ventura and Zink, 2002
Supplementary Table 1. Strains used of the species B. animalis and B. lactis
*
T
, type strain; LMG, BCCM
TM
/LMG Bacteria Collection; ATCC, American Type Culture Collection; NCC, Nestlé Culture Collection
Species Strain G+C content
(mol%)
L
M
G
1
0
5
0
8T
L
M
G
1
8
9
0
0
L
M
G
1
8
3
1
4T
L
M
G
1
1
6
1
5
L
M
G
1
8
9
0
6
L
M
G
1
1
5
8
0
L
M
G
1
5
1
3
2T
B. animalis LMG 10508
T 61.3 100 95 90 76 91 94 1
LMG 18900 61.3 100† 100 91 80 96 91
B. lactis LMG 18314
T 60.3 90 93 100 89 100† 100† 1
LMG 11615 61.1 97 91 100† 100 100† 100†
LMG 18906 61.4 85 83 93 85 100 97
LMG 11580 61.3 89 90 94 86 100† 100
Lb. kefirgranum LMG 15132
T 1 1 100
† Values over 100 % were cut down to 100 %
Supplementary Table 2. DNA base compositions and levels of DNA relatedness of B. lactis and B. animalis.
% DNA-DNA reassociation*
* Results are expressed as means of four determinations. Reciprocal hybridisations showed a maximum standard deviation of 7 %.

Chapter 4
Culture-dependent and culture-independent microbial analysis of
probiotic products claiming to contain bifidobacteria
4.1. Culture-dependent and culture-independent
qualitative analysis of probiotic products
claiming to contain bifidobacteria
Masco L., Huys G., De Brandt E., Temmerman R. and
Swings J. (2005). International Journal of Food
Microbiology 102:221-230.
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Summary
A total of 58 probiotic products obtained worldwide, which were claimed to contain
Bifidobacterium strains (including 22 yoghurts, 5 dairy fruit drinks, 28 food supplements and
3 pharmaceutical preparations) were investigated in parallel using a culture-dependent and a
culture-independent approach. Three isolation media previously reported as selective for
Bifidobacterium were evaluated for their suitability in the quality analysis of these products.
Subsequently, possible bifidobacterial colonies were picked from the best medium and identified
by means of rep-PCR fingerprinting using the BOXA1R primer (BOX-PCR). Bifidobacterium
animalis subsp. lactis, formerly classified as Bifidobacterium lactis, was most frequently
found, but strains belonging to Bifidobacterium longum biotypes longum and infantis,
Bifidobacterium bifidum, and Bifidobacterium breve were recovered also. In parallel, all
products were also subjected to culture-independent analysis which involved a nested-PCR
step on total bacterial DNA extracted directly from the product, followed by separation of the
amplicons by Denaturing Gradient Gel Electrophoresis (DGGE) and subsequent identification
of species from the band patterns. By conventional cultivation, 70.7 % of the products analysed
were found to contain culturable bifidobacteria whereas by culture-independent DGGE analysis,
members of the genus Bifidobacterium could be detected in 96.5 % of the analysed products.
Genotypic characterization of a number of bifidobacterial isolates at the strain level by means
of Pulsed-Field Gel Electrophoresis (PFGE) revealed a relatively high degree of genomic
homogeneity among the Bifidobacterium strains currently used in the probiotic industry.
Keywords: Bifidobacterium, probiotic products, DGGE, BOX-PCR, PFGE
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Introduction
Together with Lactobacillus species, bifidobacteria are the most commonly used
group of lactic acid bacteria (LAB) in the production of human probiotics. In particular, strains
of Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Bifidobacterium breve
and Bifidobacterium longum biotypes infantis and longum are often implemented in probiotic
products in combination with other LAB.  Despite the fact that the use of probiotics to improve
human health has gained widespread popularity in recent years, there is a growing concern on
the side of consumers and consumer organisations regarding the quality and the labelling of
commercial probiotic products. A number of studies have demonstrated that the recovery of
the incorporated probiotic organisms including bifidobacteria is often poor and that more
attention should be paid to describe the identity, safety and functionality of these microorganisms
more accurately (Hamilton-Miller et al., 1999; Temmerman et al., 2003a).
Ideally, microbial analysis of Bifidobacterium-containing products for taxonomic
purposes requires standardized and accurate procedures for both the isolation and the
identification of the implemented bifidobacterial strains. In practice, however, enumeration
and isolation of probiotic bifidobacteria from a product is still problematic since there is no
standard medium available that allows selective differentiation of bifidobacteria from other
LAB. Currently available isolation media are usually insufficiently selective or elective, which
in both cases results in inaccurate and/or irreproducible quantitative results (Roy, 2001), and
many of them are not commercially available and hence laborious to prepare. Nevertheless,
plate count methods are still routinely used in the quality control assessment of probiotic
products often being followed by identification of a limited number of isolates at the species
level.  A variety of methods mainly based on DNA fingerprinting (Masco et al., 2003; Ventura
et al., 2003) or on sequence analysis of ribosomal and housekeeping genes (Matsuki et al.,
1999; Zhu et al., 2003) are currently available for the reliable speciation of bifidobacteria.  In
contrast, very few studies have attempted to differentiate bifidobacterial isolates from probiotic
products at the individual strain level although this is an important tool in functionality and
safety assessments.
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The combination of a conventional isolation strategy with culture-dependent
identification usually renders microbial analysis of probiotic products relatively time consuming,
and results may be biased by poor viability or low densities of the target organism. For this
reason, culture-independent analysis has recently been promoted as an alternative and/or
complementary approach for quality control measurements of probiotic products (Temmerman
et al., 2003b, c). Essentially, this cultivation-independent detection and identification is based
on extraction of total bacterial DNA from the probiotic product followed by selective
amplification of a specific part of the bacterial 16S rRNA gene and separation of the resulting
amplicons by Denaturing Gradient Gel Electrophoresis (DGGE).
In the present study, we compared the performance of a culture-dependent and a
culture-independent approach to study the taxonomic composition of 58 worldwide collected
probiotic products labeled as containing Bifidobacterium. Culture-dependent analysis involved
the evaluation and use of Bifidobacterium-selective media, followed by repetitive sequence-
based (rep-) PCR fingerprinting and Pulsed-Field Gel Electrophoresis (PFGE) of a selection
of isolates. In parallel, all products were also subjected to a culture-independent analysis
based on DGGE analysis of 16S rDNA nested-PCR products.
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Material and methods
Evaluation of isolation media
Three media developed for the isolation of bifidobacteria, namely Dicloxacillin-Propionic acid
medium (DP), Bifidobacterium medium (BFM) and Arroyo, Martin and Cotton agar (AMC), were prepared
as described previously (Bonaparte et al., 2001; Nebra and Blanch, 1999; Payne et al., 1999). Their ability
to support growth of probiotic Bifidobacterium strains and to inhibit growth of yoghurt starter cultures
and probiotic non-bifidobacteria was assessed using the organisms listed in Table 1. The capacities of
the selected Bifidobacterium strains to grow on the three selective media were evaluated quantitatively
against their growth on a reference medium, Modified Columbia Agar [MCA; 23 g special peptone (L72,
Oxoid, Drongen, Belgium), 1 g soluble starch, 5 g NaCl, 0.3 g cystein-HCl-H
2
O (C-4820, Sigma, Bornem,
Belgium), 5 g glucose and 15 g agar dissolved in 1 litre of distilled water]. Depending on the result
obtained with each of the type strains using the spread or pour plate technique, the other reference
strains of the corresponding species were grown using the best plating technique. All cultures were
incubated overnight at 37 °C under anaerobic conditions (84 % N
2
, 8 % H
2
, 8 % CO
2
) on MCA.
Subsequently, a suspension of each strain with an optical density (600nm) (OD
600
) of approximately 0.2
was prepared in 10 ml Modified Columbia Broth (MCB). A serial dilution was prepared in peptone
physiological saline solution [PPS, 0.1 % (w/v) Bacteriological Peptone (L37, Oxoid) and 0.85 % (w/v)
NaCl in distilled water] of which the 10-4 – 10-6 dilutions were plated in triplicate on each of the three test
media and on MCA. For spread plating, 50 µl of each dilution was plated whereas in case of the pour
plate technique, 1 ml of each dilution was pipetted in a petri dish to which medium cooled to 55 °C was
added. All plates were subsequently incubated anaerobically at 37 °C. After 72 h of incubation, colonies
were counted and the number of CFU ml-1 was determined.
In a second part of the growth evaluation the performances of the three Bifidobacterium
specific selective media were tested for a selection of yoghurt starter cultures, probiotic non-bifidobacteria
and strains of Bifidobacterium animalis subsp. lactis. Bifidobacterial isolates were grown in MCB and
incubated anaerobically at 37 °C, whereas non-bifidobacteria were inoculated into MRS broth and
incubated as recommended (http://www.belspo.be/bccm/lmg.htm). From an overnight grown culture, 1
ml was plated using the pour plate technique after which the plates were incubated anaerobically at 37 °C
for 72 h. Growth was scored as positive or negative based on the visible presence or absence of colonies,
respectively.
Probiotic products
The 58 probiotic products collected from 13 countries comprised 22 yoghurts, 28 food
supplements, 5 dairy fruit drinks and 3 pharmaceutical preparations. After purchase, the recommended
storage conditions were maintained. All products were analysed before the end of their shelf-life.
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Bacterial isolation
Depending on the type of product, 1 ml of product was dissolved in 9 ml PPS (dairy products)
or a 10-1 dilution was prepared by adding the appropriate amount of PPS to a weighted amount of product
(food supplements and pharmaceutical preparations). A 10-fold dilution series was prepared in PPS and
pour plated using the most suitable isolation medium, i.e. DP and/or BFM. All plates were incubated
anaerobically at 37 °C for 72 h. Subsequently, 10 colonies/product/isolation medium were picked and
purified on MCA. Products, which yielded no colonies were subjected to a second isolation procedure
after enrichment in MCB.
DNA extraction
Extraction of total genomic DNA from pure cultures was based on the method of Pitcher et al.
(1989) with slight modifications as described by Masco et al. (2003). Extraction of total bacterial DNA
from the probiotic product was also based on the method of Pitcher et al. (1989) with slight modifications
depending on the product type as described by Temmerman et al. (2003b).
Nested PCR, DGGE analysis and gel processing
Nested PCR amplification using Bifidobacterium-specific 16S rDNA primers (Kaufmann et al.,
1997) generated amplicons, which served as templates in the second reaction using primers that multiply
the V3 region of the bacterial 16S rRNA gene. The resulting V3 amplicons were analysed on 50-70 %
DGGE gels. Every six lanes a reference DNA ladder was loaded (Temmerman et al., 2003c) which allowed
normalization of the gels by reference to the standard pattern. Subsequently, every band position within
a lane was compared with those of identified reference strains present in a user-generated BioNumerics
database (Applied Maths, Sint-Martens-Latem, Belgium) (Temmerman et al., 2003c).
Identification of bacterial isolates
Isolates were first identified as members of the genus Bifidobacterium by subjecting DNA
obtained from alkaline extraction to PCR amplification using genus-specific primers (Kaufmann et al.,
1997). After agarose gel electrophoresis, three confirmed bifidobacterial isolates per product and isolation
medium were retained for further identification at the species level, using BOX-PCR fingerprinting, as
described previously (Masco et al., 2003).
Typing of bifidobacterial isolates
The genotypic relatedness among the isolates was assessed by means of Pulsed-Field Gel
Electrophoresis (PFGE) typing. The preparation of genomic DNA for PFGE was performed in situ in
agarose blocks, according to the method of Hung and Bandzulius (1990) with slight modifications
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(Neysens et al., 2003). Genomic DNA was digested overnight at 37 °C with restriction endonuclease SpeI
(20U) (Promega, Madison WI, US). Macrorestriction fragments were separated on a 1.1 % PFGE-certified
agarose gel (Bio-Rad, Nazareth Eke, Belgium) in 0.5x TBE (10x TBE: 108 g Tris-base; 55 g Boric acid; 9.3
g Na
2
 EDTA 2H
2
O) using the CHEF Mapper pulsed-field electrophoresis system (Bio-Rad) with the two-
state algorithm program (current: 5.3 V cm-1; run time: 24 h; included angle: 120 °; switch time: 2-30 s at 14
°C).
Phenotypic characterization of bifidobacterial isolates
Strains were phenotypically characterized using the AN MicroPlate system (Biolog) according
to the instructions of the manufacturer. Cells were subcultured twice on MCA, after which the MicroPlates
were incubated under a hydrogen-free anaerobic atmosphere (100 % CO
2
) during 24 h. The MicroPlates
were spectrophotometrically read using the Biolog Micro Station-reader.
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Results
Evaluation of isolation media
The DP medium was developed for the enumeration of bifidobacteria in fermented
milks (Bonaparte et al., 2001) and is based on Columbia agar supplemented with dicloxacillin
for inhibition of streptococci and lactococci (Sozzi et al., 1990) and with propionic acid to
stimulate bifidobacterial growth (Beerens, 1991). DP medium was able to sustain growth of
all tested strains of Bifidobacterium animalis subsp. animalis, Bifidobacterium breve,
Bifidobacterium animalis subsp. lactis and Bifidobacterium longum biotype longum but it
was not able to support growth of Bifidobacterium adolescentis, Bifidobacterium bifidum
and Bifidobacterium longum biotype infantis. However, this medium inhibited growth of
several non-bifidobacteria, such as the yoghurt starter cultures, as well as the (sub)species
Lactobacillus acidophilus, Lactobacillus paracasei subsp. paracasei and Lactococcus
lactis subsp. lactis (Table 1).
BFM is antibiotic-free and includes lactulose as the main carbon source (Nebra and
Blanch, 1999) as well as propionic acid and the inhibitory agents methylene blue and lithium
chloride. BFM was able to sustain growth of all tested strains except for the type strain of
Bifidobacterium bifidum and strain LMG 11084 of Bifidobacterium breve. Overall, colonies
obtained on BFM tended to be very small and hence difficult to pick. BFM did not allow
growth of the yoghurt starter cultures and Lactobacillus acidophilus (Table 1).
AMC is based on the commercially available Reinforced Clostridial Agar (CM151,
Oxoid) to which a number of supplements (i.e. lithium chloride, sodium propionate, iodoacetate
and 2,3,5 trifenyltetrazolium) and antibiotics (nalidixic acid, polymyxin B sulphate and kanamycin
sulphate) are added. AMC supported growth of all tested Bifidobacterium strains, but failed
to inhibit growth of several of the most important non-bifidobacteria such as Streptococcus
thermophilus. Thus, none of the media were completely selective for the isolation of
Bifidobacterium in the presence of non-bifidobacteria. The DP and BFM media were
moderately selective and, more importantly, they were complementary in supporting growth
of all tested Bifidobacterium strains. Therefore, for the isolation of bifidobacteria from probiotic
products, DP and/or BFM were used, depending on the species claimed on the product
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label. The pour plate technique was the method of choice for isolation of bifidobacteria from
probiotic products.
Culture-dependent analysis of probiotic products
Analysis of 58 probiotic products yielded 626 isolates of which 434 were confirmed
as bifidobacteria with the genus-specific PCR test. From 15 food supplements (53.6 %), one
pharmaceutical preparation (33.3 %) and one yoghurt (4.6 %), no bifidobacteria could be
recovered, even after a second round of isolation following enrichment in MCB. Because
none of the isolation media used in this study were totally selective, it was not possible to
obtain specific bifidobacterial counts. The total counts obtained either on DP or BFM from
yoghurts and dairy fruit drinks were in the range of 103-108 CFU ml-1 and 104-106 CFU ml-
1, respectively; whereas food supplements and pharmaceutical preparations yielded,
respectively, 102-109 CFU g-1 and 107 CFU g-1 of product.
Of 434 confirmed bifidobacterial isolates, 154 were identified to the species level
with BOX-PCR fingerprinting (Table 2). Bifidobacterium animalis subsp. lactis (in 80 %
of the products) and Bifidobacterium breve (20 %) were the main species isolated from the
dairy fruit drinks, whereas from the yoghurts mainly Bifidobacterium animalis subsp. lactis
(90.9 %) was isolated except for one product, which yielded Bifidobacterium longum biotype
longum isolates (4.55 %). From food supplements, Bifidobacterium animalis subsp. lactis
(28.6 %), Bifidobacterium bifidum (7.1 %) and Bifidobacterium longum biotype longum
(17.9 %) were isolated, whereas from the pharmaceutical preparations Bifidobacterium
bifidum (33.3 %) and Bifidobacterium longum biotype infantis (33.3 %) were the only two
species retrieved.
Culture-independent analysis of probiotic products
Except for one product, the bifidobacterial compositions of the dairy fruit drinks and
the yoghurts as determined by culture-dependent and culture-independent approaches were
comparable. From one product (i.e. Yoghurt natural), no bifidobacteria could be isolated on
DP or BFM whereas DGGE revealed the presence of two Bifidobacterium species. In
contrast, several discrepancies between the methodologies were found with some of the food
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supplements and pharmaceutical preparations. For these products, three types of relationship
between culture-dependent and culture-independent analyses could be distinguished. For 13
products (41.9 %), the results of the analyses coincided. This group included two products in
which no bifidobacteria could be detected using DGGE, which is in agreement with the finding
that bifidobacteria were not recovered on DP or BFM. For 17 products (54.9 %), DGGE
analysis detected more species than were recovered by isolation. For one product (i.e. Friendly
Bifidus), two species were isolated from the product whereas only one was detected with
DGGE.
Typing of bifidobacterial isolates
From the 154 Bifidobacterium isolates subjected to BOX-PCR, a subset of 48
isolates (mainly corresponding to one isolate/species/product) was included for PFGE typing,
to study the genotypic diversity of these commercially used strains. This selection included 39
Bifidobacterium animalis subsp. lactis isolates, six Bifidobacterium longum biotype longum
isolates and three Bifidobacterium bifidum isolates (Table 2). Within the Bifidobacterium
animalis subsp. lactis subset, four PFGE types could be distinguished. The majority of the
isolates gave highly similar or identical macrorestriction patterns with SpeI digestion, whereas
the three remaining isolates gave unique PFGE fingerprints. To verify the robustness of these
clusters, an additional restriction enzyme (i.e. XbaI) was used with a subset of 11 strains
representing all four PFGE types obtained after SpeI restriction analysis. Although the four
PFGE types were not readily distinguishable as with the SpeI restriction patterns, comparable
clusters were obtained. Furthermore, the 6 B. longum biotype longum isolates grouped in
two separate clusters, represented by respectively 5 and one isolate, which was in contrast
with the three B. bifidum isolates each of which gave a unique PFGE fingerprint.
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Species (no. of strains)
a
AMC
b
BFM
b
DP
b
B. adolescentis (n=6) + + -
B. animalis subsp. animalis (n=2) + + +
B. bifidum (n=5) + +, except for LMG 11041
T -
B. breve (n=4) + +, except for LMG 11084 +
B. longum biotype infantis (n=6) + + -
B. animalis subsp. lactis (n=8) + + +
B. longum biotype longum (n=5) + + +
Bacillus sp. (n=1) + + +
E. faecium (n=6) + + +
L. acidophilus (n=7) - - -
L. amylovorus (n=1) + + -
L. delbrueckii subsp. bulgaricus (n=3) - - -
L. crispatus (n=1) - - -
L. johnsonii (n=5) + + -
L. lindneri -like (n=1) + + +
L. paracasei subsp. paracasei (n=3) + + -
L. plantarum (n=2) + + +
L. reuteri (n=2) + + +
L. rhamnosus (n=6) + + +
Lc. lactis subsp. lactis (n=4) + + -
P. acidilactici (n=2) + + +
S. thermophilus (n=13) + - -
b
AMC: Arroyo, Martin and Cotton agar; BFM: Bifidobacterium medium; DP: Dicloxacillin-Propionic acid medium;
Table 1. List of species used for the evaluation of three Bifidobacterium -specific isolation media
+: growth; -: no growth; LMG: BCCM/LMG Bacteria Collection
a
B.: Bifidobacterium; L.: Lactobacillus; Lc.: Lactococcus; S.: Streptococcus; E.: Enterococcus; P.: Pediococcus
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Product name Producing Microbial claim Culture-independent analysis
country on product label BOX-PCR identification PFGE Nested-PCR DGGE
type
a
identification
YOMO Italy Bifidobacterium B. animalis subsp. lactis I B. animalis subsp. lactis
Crema actidrink Germany Bifidobacterium B. animalis subsp. lactis I B. animalis subsp. lactis
Lactis (BB12)
Nutrigen Malaysia Bifidobacterium B. animalis subsp. lactis I B. animalis subsp. lactis
Bio drink Spain Bifidobacterias B. animalis subsp. lactis I B. animalis subsp. lactis
Yakult bifiel Japan B. breve Yakult strain B. breve ND B. breve
Actilus France Bifidobacterium B. animalis subsp. lactis I B. animalis subsp. lactis
Activia France Bifidus essensis B. animalis subsp. lactis I B. animalis subsp. lactis
B’A (citron) France Bifidus Actif B. animalis subsp. lactis I B. animalis subsp. lactis
B’A (vanille) France Bifidus Actif B. animalis subsp. lactis I B. animalis subsp. lactis
Benecol UK Active bifidus B. animalis subsp. lactis I B. animalis subsp. lactis
Bifidus 1 Belgium Bifidus B. animalis subsp. lactis I B. animalis subsp. lactis
Bifidus 2 Belgium Bifidus B. animalis subsp. lactis I B. animalis subsp. lactis
Bifidus 3 Belgium Natural bifidus B. animalis subsp. lactis I B. animalis subsp. lactis
Bifidus nature France Bifidobacterium B. animalis subsp. lactis I B. animalis subsp. lactis
Bifidus y acidophilus Spain Bifidobacterium B. animalis subsp. lactis I B. animalis subsp. lactis
Bio con bifido activo Spain Bifidobacterias B. animalis subsp. lactis I B. animalis subsp. lactis
Bio Life UK No bifidobacteria claimed B. animalis subsp. lactis I B. animalis subsp. lactis
Joghurt Gold Germany B. bifidum B. animalis subsp. lactis I B. animalis subsp. lactis
KYR Italy Bifidobacterium Bb12 B. animalis subsp. lactis I B. animalis subsp. lactis
MIO France Bifidus BL B. animalis subsp. lactis I B. animalis subsp. lactis
Nature bifidus Switzerland Bifidusbakterien B. animalis subsp. lactis I B. animalis subsp. lactis
& acidophilus
Natural bio yoghurt UK Bifidobacteria B. animalis subsp. lactis I B. animalis subsp. lactis
Teddi Italy Bifidobacterium B. animalis subsp. lactis I and II B. animalis subsp. lactis
Vitality Germany Bifidobacterium sp. B. animalis subsp. lactis I B. animalis subsp. lactis
Yogosan Germany Bifidobacterium BB12 B. animalis subsp. lactis I B. animalis subsp. lactis
Lactoferrin yoghurt Japan Bifidus BB536 B. longum biotype longum I B. longum biotype longum
Yoghurt natural Malaysia Bifido bacterium NB B. animalis subsp. lactis,
B. bifidum
Culturelle South-Africa Bifidobacterium longum B. animalis subsp. lactis I B. animalis subsp. lactis
Debaflor Belgium Lactobacillus bifidus B. animalis subsp. lactis I B. animalis subsp. lactis
Ecoflor The Netherlands Bifidobacterium Lactis B. animalis subsp. lactis I B. animalis subsp. lactis
Hygiaflora France B. bifidum B. animalis subsp. lactis III B. animalis subsp. lactis,
B. longum biotype longum
Proflora Belgium Bifidobacterium B. animalis subsp. lactis I B. animalis subsp. lactis
Pronopal plus Belgium No bifidobacteria claimed B. animalis subsp. lactis I B. animalis subsp. lactis
Biodophilus UK Bifidobacterium Bifidum- B. animalis subsp. lactis, I and B. animalis subsp. lactis,
bacteriën stam, INT9 B. bifidum III B. bifidum
Friendly bifidus Malaysia Bifidobacterium longum, B. animalis subsp. lactis, IV and B. animalis subsp. lactis
Bifidobacterium infantis, B. bifidum II
Bifidobacterium lactis,
Bifidobacterium bifidum
Beneflora Belgium Bifidobacterium species B. longum biotype longum I B. animalis subsp. lactis,
Bifidobacterium longum B. longum biotype longum
Combiforte South-Africa Bifidobacterium longum, B. longum biotype longum I B. longum biotype longum
Bifidobacterium bifidum
Infantiforte South-Africa Bifidobacterium infantis B. longum biotype longum I B. longum biotype longum
Table 2. Overview of culture-dependent and culture-independent analysis of 58 probiotic products
Culture-dependent analysis
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Product name Producing Microbial claim Culture-independent analysis
country on product label BOX-PCR identification PFGE Nested-PCR DGGE
type
a
identification
Lactoferrin active Japan B. longum BB536 B. longum biotype longum I B. longum biotype longum
Lola Japan Bifidus B. longum biotype longum II B. longum biotype longum
Bifibiol Malaysia Bifidobacterium bifidum NB B. animalis subsp. lactis,
B. bifidum, B. longum
biotype longum
Bioprotus France Bifidobacterium longum NB B. animalis subsp. lactis,
Bifidobacterium bifidum B. longum biotype
longum, B. bifidum
Decoflor Belgium L. bifidus NB B. animalis subsp. lactis,
B. bifidum
Lacto Ca Canada L. Bifidus NB B. animalis subsp. lactis,
B. bifidum
Lactofer-200 Italy Lactobacillus bifidus NB /
Natural factors Canada B. bifidum NB B. bifidum
Neolactoflorene Capsule Italy Bifido bacterium bifidum NB B. animalis subsp. lactis
Neolactoflorene Flacon Italy Bifido bacterium bifidum NB B. animalis subsp. lactis
Platte buik France Bifidobacterium bifidum NB B. animalis subsp. lactis
Swiss 3 Canada L. Bifidus NB B. animalis subsp. lactis,
B. bifidum
Junior Australia bifido bacteria NG B. animalis subsp. lactis
Platte buik France Bifidobacterium bifidum NG /
Prunellines France Bifidobacterium bifidum NG B. animalis subsp. lactis,
B. longum biotype longum
Transiphyt France Bifidobacterium bifidum NG B. animalis subsp. lactis,
B. bifidum
Vivaflore France Bifidobactérium bifidum NG B. animalis subsp. lactis
Infloran Berna Italy Bifidobacterium bifidum B. bifidum I B. bifidum
Probiotical Belgium Bifidobacterium infantis, B. longum biotype infantis ND B. longum biotype infantis,
B. bifidum
Bifidobacterium lactis
Yovis Italy Bifidobacteria (B. breve, NB B. animalis subsp. lactis
B. infantis, B. longum)
Table 2. Continued
Culture-dependent analysis
NB: no bifidobacteria identified by genus-specific 16S rDNA PCR; NG: no growth.
a
Based on macrorestriction analysis with Spe I
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Discussion
Despite the fact that many media have been described for the elective, selective or
differential enumeration and isolation of bifidobacteria (Roy, 2001), the recovery of these
organisms from food or other matrices remains problematic. For the purpose of isolating
bifidobacteria from probiotic products, three previously described media were evaluated.
Overall, the DP medium produced the highest colony yield of these three despite the fact that
we found it to be too selective. In contrast to the complex compositions of BFM and AMC,
the DP medium is relatively easy to prepare, which makes it more suitable for routine
enumeration of bifidobacteria from probiotic products.  However, to guarantee the isolation
of the entire taxonomic range of currently used probiotic bifidobacteria, the complementary
use of a second medium was indispensable. These findings reinforce the opinion of Pacher
and Kneifel (1996) that reliable enumeration of bifidobacteria can only be achieved successfully
when the particular Bifidobacterium strain used in the product is known. Furthermore, it has
also been shown that the plating methodology can influence the accuracy of bifidobacterial
counts (Payne et al., 1999.). In the present study, the pour plate technique was superior to
spread plating for growth of bifidobacteria, presumably because pour plating is more effective
for creating the anaerobic conditions favorable for these organisms. Additionally, pour plating
facilitated the development of separate colonies.
From both the culture-dependent and culture-independent methodologies, it is clear
that the microbial qualities of the freeze-dried products are not as good as those of the dairy
products. From 16 of the freeze-dried products (51.6 %) it was not possible to isolate
bifidobacteria despite the fact that all but two of these products were found (by nested 16S
rDNA-DGGE analysis) to contain at least one Bifidobacterium species. These findings may
point to the fact that the lyophilization and encapsulation processes significantly reduced the
recovery on DP or BFM media of some Bifidobacterium strains. Furthermore, it is likely that
some of the products no longer contain viable bacteria, which must raise questions about their
claimed probiotic effects. Despite the fact that some of these effects might also be exerted by
dead bacteria, it can be assumed that most of the beneficial effects of probiotics, such as
stimulation of the immune system, anti-tumor activity and reduction of faecal enzyme activity
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require metabolically active cells (Ouwehand and Salminen, 1998). In contrast, only one
yoghurt did not yield viable bifidobacteria despite the fact that DGGE analysis indicated the
presence of Bifidobacterium animalis subsp. lactis and Bifidobacterium bifidum. In the
majority of the cases (i.e. 96,8 %), DGGE was able to detect all or more species than the
culture-dependent approach. However, DGGE analysis does not provide information regarding
the viability of the microorganisms, which highlights the continuing need for culture-dependent
analysis for quality control in the production of probiotic products. In one case, more species
than could be detected by DGGE were isolated. Presumably, the undetected species was
present in numbers beyond the DGGE detection limit of 104 CFU ml-1 (Temmerman et al.,
2003b).
At present, the (sub)species Bifidobacterium bifidum, Bifidobacterium breve,
Bifidobacterium longum biotypes infantis and longum and Bifidobacterium animalis subsp.
lactis, formerly classified as Bifidobacterium lactis (Masco et al., 2004) represent the
Bifidobacterium taxa that are most frequently used as probiotics. After identification of 154
isolates with BOX-PCR fingerprinting, Bifidobacterium animalis subsp. lactis proved to
be the most frequently found species in yoghurts and fruit drinks. It was also present, to a
lesser extent, in food supplements. This was not unexpected since strains belonging to this
subspecies are known to be relatively oxygen tolerant (Meile et al., 1997), which favours the
maintenance of a high number of viable bifidobacteria in a commercial product. In contrast,
Bifidobacterium adolescentis was not found in the present study although strains of this
species have been reported as potential probiotics (Holzapfel et al., 1998).
 For each of the detected Bifidobacterium species macrorestriction analysis with SpeI
indicated that each was represented by a small number of unique types. This was particularly
the case for Bifidobacterium animalis subsp. lactis and the Bifidobacterium longum biotype
longum isolates, most of which (respectively 92.3 % and 83.3 %) gave identical PFGE profiles.
The high level of genotypic relatedness among B. animalis subsp. lactis was also reflected
phenotypically by AN MicroPlate (Biolog) analysis of a subset of eight product isolates
belonging to PFGE types I-IV (data not shown).  Interestingly, one of these isolates was
somewhat atypical by its inability to ferment glucose and its ability to ferment lactose which
was in contrast with all other isolates tested, even the ones belonging to PFGE types II, III
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and IV. Although PFGE is often considered as the gold standard of bacterial typing, this
finding illustrates that caution is needed in the interpretation of such results. Nevertheless, our
PFGE typing data clearly indicate that the number of unique Bifidobacterium animalis subsp.
lactis and Bifidobacterium longum biotype longum strains used as commercial probiotics is
surprisingly low in view of the great diversity of Bifidobacterium-claiming products analyzed
in this study.
In conclusion, this is one of the first studies combining the aspects of isolation, molecular
identification and typing to characterize the taxonomic contents of a worldwide collection of
Bifidobacterium-claiming probiotic products. In agreement with previous product quality
studies (Hamilton-Miller et al., 1999; Temmerman et al., 2003a), our data indicate that a
large number of dried probiotic products inadmissibly lack the presence of any viable
microorganisms and that a rather high percentage of probiotic products are incorrectly labeled
with respect to the identity of the incorporated strains. DGGE proved to be a fast and
reproducible culture-independent approach for taxonomic analysis of probiotic products and
had a greater detection potential than conventional culture-dependent analysis. Nevertheless,
DGGE is unable to provide information on the metabolic status or strain diversity of the
incorporated microorganisms, which makes cultivation indispensable for reliable qualitative
analyses. Demonstration of the presence of viable probiotic microorganisms is only the first
step in the assessment of product quality. Quantitative measurements and assessments of
functionality and safety are other requirements for validation of the quality of a given probiotic
product.
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Summary
The application of real-time PCR targeting the multicopy 16S rRNA gene and the
single copy recA gene was evaluated for the enumeration of bifidobacteria in 29 probiotic
products claimed to contain these organisms. Both assays relied on the use of genus-specific
primers and the non-specific SYBR Green I chemistry. For both applications, the calibration
curve was constructed using the type strain of Bifidobacterium animalis subsp. lactis. Upon
correction with a factor corresponding to the 16S rRNA gene copy number, both assays
generally produced comparable enumeration results. Only in exceptional cases, differences
between both gene targets were found in probiotic products containing low amounts of
bifidobacteria in which case the quantification of the multicopy 16S rRNA gene turned out to
be more sensitive than the recA-based assay. On the other hand, the use of the latter single
copy gene in real-time PCR quantification offers the advantage that no prior knowledge of
bacterial content is required when using genus-specific primers, since no correction for multiple
gene copies has to be performed. Only 11 of the analysed products (38%), including one
dairy based product and ten dried products, contained a minimal Bifidobacterium concentration
of 106 CFU per ml or g of product. Depending on the application, both assays proved to be
rapid and reproducible alternatives for culture-based detection and quantification of
bifidobacteria in probiotic products.
Keywords: Real-time PCR, 16S rRNA gene, recA gene, Bifidobacterium, probiotic products
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Introduction
Bifidobacteria are natural inhabitants of the human gastrointestinal tract and are known
to contribute to a balanced intestinal microflora. Because of their probiotic potential, interest
in the commercial exploitation of selected bifidobacterial strains in the functional food industry
is growing rapidly. In parallel, this evolution has stimulated the need for advanced methods to
perform qualitative and quantitative control measurements of newly developed probiotic
products. In terms of quantification, traditional culture-dependent methods are still frequently
used despite the fact that they are labour intensive and time consuming. In case of bifidobacteria,
the reliability of many enumeration procedures is compromised by the lack of suitable media
for the selective isolation of these organisms from probiotic products, which often also contain
other lactic acid bacteria such as lactobacilli and Streptococcus thermophilus (Hamilton-
Miller et al., 1999; Temmerman et al., 2003; Masco et al., 2005). Triggered by these
shortcomings, culture-independent methods such as enzymatic-colorimetric assays (Bibiloni
et al., 2000) and real-time PCR (Vitali et al., 2003) have been developed for the enumeration
of bifidobacteria in probiotic products that overcome the limitations of conventional cultivation.
Real-time PCR has been successfully applied for the detection and quantification of a variety
of microorganisms in food, including pathogens (McKillip and Drake, 2004) and lactic acid
bacteria (Pinzani et al., 2004; Furet et al., 2004). However, when it comes to enumerating
bifidobacteria, most studies using real-time PCR have mainly focussed on the quantification of
these organisms in faecal samples (Requena et al., 2002; Queimonde et al., 2004; Matsuki
et al., 2004). For the construction of the calibration curve, being one of the most critical
aspects of real-time PCR-based quantification, most methodologies traditionally rely on plate
counting for the determination of the initial number of bifidobacteria. Whereas this approach
may be suitable for the enumeration of bacteria represented by low numbers, it is difficult to
extrapolate towards high bacterial concentrations. At present, the majority of the real-time
PCR applications are based on the quantification of the 16S rRNA gene. However, the fact
that 16S rRNA genes can be present in multiple copies in the bifidobacterial chromosome
may compromise the interpretation of quantitative data obtained by real-time PCR.
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This study describes the development and evaluation of a real-time PCR methodology
for the culture-independent quantitative analysis of 29 probiotic products claimed to contain
bifidobacteria. Prior to real-time PCR analysis, five DNA extraction methods were evaluated.
A standard curve was generated by determining the bacterial concentration of a dilution series
of the Bifidobacterium animalis subsp. lactis type strain by plate counting and by flow
cytometry. This standard curve formed the basis for quantification of bifidobacteria in the
product matrix by real-time PCR analysis. For this purpose, the use of two primer sets targeting
either the multicopy 16S rRNA gene or the single copy recA gene, respectively, was evaluated.
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Materials and methods
Strain and sample collection
The type strain of B. animalis subsp. lactis (LMG 18314T) that was used for the optimisation of
real-time PCR, and strains B. adolescentis LMG 10502T, B. animalis subsp. animalis LMG 10508T, B.
bifidum LMG 11582 and B. longum biotype longum LMG 13197T used for the determination of the
ribosomal RNA (rrn) operon copy number were obtained from the BCCM/LMG Bacteria Collection,
Ghent University, Belgium (http://www.belspo.be/bccm/lmg.htm). All nonbifidobacterial strains used in
this study were obtained from our research collection and included 13 strains representing five lactic
acid bacteria (LAB) genera (i.e. Lactobacillus, Enterococcus, Pediococcus, Lactococcus and
Streptococcus). Bifidobacterial strains were grown overnight at 37 °C under anaerobic conditions (84 %
N
2
, 8 % H
2
, 8 % CO
2
) on modified Columbia agar (MCA) comprising 23 g special peptone (Oxoid), 1 g
soluble starch, 5 g NaCl, 0.3 g cystein-HCl-H
2
O (Sigma), 5 g glucose and 15 g agar dissolved in 1 litre of
distilled water. All LAB strains were grown overnight at 30 °C on MRS agar (Oxoid). Extraction of total
bacterial DNA was performed as described by Pitcher et al. (1989) with slight modifications as described
by Masco et al. (2003). A total of 29 probiotic products were collected from 11 countries worldwide,
including 19 food supplements (FS1 –FS19), five yoghurts (Y1 – Y5), two dairy drinks (D1 – D2) and
three pharmaceutical preparations (PH1 – PH3) (Table 1). After purchase, the recommended storage
conditions were used. All products were analysed before the end of their shelf life.
Evaluation of total DNA extraction methods
For a subset of three probiotic products including one yoghurt, one food supplement and one
dairy drink, five different total DNA extraction methods were evaluated on the basis of spectrophotometric
determination of OD
260/280
 ratios and performance in real-time PCR analysis. Unless indicated otherwise,
the product sample consisted of 1 ml yoghurt, 1 ml dairy drink or of 1 ml of a 10-1 dilution of the food
supplement or the pharmaceutical preparation in peptone physiological saline solution (PPS, 0.1 % (w/
v) Bacteriological Peptone (Oxoid) and 0.85 % (w/v) NaCl in distilled water). Subsequently, product
samples were centrifuged at 13000 rpm during 10 min. after which the supernatant was removed and the
remaining pellet was subjected to five different extraction protocols: (i) the method of Pitcher and co-
workers (1989) with slight modifications as described by Masco et al. (2003) and hereafter referred to as
the modified Pitcher method; (ii) the phenol-chloroform method as described by Gevers et al. (2001); (iii)
the alkaline extraction method during which 1 ml of lysis buffer (25 µl 10 % SDS and 50 µl 1N NaOH
dissolved in 925 µl MQ) was added to the product pellet and heated during 15 min. at 95 °C. After cooling
on ice, the lysed suspension was centrifuged for a few seconds at 13000 rpm and 9 ml of MQ was added
followed by a final centrifugation step (5 min. at 13000 rpm) and removal of the supernatant; (iv) the
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QIAamp® DNA stool mini kit (Qiagen) and (v) the NucleoSpin® food kit (Macherey-Nagel) were used
following the instructions of the respective manufacturers. DNA pellets were dissolved in 100 µl TE-
buffer (1 mM EDTA pH 8.0; 10 mM Tris-HCl pH 8.0).
Real-time PCR
Real-time PCR amplification reactions were performed with the LightCycler (Roche diagnostics)
using two different primer sets. The first set of primers, g-Bifid-F (5’-CTCCTGGAAACGGGTGG-3’) and
g-Bifid-R (5’-GGTGTTCTTCCCGATATCTACA-3’), described by Matsuki et al. (2002), targets a 596 bp
region of the 16S rRNA gene. The second set of primers was designed using the Kodon (version 1.0)
software (Applied Maths) and amplified a 203 bp fragment of the single copy gene recA (the sequence
corresponds to the nucleotide numbers 338-541 of the recA sequence of E. coli), i.e. recA-F (5’-
CGTYTCBCAGCCGGAYAAC-3’) and recA-R (5’-CCARVGCRCCGGTCATC-3’). Specificity of both primer
sets was tested for B. adolescentis, B. animalis subsp. lactis, B. bifidum, B. breve, B. longum biotype
longum and infantis and for 13 non-bifidobacterial strains representing the genera Lactobacillus,
Enterococcus, Pediococcus, Lactococcus and Streptococcus. The optimal MgCl
2 
concentration for
each primer set was determined using the 10-1 and 10-2 dilutions of strain LMG 18314T using the PCR
program described below. Target DNA was amplified in the presence of different MgCl
2 
concentrations,
ranging from 1-5 mM, obtained by altering the amounts of MgCl
2 
and PCR water in the PCR reaction mix.
After determination of the optimal MgCl
2 
concentration the composition of reaction mix per sample was
formulated as follows: 9.6 µl PCR water, 2.4 µl MgCl
2 
(25mM), 2 µl of each primer (0.5 µM), 2 µl template
DNA and 2 µl of FastStart DNA Master SYBR Green I (Roche) which includes Taq polymerase, reaction
buffer, a deoxynucleotide triphosphate mixture, SYBR Green I dye and Hot Start antibody. The PCR
programme consisted of an initial denaturation and anti-Taq DNA polymerase antibody-inactivation
step (10 min. 95°C), an amplification step (40 cycles of 0 sec at 95 °C, 5 sec at 65 °C for g-Bifid-R/g-Bifid-
F or at 60 °C for recA-F/recA-R and 23 sec for g-Bifid-R/g-Bifid-F or 9 sec for recA-F/recA-R at 72 °C) and
a melting-curve determination step (from 70 °C for g-Bifid-R/g-Bifid-F or 65 °C for recA-F/recA-R to 95 °C
at a transition rate of 0.1 °C sec-1). Measurement of SYBR green fluorescence was performed at the end
of each amplification step and continuously during the melt-curve analysis.
Standard curve
For quantification of bifidobacteria in an unknown sample, a standard curve was generated and
used in subsequent analyses. A tenfold serial dilution of an overnight grown culture of strain B. animalis
subsp. lactis LMG 18314T, which represents the most frequently isolated Bifidobacterium species from
probiotic products (Temmerman et al., 2003; Masco et al., 2005), was prepared in a particle-free sterile
saline solution after which triplicate aliquots of 50 µl of each dilution were spread-plated on MCA
medium. After 72 h of anaerobic incubation at 37 °C, colonies were counted. In parallel, the dilution series
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was also quantified using the CyAn (DakoCytomation) flow cytometer. Initially, live/dead analysis was
performed of the 10-2 and 10-3 dilutions in order to determine the relationship between both fractions. A
two-color nucleic acid fluorescence assay was performed using the LIVE/DEAD® Baclight Bacterial
Viability kit (Molecular probes), which consists of a mixture of the green-fluorescent SYTO® 9 for total
cell staining and the red-fluorescent propidium iodide for staining cells with damaged membranes. As a
result, bacteria with intact cell membranes stain fluorescent green, whereas bacteria with damaged
membranes stain fluorescent red. First, 500 µl of a 10-1 dilution of the staining mixture was added to 500
µl of each sample dilution and incubated in the dark at room temperature during 15 min. before measurement.
The actual cell number was subsequently determined by mixing 100 µl of each dilution (10-1-10-5) with 900
µl saline solution and 0.5 µl SYTO® 16 green-fluorescent nucleic acid stain (Molecular Probes), followed
by incubation for 1h at 4 °C, and analysis of each dilution after addition of 105 beads per ml.
Finally, DNA extracted from the initial dilution series was analyzed using the real-time PCR protocol as
described above. Quantitative data from MCA plating and flow cytometric analysis obtained within the
most suitable dilution range were subsequently used to generate a standard curve in which the bacterial
cell numbers ml-1 was plotted against the C
T
 value, being the minimal cycle number at which the fluorescence
signal exceeds the threshold level.
Quantification
Each probiotic product was analyzed in triplicate using both the 16S rRNA gene and the recA
targeting primers. As a standard calibration point, each run included one DNA sample from the dilution
series originally used to create the standard curve. Following each real-time assay, the LightCycler
software adjusts the standard curve using this point and calculates the bacterial cell numbers ml-1 or g-
1 on the basis of the C
T
 value of each sample. This protocol was subsequently evaluated on 29 probiotic
products claiming to contain bifidobacteria.
Southern hybridization
For determination of the 16S rRNA gene copy number, single strains of B. adolescentis, B.
animalis subsp. animalis and subsp. lactis, B. bifidum and B. longum biotype longum were subjected
to Pulsed-Field Gel Electrophoresis (PFGE) fingerprinting as described previously (Masco et al., 2005).
Two different macrorestriction enzymes, SpeI and XbaI (Promega), were used. Probe labeling and southern
hybridization were performed using the ECL Direct Nucleic Acid Labeling and Detection System
(Amersham Biosciences) according to the manufacturer’s instructions. A 1417 bp genus-specific 16S
rRNA gene PCR product (Kaufmann et al., 1997) was used as probe.
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Results and Discussion
Although still a matter of debate, it is assumed that a minimal concentration of 106
CFU per ml or g of product is needed for probiotic bacteria to exert a health-promoting effect
(Kailasapathy and Chin, 2000). Consequently, the correct enumeration of probiotic bacteria
in commercial products on a routine basis is indispensable in the process of delivering a
functional product. Due to the lack of suitable isolation media, culture-dependent methods
are intrinsically limited in reliability and sensitivity for the selective detection and enumeration
of bifidobacteria. In the present study, a new method based on real-time PCR was evaluated
for its use as a more rapid and sensitive culture-independent alternative for the quantification
of bifidobacteria in probiotic products.
Evaluation of DNA extraction methods
When performing real-time PCR for quantitative means, differences in DNA extraction
efficiency (incl. cell lysis and DNA elution) between different extraction methods may influence
the outcome of the results. For this purpose, the performance of five DNA extraction methods
was evaluated on the basis of OD measurement and performance in real-time PCR analysis.
DNA preparations of sufficient purity (1.8 £ OD260/280 £ 2.2) were only obtained using the
modified Pitcher method (Masco et al., 2003) and the phenol chloroform method (Gevers et
al., 2001). However, when performing real-time PCR analysis with genus-specific 16S rRNA
gene and recA primers, only the melting curves resulting from the modified Pitcher DNA
extracts indicated that a Bifidobacterium-specific product had been amplified. This observation
was further substantiated by the fact that the lowest CT values were observed when quantifying
DNA samples extracted using the modified Pitcher method. Based on these results, the latter
method was considered the most optimal choice for DNA extraction from pure cultures and
probiotic products.
The reproducibility of the modified Pitcher method in real-time PCR applications was
assessed for three probiotic matrices (i.e. one dairy based product, one tablet and one capsule)
by sampling each product four times a day during two subsequent days after which the resulting
DNA samples were analyzed in a single real-time PCR run. In total, eight CT values were
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obtained per product from which the average and standard deviation (SD) were calculated.
Whereas the SD values were moderately low for the capsule sample (SD = ±0.31 cycles)
and the dairy based sample (SD = ±1.95 cycles), a higher SD of ±6.01 cycles was obtained
for the tablet sample. Possibly, the relatively high rate of variation obtained for the latter
product type may have partly originated from the additional grinding step necessary to obtain
a homogenous sample suspension.
Real-Time PCR
In the real-time PCR assay, the non-selective fluorescent dye SYBR Green I was
used in combination with Bifidobacterium-specific primers. The SYBR Green I chemistry is
considered to be equally sensitive as the Taqman chemistry (Malinen et al., 2003) and is
particularly useful when there is little or no information on the species-specific content of the
sample prior to its analysis. In this case, additional qualitative data can be obtained by analysing
the amplicons generated using genus-specific primers by Denaturing Gradient Gel
Electrophoresis (DGGE) (Requena et al., 2002), without the need for separate primers or
probes for each possible Bifidobacterium species.
Although frequently used as target molecule for real-time quantification, it is well
documented that in many bacteria the 16S rRNA gene can be present in multiple copies
(http://rrndb.cme.msu.edu/rrndb/servlet/controller), possibly resulting in an overestimation of
the number of bacteria in a product sample. This problem can be solved by determining the
copy number of the 16S rRNA gene of the detected species, which allows to correct the raw
quantitative data, or by targeting a single copy gene. Both approaches were investigated in
this study. By southern hybridisation with a ribosomal probe, the number of 16S rRNA gene
operons (n) was determined for the type strains of B. adolescentis (n = 3), B. longum biotype
longum (n = 4), B. animalis subsp. animalis (n = 3) and subsp. lactis (n = 3) and for
reference strain B. bifidum LMG 11582 (n = 2). The rrn copy number of B. breve (n = 3)
and B. longum biotype infantis (n = 3) were previously determined by Bourget and co-
workers (1993). The recA gene was selected as an alternative real-time PCR target for the
16S rRNA gene because it is present only in a single copy and it has also been proposed as
a phylogenetic marker for the differentiation of bifidobacterial species (Kullen et al., 1997).
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In the present study, new PCR primers (recA-F and recA-R) were designed for the
amplification of a 203 bp recA fragment of B. bifidum, B. breve, B. longum biotypes longum
and infantis and B. animalis subsp. lactis. The specificity of the 16S rRNA gene and recA
targeting primers was tested for 13 non-bifidobacterial strains representing the genera
Lactobacillus, Enterococcus, Pediococcus, Lactococcus and Streptococcus. None of these
strains yielded a PCR product with either of the two primer sets. Optimisation of the real-time
PCR protocol for both the 16S rRNA gene and recA primer sets was performed using the
type strain of B. animalis subsp. lactis LMG 18314T. MgCl2 titration indicated that 4 mM
was the optimal concentration for both PCR mixes based on the observation that the obtained
curves exhibited the lowest crossing point, the highest fluorescence intensity and the steepest
curve slope.
In order to quantify bifidobacteria in probiotic product samples, a standard curve for
each real-time PCR target was generated for the mathematical conversion of CT values into
bacterial cell numbers per ml or g of product. In most real-time PCR studies, the initial number
of bacteria necessary for the construction of a standard curve is determined by conventional
plate counting. In practice, however, this approach can only be used in the low concentration
range, given the fact that colony counting of plated samples ≥ 104 CFU ml-1 is unreliable, and
cannot be extrapolated towards high bacterial concentrations. For this reason, bacterial cell
numbers of a dilution series of reference strain LMG 18314T, which harbors the relevant PCR
targets, were determined both by traditional plate counting and by flow cytometric analysis.
The latter method allowed an accurate quantification of the dilution series in the range of 104
– 108 bacterial cell numbers ml-1. Prior live/dead analysis indicated that the fraction of dead
cells (1.07 % ±0.25) was negligible compared to the fraction of live cells (95.18 % ±0.96)
resulting in a good correlation between the culture-dependent and culture-independent detection
ranges. Hence, the results from both approaches were considered complementary for the
construction of a standard curve in the range of 101 – 108 bacterial cell numbers per ml. The
standard curve was generated from real-time PCR analysis of DNA extracts using 16S rRNA
and recA as target genes. A linear relation between initial bacterial concentration and CT
values was obtained in the range corresponding to 102 –108 and 103 – 108 bacterial cell
numbers using the protocols based on the 16S rRNA gene (R² = 0,99) and recA gene (R² =
0,98), respectively.
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Using both target genes, 29 probiotic products claimed to contain bifidobacteria were
subjected to real-time PCR analysis. For each product sample, the bifidobacterial concentration
was determined by comparing the obtained CT value to the standard curve generated from an
included standard calibration point (Table 1). Linear regression analysis demonstrated a good
correlation (R² = 0.9625) between the real-time PCR results based on the quantification of
the 16S rRNA gene and the recA gene. For 23 products (79,3 %), Bifidobacterium numbers
obtained from real-time PCR analysis, using both gene targets, were in agreement within a
range of one log unit. In fact, major differences between the two genes were only found in
dried probiotic products in which low amounts of bifidobacteria were detected (102 - 104
bacterial cell numbers g-1). For the products FS10 and 17, bacterial cell numbers obtained
using recA primers were two log units higher than when using 16S rRNA gene primers. However,
in four other products (i.e. FS3, 11, 18 and 19) real-time PCR analysis using 16S rRNA gene
targeting primers was able to detect bifidobacteria down to 102 bacterial cell numbers g-1
whereas the recA primers were not able to detect any bifidobacteria. This may be due to the
fact that the use of single-copy genes in real-time PCR such as recA may result in a higher
detection limit compared to the use of the multi-copy 16S rRNA gene. Based on real-time
PCR quantification results obtained for 29 probiotic products, the estimated detection limit
was found to be 2.5x 102 CFU per weight unit for the 16S rRNA gene assay and 5x 103 CFU
per weight unit for the recA targeting assay. The lower detection limit of the 16S rRNA gene
assay makes it somewhat more sensitive than recA for bacterial quantification, although the
multi-operon effect remains an important drawback of this method when analysing unknown
samples using universal primers. In case of the products Y2 and FS7, real-time PCR did not
produce a detectable Bifidobacterium-specific amplicon using either of the two primer sets.
This may be due to the fact that the bifidobacterial concentration in these products was below
the detection limit of both assays or to the presence of possible PCR inhibitors.
Independent from the gene target used for real-time PCR quantification, it was striking
to see that the 29 products displayed a very broad distribution of bifidobacterial concentrations
ranging from 0 – 108 CFU g-1 or ml-1. In fact, only 11 products (38 %) fulfilled the proposed
minimum probiotic concentration of 106 CFU g-1 or ml-1 (Kailasapathy and Chin, 2000) when
only bifidobacteria are taken into consideration. Although the scientific basis for defining minimum
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probiotic dosages is still a matter of debate, it is indeed unlikely that Bifidobacterium strains
present in probiotic products at concentrations of 101-104 CFU per weight unit can contribute
to the host’s intestinal health. On the other hand, it is clear that also other criteria of probiotic
bacteria such as viability in the product, survival capacity through the gastrointestinal tract,
colonization potential and immunological properties should be considered in order to deliver
a probiotic product that answers to the claimed health-promoting effects.
In the present study, we investigated the applicability of real-time PCR for the
quantitative analysis of bifidobacteria in commercial probiotic products. The preliminary
results indicate that the method described provides a molecular tool for high throughput
quantitative analysis of bifidobacteria in commercial probiotic products. Despite the
inherent differences in sensitivity and the requisite for prior knowledge of bacterial content,
the real-time PCR assays based on 16S rRNA and recA gene detection are promising
alternatives for culture-based detection and quantification of probiotic organisms in various
product types. Due to the fact that real-time PCR analysis is based on the detection of both
living and dead bacteria, however, it is important to keep in mind that this results in an
overestimation of the number of intact metabolically active Bifidobacterium cells.
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using recA and 16S rDNA targeting primers
Product Bifidobacterium species identified by DGGE
a
recA 16S rDNA
Yoghurt:
Y1 B. animalis subsp. lactis 7.02 E+04 ±1.31 E+04 1.12 E+05 ±6.39 E+04
Y2 B. animalis subsp. lactis 0 0
Y3 B. animalis subsp. lactis 2.40 E+04 ±4.55 E+03 8.29 E+04 ±1.06 E+05
Y4 B. animalis subsp. lactis 2.17 E+05 ±1.34 E+05 9.00 E+04 ±7.42 E+04
Y5 B. animalis subsp. lactis 1.55 E+04 ±3.88 E+03 2.59 E+04 ±2.48 E+04
Drink:
D1 B. animalis subsp. lactis 1.76 E+05 ±5.12 E+04 1.58 E+05 ±8.28 E+04
D2 B. breve 1.08 E+06 ±3.50 E+05 2.90 E+05 ±2.27 E+05
Capsule
FS1 B. animalis subsp. lactis, B. bifidum 2.19 E+06 ±7.22 E+04 6.74 E+06 ±2.15 E+06
d
FS2 B. longum biotype longum 1.04 E+06 ±3.95 E+05 2.34 E+06 ±1.34 E+06
FS3 B. animalis subsp. lactis, B. bifidum 0 3.46 E+03 ±1.28 E+03
d
FS4 B. animalis subsp. lactis 7.00 E+06 ±2.18 E+06 2.83 E+07 ±9.38 E+06
FS5 B. longum biotype longum 1.36 E+05 ±5.57 E+04 4.97 E+05 ±1.90 E+05
FS6 B. animalis subsp. lactis 3.61 E+05 ±8.52 E+04 4.82 E+05 ±2.14 E+05
FS7 B. animalis subsp. lactis, B. bifidum 0 0
FS8 B. bifidum 3.20 E+06 ±3.08 E+05 3.12 E+06 ±1.41 E+06
FS9 B. animalis subsp. lactis 1.32 E+06 ±2.85 E+05 1.77 E+06 ±1.01 E+06
FS10 B. animalis subsp. lactis 1.47 E+04 ±7.62 E+03 7.65 E+02 ±6.81 E+02
FS11 B. animalis subsp. lactis, B. bifidum 0 9.91 E+03 ±4.73 E+03
d
Powder
FS12 B. animalis subsp. lactis, B. bifidum, B. longum biotype longum 4.84 E+05 ±1.96 E+05 7.55 E+05 ±4.74 E+05
d
FS13 B. animalis subsp. lactis 5.23 E+05 ±5.68 E+04 1.46 E+06 ±5.89 E+05
FS14 B. animalis subsp. lactis, B. longum biotype longum 1.00 E+04 ±0.00
c
2.51 E+03 ±1.55 E+03
d
FS15 B. animalis subsp. lactis 1.06 E+07 ±2.00 E+07 2.21 E+07 ±7.27 E+06
Tablet
FS16 B. longum biotype longum 4.21 E+03 ±1.62 E+03 4.80 E+03 ±4.99 E+03
FS17 B. animalis subsp. lactis, B. longum biotype longum 4.60 E+04 ±6.15 E+03 6.74 E+02 ±1.80 E+02
d
FS18 B. animalis subsp. lactis, B. bifidum 0 2.71 E+02 ±1.48 E+02
d
FS19 B. animalis subsp. lactis 0 1.31 E+03 ±0.00
c
Capsule
PH1 B. longum biotype infantis, B. bifidum 3.07 E+06 ±2.64 E+06 5.71 E+06 ±1.62 E+06
d
PH2 B. bifidum 2.18 E+06 ±2.88 E+05 2.00 E+07 ±6.08 E+06
Powder
PH3 B. animalis subsp. lactis 3.82 E+07 ±4.01 E+07 2.22 E+08 ±3.52 E+08
c
Single experiment
d
Corrected concentrations obtained by dividing the original bacterial cell numbers ml
-1
or g
-1
values by the average rrn copy number of the included species
Table 1. Results of real-time quantification of bifidobacteria in probiotic products
Bifidobacterial concentration determined
a
Masco et al ., 2005
b
Mean concentrations and standard deviations were calculated from triplicate determinations from the same DNA extract
Pharmaceutical preparations:
Freeze-dried products (bacterial cell number g
-1
)
Dairy based products (bacterial cell number ml
-1
)
by real-time PCR based on
b
:
Food supplements:
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Safety assessment of potentially probiotic Bifidobacterium strains
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5.1. Antimicrobial susceptibility of
Bifidobacterium strains from humans, animals
and probiotic products.
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Summary
The aim of this study was to assess the antimicrobial susceptibility of a taxonomically
diverse set of Bifidobacterium strains to different classes of antimicrobial agents using a
recently described medium. The susceptibility of 100 strains encompassing 11 bifidobacterial
species originating from humans, animals and probiotic products to 12 antimicrobial agents
was tested by agar overlay disc diffusion. Based on these results, one or two strains per
species were selected for susceptibility testing to nine antibiotics by broth microdilution using
the Lactic acid bacteria Susceptibility test Medium (LSM) supplemented with cysteine. The
genotypic basis of atypical tetracycline resistance was further characterized using PCR, Southern
blotting and partial sequencing. Based on the distribution of inhibition zone diameters and
MIC values, all strains tested were susceptible to amoxicillin, chloramphenicol, erythromycin,
quinupristin-dalfopristin, rifampicin and vancomycin. Our data also reinforce earlier
observations indicating that bifidobacteria are intrinsically resistant to gentamicin,
sulphamethoxazole and polymyxin B. Susceptibility to trimethoprim, trimethoprim/
sulphamethoxazole, ciprofloxacin, clindamycin, tetracycline and minocycline was variable.
The tet(W) gene was responsible for tetracycline resistance in 15 strains including 7 probiotic
isolates belonging to the taxa B. animalis subsp. lactis and B. bifidum. This gene was present
in a single copy on the chromosome and did not appear to be associated with the conjugative
transposon TnB1230 previously found in tet(W)-containing Butyrivibrio fibrisolvens. The
use of the LSM + cysteine medium allowed us to discriminate between intrinsic and atypical
resistance properties of bifidobacteria, and sets the scene for future definition of epidemiological
cut-off values for all important Bifidobacterium species. The presence of an acquired tet(W)
gene in several probiotic product isolates stresses the need for a minimal safety evaluation
during the selection of Bifidobacterium strains for probiotic use.
Keywords: Bifidobacterium, disc diffusion, MICs, LSM, tetracyclines, tet(W),
probiotics
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Introduction
Bifidobacteria are Gram-positive, bifid-shaped anaerobes, that constitute a major
group of the human and animal gastrointestinal microbiota. Because these organisms are known
to play a pivotal role in maintaining the microbial balance of a healthy intestinal tract, they are
frequently applied as probiotics in health-promoting dairy products and dried food supplements
(Gomes and Malcata, 1999). Therapeutic administration of antimicrobial agents is likely to
affect the intestinal microbial balance, e.g. by suppressing bacterial groups such as bifidobacteria
that are beneficial to the host, and often results in intestinal disorders. In co-administration
with antibiotics in order to restore the intestinal health of the host, the presence of antimicrobial
resistance in probiotic Bifidobacterium strains might be regarded as a desirable trait to allow
their survival in the gastrointestinal tract. On the other hand, there is also the growing concern
that these antimicrobial resistances, if encoded by genes located on mobile elements, may be
potentially transferable from probiotic strains to commensal flora or human opportunists. For
this reason, the presence of acquired antimicrobial resistances is one of the first safety criteria
to be checked during the selection process of a potentially probiotic strain.
Bifidobacteria are generally considered to be food-grade organisms that do not impose
health risks on the consumer or the environment. Nevertheless, it should be noted that rare
cases of Bifidobacterium-associated gastrointestinal and extra-intestinal infections have been
described (Brook and Frazier, 1993; Ishibashi and Yamazaki, 2001). In contrast to susceptibility
testing of clinically important bacteria (BSAC, Andrews and the BSAC Working Party on
Susceptibility Testing, 2001; CLSI, 2005), no standard procedures are specifically dedicated
to the determination of resistance phenotypes in Bifidobacterium strains. To date, a large
variety of methods and protocols have been described for antimicrobial susceptibility testing
of bifidobacteria, including agar (overlay) disc diffusion (Charteris et al., 1998; Yazid et al.,
2000; Moubareck et al., 2005), broth dilution (Matteuzzi et al., 1983; Lim et al., 1993) and
agar dilution (Moubareck et al., 2005). In addition, various growth media have been used
primarily on the basis that they meet the complex growth requirements of bifidobacteria. As
opposed to conventional susceptibility test media such as Mueller-Hinton (NLSI) and Iso-
Sensitest medium (BSAC), none of these Bifidobacterium-specific media are well-defined
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in terms of minimal interaction between specific antimicrobial agents and growth medium
components.
Recently, a newly defined medium formulation referred to as the Lactic acid bacteria
Susceptibility test Medium supplemented with cysteine (LSM + cysteine) was proposed for
susceptibility testing of bifidobacteria (Klare et al., 2005). The LSM + cysteine medium was
tested for a minimal set of Bifidobacterium reference strains and was not found to display
significant antagonistic effects with any of the tested agents. In the present study, the LSM +
cysteine medium was used to determine the susceptibility profile of 100 bifidobacterial isolates
to 15 common antimicrobial agents, including inhibitors of cell wall synthesis, protein synthesis,
nucleic acid synthesis and cytoplasmic membrane function using the agar overlay disc diffusion
method and the broth microdilution method. The bifidobacterial isolates under investigation
represent 11 species encompassing strains of human and animal origin, strains previously
isolated from probiotic products (Masco et al., 2005) as well as strains isolated from dental
caries (Scardovi and Crociani, 1974) and clinical sources (Hoyles et al., 2002). For a subset
of strains, the genotypic basis of tetracycline resistance was characterized.
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Materials and methods
Bacterial strains
A total of 100 Bifidobacterium strains were investigated in this study, including 50 type and
reference strains obtained from the BCCM™/LMG Bacteria Collection, Ghent University, Belgium (http:/
/www.belspo.be/bccm/lmg.htm) and 50 isolates obtained from a variety of probiotic products (Masco et
al., 2005). The strain selection included representatives of the following species: B. adolescentis (n = 6),
B. angulatum (n = 2), B. animalis subsp. animalis (n = 2), B. animalis subsp. lactis (n = 44), B. bifidum
(n = 8), B. breve (n = 7), B. catenulatum (n = 2), B. dentium (n = 3), B. gallicum (n = 1), B. longum biotype
infantis (n = 7), B. longum biotype longum (n = 11), B. pseudocatenulatum (n = 5) and B. scardovii (n =
2).
Agar overlay disc diffusion testing
Susceptibility testing was based on the agar overlay disc diffusion (DD) method described by
Charteris et al. (1998) with slight modifications as described by Huys et al. (2002). Initially, 10 strains
were used to compare the performance of two complex growth media for DD testing, i.e. LSM + cysteine
[i.e. 90 % Iso-sensitest broth, 10 % MRS broth and 15 g/l agar, supplemented with 0.3 g/l L-cystein-HCl
(Sigma, C-4820)]10 and Modified Columbia Agar (MCA) [i.e. 23 g special peptone (Oxoid, L72), 1 g soluble
starch, 5 g NaCl, 0.3 g L-cystein-HCl, 5 g glucose and 15 g agar dissolved in 1 litre of distilled water]. The
10 strains used for the comparison of both media represented the species B. animalis subsp. animalis
and subsp. lactis, B. bifidum, B. breve, B. dentium, B. longum biotype infantis and biotype longum and
B. scardovii. Subsequently, the most suitable medium was used for antimicrobial susceptibility testing
of all 100 bifidobacterial strains. Strains were grown overnight in the corresponding broth medium at 37
°C under anaerobic conditions (84% N
2
, 8% H
2
, 8% CO
2
). Cell suspensions with an inoculum density
(OD
590
) of 1.0 ± 0.05 were prepared using a vitalab 10 spectrophotometer (Vital Scientific). Further
manipulations were performed as described by Huys et al. All plates were subsequently incubated under
anaerobic conditions at 37 °C during 24h. In the exceptional case that inhibition zones could not be
measured accurately after 24h of incubation, plates were incubated for another 48h. Susceptibility was
tested against antimicrobial agents (Oxoid) representing inhibitors of cell wall synthesis (i.e. amoxicillin,
AMX10), protein synthesis (i.e. gentamicin, GEN10; tetracycline, TET30; chloramphenicol, CHL30;
erythromycin, ERY15; clindamycin, CLI2 and quinupristin/dalfopristin, Q/D15), nucleic acid synthesis
(i.e. rifampicin, RIF5; ciprofloxacin, CIP5; sulphamethoxazole, RL100 and trimethoprim, TMP5) and
inhibitors of cytoplasmic membrane function (i.e. polymyxin B, PB300). Inhibition zones were measured
using digital callipers (Mauser digital 2). Partial inhibition was defined as a slightly turbid inhibition zone
close to the disc compared to areas of no inhibition further away from the disc. In these cases, inhibition
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zone diameters were measured as far as the turbid zone. B. animalis subsp. animalis strain LMG 10508T
was included as a control strain in every DD assay.
Determination of the Minimal Inhibitory Concentration (MIC)
Strains were grown overnight in LSM + cysteine broth under anaerobic conditions at 37 °C.
Fresh inocula with a density of OD
590
 0.1 ± 0.01 were prepared using a Biolog reader (Biolog). In order
to obtain a 1/100 dilution, 100 µl of this suspension was transferred to 9.9 ml LSM + cysteine broth. For
each agent, two sterile stock solutions were prepared from which a 2-fold dilution series was prepared in
LSM + cysteine broth each encompassing a range of four concentrations. Subsequently, 50 µl of each
agent dilution was added to the wells of a microtiter plate and mixed with 50 µl of the 1/100 diluted cell
suspension. Each plate also included a well only containing 50 µl LSM + cysteine broth as a negative
control. Inoculated plates were incubated for 24h under anaerobic conditions at 37 °C. For a selection of
strains, the MIC of the following antimicrobial agents was determined: tetracycline (Sigma, T-3383),
minocycline (Sigma, M-9511), clindamycin (Sigma, C-5269), ciprofloxacin (Fluka, 17850), polymyxin B
(Sigma, P-4932), vancomycin (Sigma, V-2002), trimethoprim (Sigma, T-0667)), sulphamethoxazole (Sigma,
S7507) and sulphamethoxazole/trimetoprim (20/1).  The MIC was determined as the lowest concentration
of antimicrobial agent at which no visible growth was recorded. The MIC
90
 was defined as the lowest
concentration of a given agent that inhibited growth of 90% of the tested strains. For each agent tested,
a control strain of which the MIC was located within the concentration range tested, was included for
reproducibility assessment.
Molecular detection of tet genes and TnB1230 in strains showing atypical tetracycline resistance
Total genomic DNA was extracted as described previously (Masco et al., 2003). The 50 µl PCR
assay mix used for detection of tetracycline resistance genes contained 32.8 µl MQ, 5 µl 10x PCR buffer
including 15 mM MgCl
2
 (Applied Biosystems), 200 µM of each of four dNTPs (dATP, dCTP, dGTP and
dTTP), 3 µl oligonucleotide primer (10 pmol/µl) (Table 1) and 1 U AmpliTaq DNA polymerase (Applied
Biosystems). A 50 ng/µl dilution of total genomic DNA was used as template. All PCR amplifications were
performed using a Perkin Elmer 9600 thermal cycler. In a first PCR assay, the presence of tetracycline
resistance genes encoding a ribosomal protection (RP) mechanism was investigated with the group-
specific degenerate primer pairs DI/DII and Ribo-2-FW/Ribo-2-RV. The following temperature program
was used for primer pair DI/DII: initial denaturation (95 °C, 5 min); 35 cycles of denaturation (95 °C, 45 s),
annealing (45 °C, 45 s) and extension (72 °C, 1 min); final extension (72 °C, 10 min). For the degenerate
Ribo2 primers, a touchdown PCR was performed as follows: initial denaturation (95 °C, 5 min); 22 cycles
of denaturation (94 °C, 30 s), annealing (30 s with 1 °C decrements from 72 °C to 50 °C), and extension (72
°C, 30 s); 20 cycles of 94 °C for 30 s, 50 °C for 30 s, and 72 °C for 30 s; final extension (72°C, 7 min). Strains
containing an RP-type tet gene were subjected to additional PCR assays with primers specific for individual
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genes of the RP group, i.e. tet(M), tet(O), tet(S), tet(T) and tet(W). In addition, strains with atypical
resistance for tetracycline were also tested for the presence of the tetracycline efflux genes tet(K) and
tet(L). For the detection of the RPP tet genes as well as the tetracycline efflux genes, the following
temperature program was used: initial denaturation (95 °C, 5 min), followed by 25 cycles of denaturation
(94 °C, 45 s), annealing [primer-specific temperature, 1 min (Table 1)], extension (72 °C, 1 min), and a
single final extension step (72 °C, 10 min). PCR products were visualized by electrophoresis on a 1 %
agarose gel stained with ethidium bromide.
The presence of transposon TnB1230 was verified by PCR using primers designed by Dr. Katarzyna
Kazimierczak (personal communication) based on the published sequence of TnB1230 (accession number:
AJ222769) (Melville et al., 2004), as well as by hybridisation of the DNA samples of all tet(W)-positive
strains with a TnB1230 specific PCR product, derived from Butyrivibrio fibrisolvens (DNA of this
organism was kindly provided by Dr. Karen Scott).
Localisation and copy number determination of the tet(W) gene
Isolation of plasmid DNA was based on the alkaline lysis method of Anderson and McKay
(1983). B. breve strain LMG 13194, which is known to possess one plasmid of size 5.6 kb (Bourget et al.,
1993), was used as a positive control for plasmid DNA extraction. Plasmids were separated after
electrophoresis on a 0.7 % agarose gel during 3.5h at 100V and visualized by ethidium bromide staining.
Total genomic DNA was prepared in situ in agarose blocks and digested with endonucleases SpeI and
XbaI and subsequently separated using Pulsed-Field Gel Electrophoresis (PFGE) as described previously
(Masco et al., 2005). Probe labeling and southern hybridization were performed using the ECL Direct
Nucleic Acid Labeling and Detection System (Amersham Biosciences) according to the manufacturer’s
instructions. A 1,100 bp tet(W)-specific amplicon generated with PCR primers DI/DII was used as probe.
Partial sequencing of the tet(W) gene
The tet(W) gene of a selection of strains, including two B. pseudocatenulatum strains, two B.
animalis subsp. lactis strains and one B. adolescentis strain, was amplified using the degenerate primer
pair DI/DII as described above. PCR products were purified using a QIAquick PCR Purification kit
(Qiagen) according to the instructions of the manufacturer. Sequence analysis was performed using the
Big DyeTM Termination RR Mix V3.1 (Applied BioSystems) on an ABI 3100 automated DNA sequencer
(Applied BioSystems). For each sequencing reaction, a 10 µl reaction mixture was prepared containing
0.67 µl Big DyeTM, 1.66 µl 5x sequencing buffer (Applied BioSystems), 3 µl DI or DII (5 µM), 3.67 µl sterile
Milli-Q water and 1 µl of the purified PCR product. The temperature program consisted of 30 cycles of
denaturation (96°C, 15 s), annealing (35°C, 1 s) and extension (60°C, 4 min). PCR products were purified
using the Genesis workstation 200 (Tecan Customized Solutions). Sequence analysis was performed
using the software package Kodon  (Applied Maths) and sequences were blasted against the EMBL
sequence database to confirm the tet(W) identity of the amplicons.
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Nucleotide sequence accession numbers
The tet(W) sequences determined in this study have been submitted to the EMBL database
under the following accession numbers: B. pseudocatenulatum LMG 11593, AM181315; B.
pseudocatenulatum LMG 10505T, AM181316; B. animalis subsp. lactis LM 624, AM181317; B.
animalis subsp. lactis LMG 18314, AM181318; B. adolescentis LMG 11579, AM181319.
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Results
Agar overlay disc diffusion testing
The effect of the growth medium on the inhibition zone sizes of 12 antimicrobial agents
determined with the agar overlay DD method was assessed for 10 Bifidobacterium strains.
For this purpose, the MCA medium was compared with the LSM + cysteine medium. For all
disc types tested, differences in inhibition zones between both media increased with the zone
diameter thus indicating that the diffusion gradient of the antimicrobial agent is mostly affected
by the medium composition at lower concentrations. Differences in inhibition zones between
both media of more than 3 mm (40 of 120 strain-disc combinations) were mostly found for
zone diameters > 20 mm (29 of 40 strain-disc combinations). In 72,4 % of these 29 strain-
disc combinations a larger inhibition zone was found on LSM + cysteine medium which suggests
that this medium exerts lower overall antagonistic effects compared to the MCA medium.
Taken together with the fact that LSM + cysteine medium was able to sustain growth of all
bifidobacterial strains so far tested (Klare et al., 2005), it was decided to use this formulation
as standard medium in all subsequent DD and MIC assays.
In order to evaluate the reproducibility of the agar overlay DD method, reference
strain LMG 10508T was included in each series of antibiogram determinations. An overall
mean standard deviation of ±1.9 mm with a maximum variation of 3 mm was obtained for all
agents tested. For a subset of strains, mainly encompassing one strain/species, antibiotic
susceptibility profiles were compared after 24h and 48h incubation. In most cases, diameters
of inhibition zones measured after 48h coincided with those obtained after 24h of incubation
(data not shown). Between both incubation times, an overall mean standard deviation of ±0.4
mm with a single maximum variation of 4 mm was obtained for all agents tested. The results of
DD susceptibility testing of 100 Bifidobacterium strains to 12 antimicrobial compounds are
summarized in Table 2. A unimodal distribution of large inhibition zones was observed for
amoxicillin (≥25 mm), chloramphenicol (≥27 mm), erythromycin (≥28 mm), quinupristin-
dalfopristin (≥25 mm) and rifampicin (≥21 mm). This type of distribution was noticed for all
species tested, which implies that the overall susceptibility to these compounds probably is
characteristic for the genus Bifidobacterium. Conversely, small unimodally distributed inhibition
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zone diameters were measured for gentamicin, sulphamethoxazole and polymyxin B, suggesting
that bifidobacteria are intrinsically resistant to these agents. However, it should be noted that
partial inhibition was occasionally noted for some of the tested species. In case of gentamicin,
slightly larger inhibition zones were observed for strains belonging to B. longum biotype
infantis compared to the other species tested (Table 2). A relatively broad distribution of
inhibition zone diameters was noticed for tetracycline (10-50 mm) and trimethoprim (6-50
mm). For these two compounds, levels of resistance appeared to be strain-specific in particular
species. In case of tetracycline, a large number of B. animalis subsp. lactis and B.
pseudocatenulatum strains as well as one B. adolescentis strain displayed smaller inhibition
zones compared to the other strains tested. In the trimethoprim DD assay, smaller inhibition
zones were measured for B. gallicum and several representatives of B. adolescentis, B.
bifidum and B. longum biotype longum. In this regard, it should be noted that the larger
zones were mainly observed in cases of partial inhibition. Finally, bimodally distributed inhibition
zone diameters were observed for clindamycin and ciprofloxacin. Strains displaying smaller
inhibition zones for ciprofloxacin belonged to the species B. animalis subsp. lactis, B. bifidum,
B. breve and B. longum biotype longum and can thus be considered as resistant to this agent.
In case of clindamycin, smaller inhibition zones pointed to reduced susceptibility to this
compound within B. animalis subsp. animalis and B. catenulatum and for some strains of
B. breve and one B. adolescentis strain.
Determination of Minimal Inhibitory Concentrations (MIC)
MICs were determined for nine antimicrobial compounds. This selection included
four agents for which bifidobacteria showed a broad or bimodal distribution of DD inhibition
zone diameters, i.e. ciprofloxacin, trimethoprim, tetracycline and clindamycin, as well as two
antibiotics to which bifidobacteria are presumed to be intrinsically resistant, i.e. polymyxin B
and sulphamethoxazole. In addition, MICs were also determined for three compounds not
included in the DD assays, i.e. minocycline, vancomycin and the therapeutic combination
trimethoprim/sulphamethoxazole. For reproducibility testing, a control strain was included in
every series of MIC determinations. A maximum deviation of one log2 dilution step was
recorded for all antimicrobial agents tested. A selection of strains displaying a broad range of
177
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inhibition zone diameters, usually encompassing two strains per species, was subjected to
MIC determination. Based on the broad zone diameter distribution obtained for this agent
(Table 2), an extended selection of strains was included for MIC measurements of tetracycline.
In addition, strains that possessed a tet(W) gene as well as some tet(W)-negative strains
were also subjected to MIC determination of minocycline. Because vancomycin was not
included in the disc diffusion assay, 78 strains were subjected to MIC determination of this
antimicrobial agent. MIC analysis of clindamycin was restricted to B. animalis subsp. animalis
and subsp. lactis in order to substantiate the differences observed among inhibition zones
(Table 2). MIC values could be classified in three categories (Table 3). In a first category,
the tested bifidobacterial strains displayed high overall MIC values indicating intrinsic resistance
of all members of the genus to the compound. This was the case for polymyxin B (MIC90: >64
mg/L) and sulphamethoxazole (MIC90: >1024 mg/L) and these findings thus confirm the results
obtained with the DD assay. As could be predicted from the large zone diameter measured in
DD testing, the type strain of B. bifidum displayed a much lower MIC of 1 mg/L for polymyxin
B. In a second category, MIC values were more variable and broadly distributed within the
strain set tested. In line with DD results, broad MIC distributions were obtained for trimethoprim
(MIC range: ≤0.5 - 64 mg/L; MIC90: 16 mg/L) and tetracycline (MIC range: ≤0.5 - 32 mg/
L; MIC90: 16 mg/L). In case of trimethoprim, most strains displayed an MIC of 8 mg/L
although some strains of B. adolescentis, B. longum biotype infantis and B.
pseudocatenulatum exhibited higher MIC values up to 64 mg/L. In agreement with DD
data, higher MIC values of tetracycline were observed for B. adolescentis, B. animalis
subsp. lactis and B. pseudocatenulatum. Overall, most strains (42,5%) displayed an MIC
value ≤0.5 mg/L for this compound. MIC values of the second-generation tetracycline
compound minocycline (MIC range: 1 - 32 mg/L; MIC90: 16 mg/L) were usually distributed
in a similar way as those of tetracycline. However, for all three B. pseudocatenulatum strains
tested, considerably lower MIC values (1 - 2 mg/L) were obtained compared to those
observed for tetracycline (32 mg/L) (Table 4). In contrast to the intrinsic sulphamethoxazole
resistance observed in DD testing, MIC values of the combined therapeutic preparation
trimethoprim/sulphamethoxazole (1/20) were broadly distributed and comparable to or lower
than the MIC values observed for trimethoprim. Although to a lesser extent, a relatively broad
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MIC distribution was also recorded for ciprofloxacin (MIC90: 16 mg/L) for which the majority
of the strains tested displayed an MIC of 4 mg/L. A third category was represented by overall
low MIC values of clindamycin and vancomycin. The latter compound is known to diffuse
poorly in agar media (Thomson et al., 1995) for which reason vancomycin resistance of
bifidobacteria was only tested by means of the broth microdilution method. The highest MIC
value of vancomycin (1 mg/L) was observed for some strains of the species B. bifidum,
whereas the majority of the strains tested were found to be inhibited at even lower concentrations
(MIC90: 0.250 mg/L). These data indicate that most members of the genus Bifidobacterium
are susceptible to this compound. As was also noticed from the DD results, MIC values of
Species (number of strains) tet gene
Tetracycline Minocycline
B. adolescentis (n = 1) 32 32 tet (W)
B. pseudocatenulatum (n = 3) 32 1-2 tet (W)
B. animalis subsp. lactis (n = 3) 32 4-16 tet (W)
B. animalis subsp. lactis (n = 7) 16 4-16 tet (W)
B. animalis subsp. lactis (n = 3) 8 4-16 tet (W)
B. animalis subsp. lactis (n = 2) 4 4 tet (W)
B. bifidum (n = 2) 4 2-4 tet (W)
B. longum biotype infantis (n = 1) 2 1 NF
B. animalis subsp. animalis (n = 2) 1 2 NF
B. pseudocatenulatum (n = 2) 1 ND NF
B. longum biotype infantis (n = 1) 1 ND NF
B. bifidum (n = 1) 1 0.5 NF
B. breve (n = 2) 0.5 0.5 NF
B. scardovii (n = 2) 0.5 ND NF
B. dentium (n = 2) 0.5 ND NF
B. gallicum (n = 1) 0.5 4 NF
B. bifidum (n = 1) 0.5 ND NF
B. adolescentis (n = 1) 0.5 ND NF
ND: Not determined: NF: Not found
Table 4. Phenotypic and genotypic characterization of tetracycline
resistance for 29 Bifidobacterium strains
MIC (mg/L)
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clindamycin for B. animalis subsp. animalis were found to be slightly higher (MIC range: 0.5
- 1 mg/L) than for B. animalis subsp. lactis (≤0.125 mg/L).
Genetic basis of tetracycline resistance
A subset of 29 strains, covering a broad tetracycline MIC range (≤0,5 - 32 mg/L),
was subjected to PCR detection of tetracycline resistance genes (Table 4). In 15 strains
displaying MICs in the range of 4 - 32 mg/L, the presence of the tet(W) gene conferring
ribosomal protection (RP) against tetracycline was detected. These strains belonged to B.
adolescentis, B. pseudocatenulatum, B. animalis subsp. lactis and B. bifidum. The identity
of the tet(W) amplicons was confirmed by partial sequence analysis (positions 319 – 1263,
i.e. 49% of the 1921 bp tet(W) gene of Butyrivibrio fibrisolvens, Acc. No. AJ427421).
These analyses included three strains with comparable MIC values for both tetracycline and
minocycline and two B. pseudocatenulatum strains for which lower minocycline MIC values
(1 - 2 mg/L) were recorded compared to those observed for tetracycline (32 mg/L). At two
positions, base substitutions resulting in a mutation at the protein level were detected in the
partial tet(W) sequence. At amino acid positions 262 and 265 of the TetW protein of
Butyrivibrio fibrisolvens, glycine and arginine were substituted in both B.
pseudocatenulatum strains by aspartic acid and leucine, respectively.
None of the 29 strains tested were positive for the efflux genes tet(K) and tet(L).
In all 15 tet(W)-positive strains, the tet(W) gene was found to be present in a single
copy on the chromosome, since no plasmids could be isolated. The presence of TnB1230
could not be demonstrated by PCR or by southern hybridisation in any of these strains.
Likewise, attempts to transfer the tet(W) gene from B. animalis subsp. lactis LMG 11615
to B. adolescentis LMG 10734 by filter mating did not result in successful transconjugants
(L. Masco, unpublished data).
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Discussion
In contrast to clinically relevant bacteria for which resistance monitoring is indispensable
(BSAC, Andrews and the BSAC Working Party on Susceptibility Testing, 2001; CLSI,
2005), no standard procedures or interpretive breakpoints have been established for
antimicrobial susceptibility testing of bifidobacteria. In this regard, several test media have
been used that meet the complex growth requirements of bifidobacteria, including tryptic soy
broth supplemented with 0.2 % yeast extract and 0.06 % L-cystein-HCl (Lim et al., 1993),
TPY medium (Charteris et al., 1998; Yazid et al., 2000; Matteuzzi et al., 1983) and Brucella
agar supplemented with 5% laked sheep blood and vitamin K1 (Moubareck et al., 2005).
However, the susceptibility test medium should not only sustain growth of the tested organisms
but should also provide a non-interfering matrix exerting minimal antagonistic effects against a
wide range of antimicrobial agents. Although the defined and universally applied test media
Iso-Sensitest Agar (ISA) (BSAC) and Mueller-Hinton agar (NLSI) meet the latter requirement,
it has been shown that they do not always support growth of any given LAB (lactic acid
bacteria) food strain (Huys et al., 2002). Recently, the newly developed LSM + cysteine
medium formulation was found to provide sufficient growth support of bifidobacterial reference
strains (Klare et al., 2005). Furthermore, the use of this formulation in a microdilution method
resulted in correct indications of known MICs for a set of international control strains. In an
initial phase of the present study, the performance of the LSM + cysteine medium was compared
to the undefined MCA medium which is routinely used to culture bifidobacteria for DD
susceptibility testing of 10 Bifidobacterium reference strains. Especially at the lower
concentrations of the gradients, it was found that inhibition zones gradually decreased on
MCA compared to those recorded on LSM + cysteine agar. This observation substantiates
the previous finding that the latter medium formulation is much more effective in minimizing
antagonistic effects between antimicrobial agents and growth medium components (Klare et
al., 2005).
Using the LSM + cysteine medium, the antibiogram of 100 Bifidobacterium strains
belonging to 11 species and representing animal and human strains as well as isolates from
probiotic products was recorded using the agar overlay DD method. A selection of these
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strains were also included for MIC determination using a broth microdilution assay. Due to
the lack of published cut-off values that allow separating strains with and without an acquired
antimicrobial resistance mechanism in Bifidobacterium, susceptibility data were interpreted
largely on the basis of histogram analyses. Depending on the relative position and the type of
distribution (unimodal, bimodal or broad) of DD and/or MIC data in these histograms, strains
were classified as resistant or susceptible. Ideally, 10 or more strains belonging to the same
taxon need to be investigated in order to delineate epidemiological cut-off values at the species
level. Because this condition was fulfilled for some but not all species in this study, interpretation
of susceptibility data was mainly restricted to the genus level. In general, anaerobes such as
bifidobacteria possess a natural resistance to aminoglycosides due to the lack of a cytochrome-
mediated drug transport (Bryan and Kwan, 1970). Accordingly, overall resistance was observed
to gentamicin, which confirms earlier findings (Matteuzzi et al., 1983; Lim et al., 1993;
Charteris et al., 1998; Yazid et al., 2000; Moubareck et al., 2005). Likewise, our data also
indicate that bifidobacteria are generally resistant to polymyxin B, a compound that is almost
exclusively active against Gram-negatives (Hoeprich, 1970). Strains were generally resistant
to sulphamethoxazole as a separate compound. However, the therapeutic combination
trimethoprim/sulphamethoxazole was highly active against most bifidobacterial strains due to
the synergetic inhibitory effect on the thymidine synthesis. This points to the fact that the
reduced resistance towards the therapeutic combination trimethoprim/sulphamethoxazole is
mainly due to the action of trimethoprim. All tested strains appeared to be uniformly susceptible
to chloramphenicol, erythromycin, rifampicin and amoxicillin, which is in agreement with data
of previous studies (Matteuzzi et al., 1983; Lim et al., 1993; Charteris et al., 1998; Yazid et
al., 2000; Moubareck et al., 2005). The overall susceptibility to the β-lactam antimicrobial
amoxicillin may be explained by the lack of β-lactamase activity in Bifidobacterium
(Moubareck et al., 2005). Although not yet reported, quinupristin-dalfopristin was also found
to be an active antimicrobial combination. Susceptibility to trimethoprim, ciprofloxacin,
tetracycline and minocycline was variable and strain-specific. The range of MIC values of
tetracyclines may be specific for some taxa (e.g. B. pseudocatenulatum), but clearly more
strains need to be tested to substantiate this observation. Except for some B. bifidum strains,
all tested Bifidobacterium strains were considered to be susceptible to vancomycin. This
finding contradicts the conclusion of Charteris and co-workers (1998) stating that vancomycin
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resistance is a general characteristic of bifidobacteria. Possibly, this discrepancy may be due
to the limited reliability of the disc diffusion method used by the latter authors considering the
fact that vancomycin is known to diffuse poorly in agar media (Thomson et al., 1995). Although
our data suggest that bifidobacteria are susceptible to clindamycin, comparison of MIC data
indicated reduced susceptibilities for some strains. In support of their recent taxonomic
description (Masco et al., 2004), strains of B. animalis subsp. animalis and subsp. lactis
included in this study could also be differentiated on the basis of quantitative differences in
clindamycin MIC values.
The tet(W) gene is known to be responsible for acquired tetracycline resistance in
several rumen anaerobes and in human Bifidobacterium longum strains (Scott et al., 2000).
Recently, this gene was also detected in single strains of tetracycline-resistant B.
pseudocatenulatum and B. bifidum (Moubareck et al., 2005). In the present study, tet(W)
was found in 15 strains encompassing the species B. pseudocatenulatum, B. bifidum, B.
animalis subsp. lactis and B. adolescentis. To our knowledge, this is the first report on the
presence of tet(W) in the latter two Bifidobacterium species. All tet(W)-positive strains
showed an MIC of tetracycline in the range of 4 – 32 mg/L, whereas all strains with lower
MIC values contained none of the tested tet genes. These findings indicate that an MIC of ≤
2 mg/L can be proposed as epidemiological cut-off value for defining tetracycline susceptibility
in bifidobacteria, but more strains need to be analyzed to substantiate this. The observation
that resistance towards tetracycline was not always joined by resistance to minocycline initiated
partial tet(W) gene sequence analyses and revealed two amino acid substitutions. However,
whether these substitutions are responsible for the difference in susceptibility remains to be
investigated.
Previously, a sequence similarity of > 99,9% was reported between the tet(W) gene
of a rumen isolate of Butyrivibrio fibrisolvens and human B. longum isolates, suggesting
that the gene is potentially exchangeable between animals and humans (Scott et al., 2000). In
Butyrivibrio fibrisolvens, the tet(W) gene is integrated in the conjugative transposon TnB1230
which is thought to be responsible for the environmental dissemination of tet(W) (Melville et
al., 2004). In contrast, none of the 15 tet(W)-positive Bifidobacterium strains in this study
were found to contain TnB1230 using both PCR-based and southern blotting detection.
Similarly, Scott and co-workers (2000) were not able to identify this mobile element in human
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B. longum isolates. This finding that a different genetic support exists for the tet(W) gene in
bifidobacteria and merits further investigation. Previously, it has been shown that the tet(W)
gene is transferable between genotypically diverse Butyrivibrio fibrisolvens strains (Scott et
al., 1997). In this study, preliminary conjugation experiments between B. animalis subsp.
lactis LMG 11615 and B. adolescentis LMG 10734 by filter mating did not result in successful
transconjugants (L. Masco, unpublished data), but do not rule out the possibility that the gene
is transferable using other recipients under different selective conditions.
Interest in the issue of antimicrobial resistance as a safety criterion for lactic acid bacteria
used in probiotic applications is growing at a steady pass. In this context, interpretive reading
of bifidobacterial resistance phenotypes has been significantly hampered by the lack of a
validated method tested on a taxonomically diverse set of strains. The use of the recently
developed LSM + cysteine medium formulation allowed us to discriminate between intrinsic
and atypical resistance properties of bifidobacteria. Together with reduced susceptibilities to
trimethoprim and/or ciprofloxacin in several strains, resistance to tetracyclines appears to
occur in multiple Bifidobacterium species. In all cases, the tetracycline resistance phenotype
was linked to the presence of an acquired non-plasmid located tet(W) gene. In follow-up
studies, the LSM + cysteine medium needs to be tested using an extended strain panel (³ 10
strains per species) which will allow to define epidemiological cut-off values (http://
www.srga.org/eucastwt/WT_EUCAST.htm) for all major Bifidobacterium species. This will
not only lead to a more widespread acceptance of the method, but will also result in the
definition of interpretive standards for use in the food industry and by regulatory agencies.
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Chapter 6
Functionality assessment of potentially probiotic
Bifidobacterium strains
6.1. Bifidobacterium strains induce in vitro
cytokine production by human peripheral blood
mononuclear  cells in a strain-specific way.
Masco L., Pot B., Foligné B., Grangette C., Swings J. and
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Summary
Imbalance of the intestinal microflora, resulting from a reduction of ‘protective’ bacteria,
is frequently associated with intestinal inflammation. Administration of probiotic strains has
been suggested as a potential therapeutic approach for the prevention and treatment of
inflammatory bowel disease (IBD). We investigated the immunomodulatory capacity of a
taxonomically diverse set of 50 Bifidobacterium strains, including commercial probiotic product
isolates as well as human commensal strains, with respect to their potential to induce the
production of the cytokines IL-10, IL-12, TNF-α and IFN-γ by peripheral blood mononuclear
cells isolated from healthy donors. The results of this in vitro analysis confirmed that cytokine
stimulation profiles are strain-specific and revealed that bifidobacteria are potent inducers of
the anti-inflammatory IL-10, while induction of IL-12, TNF-α and IFN-γ is low compared to
a pro-inflammatory control strain. Given the key role of TNF-α in IBD pathogenesis and the
fact that intestinal inflammation is associated with low IL-10 and high pro-inflammatory IL-12
and IFN-γlevels, our results suggest that administration of Bifidobacterium strains that promote
high IL-10/IL-12 and IL-10/TNF-α ratios in combination with a low induction of IFN-
γproduction may induce a shift towards a more anti-inflammatory state, resulting in alleviation
of IBD symptoms. The in vitro approach used in this study allowed to screen a set of
Bifidobacterium strains for their immunomodulatory potential in a high-throughput manner
and enabled the selection of potential candidate strains for probiotic therapy of IBD.
Keywords: Bifidobacterium, IL-10, IL-12, TNF-α, IFN-γ, IBD, probiotics
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Introduction
Most of the microorganisms that enter the human body are readily engulfed and
destroyed by phagocytes, which provide an innate, antigen non-specific first line of defence
against infection. Additional defence is provided by the acquired immune system to which
mainly dendritic cells, macrophages and B cells contribute by acting as professional antigen-
presenting cells (APC) proffering foreign antigens to naïve T cells. Macrophages in particular
react to bacterial stimulation by secreting T-cell-activating cytokines and expressing membrane
bound co-stimulatory molecules, which will bind to corresponding receptors on T cells. Local
inflammatory responses are regulated by the secretion of both pro- and anti-inflammatory
cytokines (Isolauri, 1999). Aberrant intestinal inflammatory responses can cause gastrointestinal
diseases such as Crohn’s disease and ulcerative colitis (UC). Balance control of pro- and
anti-inflammatory cytokines has been suggested to alleviate intestinal inflammation, normalize
gut mucosal dysfunction, and down-regulate hypersensitivity reactions (Isolauri et al., 2001).
Biological therapies including anti-inflammatory treatment with TNF monoclonal
antibodies (mAbs), INF-γ mAbs or IL-12 mAbs have been shown to prevent the onset of
colitis (Kojouharoff et al., 1997; Berg et al., 1996; Rennick et al., 1997). Likewise, the
systemic delivery of the anti-inflammatory cytokine IL-10 (Van Deventer et al., 1997) as well
as in situ synthesis by genetically engineered Lactococcus lactis bacteria in IL-10 knockout
mice (Steidler et al., 2000) are promising biotherapeutic strategies in the treatment of
inflammatory bowel disease (IBD).
Recent studies have focussed on the potential use of non-manipulated probiotic bacteria
exhibiting natural anti-inflammatory properties to reduce inflammation (Venturi et al., 1999;
Schultz et al., 2002; Ishikawa et al., 2003; Bibiloni et al., 2005; Peran et al., 2005).
Probiotics are defined as ‘live microorganisms which, when administered in adequate amounts,
confer a health benefit to the host’ (http://www.fao.org/es/ESN/food/
foodandfood_probio_en.stm). Members of the genus Bifidobacterium are frequently used
as probiotics, primarily because they constitute a major part of the human and animal
gastrointestinal tract and because they play an important role in the control of the intestinal
microflora and in the maintenance of its normal state (Dunne et al., 1999). Recently, it was
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shown that the administration of a B. infantis strain could alleviate symptoms in inflammatory
bowel syndrome (IBS) patients. This effect was associated with a normalization of the ratio
between the cytokines IL-10 and IL-12 towards a more anti-inflammatory state which was
characterized by an enhanced IL-10 production (O’Mahony et al., 2005). The use of VSL#3,
a probiotic preparation consisting of a mixture of eight lactic acid bacteria (LAB) including
single strains of Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium
infantis was shown to inhibit mucosal TNF-α and IFN-γ production and has been found
effective in treatment of UC (Bibiloni et al., 2005). Likewise, the preventive effect of a LAB-
fermented milk, containing Bifidobacterium breve, Bifidobacterium bifidum and
Lactobacillus acidophilus on IBD in SAMP1/Yit mice was determined (Matsumoto et al.,
2001). A lower release of TNF-α and IFN-γ and an increase of IL-10 from mesenteric
lymph node cells was observed and associated with reduced histological injury and reduced
ileal tissue weight.
The purpose of the present study was to identify pro- and anti-inflammatory
characteristics of a taxonomically diverse set of Bifidobacterium strains, including probiotic
product isolates, human commensal strains and strains implicated in clinical infections. The
effect of bifidobacteria on the immunocompetent cell-derived production of the anti-
inflammatory cytokine IL-10 and pro-inflammatory cytokines IL-12, IFN-γ and TNF-α
was assessed in vitro using human peripheral blood mononuclear cells.
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Materials and methods
Bacterial strains
A total of 50 Bifidobacterium strains were investigated in this study, including 22 type and
reference strains obtained from the BCCM™/LMG Bacteria Collection, Ghent University, Belgium (http:/
/www.belspo.be/bccm/lmg.htm) and 28 isolates obtained from various commercial probiotic products
(Masco et al., 2005). The species identity of all strains was assessed or confirmed using BOX-PCR
fingerprinting (Masco et al., 2003). The strain selection encompassed the following species: B.
adolescentis (n = 2), B. angulatum (n = 2), B. animalis subsp. lactis (n = 21), B. bifidum (n = 5), B. breve
(n = 3), B. catenulatum (n = 2), B. dentium (n = 1), B. gallicum (n = 1), B. longum biotype infantis (n = 3),
B. longum biotype longum (n = 6), B. pseudocatenulatum (n = 2) and B. scardovii (n = 2). Lactobacillus
salivarius Ls-33, kindly provided by Danisco (France), and Lactococcus lactis MG1363 (Gasson, 1983)
were included as control strains, both of which have known effects on peripheral blood mononuclear cell
(PBMC)-derived cytokine production (Foligné et al., submitted). All bifidobacterial strains were
subcultured on modified Columbia agar [23 g special peptone (Oxoid), 1 g soluble starch, 5 g NaCl, 0.3 g
L-cystein-HCl (Sigma), 5 g glucose and 15 g agar dissolved in 1 liter of distilled water (BCCMTM/LMG,
Medium 144)] at 37 °C under anaerobic conditions (84 % N
2
, 8 % H
2
, 8 % CO
2
). Strain L. salivarius Ls-33
was subcultured at 37 °C in MRS broth (Difco), whereas strain Lc. lactis MG1363 was subcultured at 30
°C in M17 supplemented with 0.5 % glucose. Subsequently, all strains were grown overnight in appropriate
broth medium. The bacteria were washed twice in phosphate-buffered saline (PBS, pH 7.2), and adjusted
to McFarland 6, which corresponded to a final concentration of 109–1010 CFU ml-1. The bacterial
suspensions were stored at –80 °C in PBS solution containing 20% glycerol.
PBMC preparation
Fresh human blood was collected from five healthy individuals at the Centre Regional de
Transmission Sanguine (CRTS) de Lille. Human PBMCs were isolated after dilution at a 1:2 ratio with PBS
(Gibco BRL, supplemented with 1.32 mg l-1 CaCl
2
 and 1 mg l-1 MgCl
2
, i.e. supplemented PBS) on a Ficoll
density gradient according to the instructions of the manufacturer (Amersham Biosciences). After
centrifugation (400x g for 20 min. at 12 °C), the PBMCs were aspirated and washed 3 times in supplemented
PBS (350x g for 10 min. at 12 °C). PBMCs were subsequently resuspended at a concentration of 2 x 106
cells ml-1 using RPMI 1640 medium (Gibco BRL) containing 10 % (w/v) heat-inactivated fetal calf serum
(Gibco BRL), 1% (w/v) L-glutamine and 150 µg ml-1 gentamicin to prevent bacterial overgrowth.
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Activation of mononuclear cells
PBMCs (2 x 106 cells ml-1) were cultured in the presence of Bifidobacterium and control strains
(2 x 107 CFU ml-1) during 24 h at 37 °C in an atmosphere of air with 5 % CO
2
. Control cultures only
contained culture medium. After incubation, the culture supernatant was collected and stored at –20 °C
until use.
Cytokine quantification
The levels of IL-10, IL12 (p70), TNF-α and IFN-γ were quantified by a specific enzyme-linked
immunosorbent assay (ELISA) (Pharmingen, according to the manufacturer’s recommendations). Briefly,
maxisorp microtiter strip wells (Nunc) were coated overnight at 4 °C with purified murine anti-human
cytokine antibodies. After incubation, the wells were incubated with PBS containing 1 % BSA to block
non-specific protein binding. A standard was prepared with known concentrations of recombinant
cytokines, covering a detection range of 31.25 to 2000 pg ml-1 for TNF-α and IFN-γ, and 15.62 to 1000 pg
ml-1 for IL-10 and IL-12. The standard series and appropriate dilutions of the samples (1/2 and 1/10 for
quantification of IL-10 and IL-12; 1/10 and 1/50 for quantification of TNF-α and IFN-γ) were added to
respective wells and incubated during 2 hours at room temperature. After washing, biotinylated antibodies
(1 µg ml-1) were added and incubated during 1 h at room temperature. Detection was performed after
incubation with streptavidine-horseradish peroxidase conjugate (Jackson) and subsequent revelation
using tetramethylbenzidine substrate. H
2
SO
4
 (2N) was added to stop the colorimetric reaction. The
plates were read at 450 nm on an ELX808 Microplate Reader (Biotek Instrument, inc). Cytokine titers were
determined using the KC4 for windows software (Biotek Instrument, inc).
Statistical analysis
For each cytokine, the response of human PBMCs to the individual strains was calculated from
the responses of five independent donors to account for donor-to-donor variation and was expressed as
means ± SEM. Statistical significance was evaluated by the Mann-Whitney U test. Differences were
considered significant at a p value of <0.05.
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Results
In the present study, human peripheral blood mononuclear cells (PBMC) isolated
from five independent blood donors were cultured with live bifidobacteria, mostly represented
by probiotic product isolates and human commensals. The results of their potential to induce
PBMC-derived production of IL-10, IL-12, IFN-γ and TNF-α are shown in Table 1.
Although a donor-related effect was observed in terms of absolute quantification, the ranking
of strains based on cytokine profiles was highly comparable between the five donors (data
not shown). Variation in induction of cytokine expression could hence be evaluated among
strains, while pro- or anti-inflammatory tendencies were evaluated by comparison to control
strains L. salivarius Ls-33 and Lc. lactis MG1363. The former strain is known to induce an
overall anti-inflammatory cytokine profile, whereas Lc. lactis MG1363 stimulates the
expression of pro-inflammatory cytokines (Foligné et al., submitted).
The bifidobacterial strains tested induced IL-10, IL-12, TNF-α and IFN-γ production
in a strain-specific manner (Table 1). Because most species were represented by only a few
strains, it was not possible to identify species-related effects on cytokine production. However,
among the 21 B. animalis subsp. lactis strains tested, cytokine induction levels were as
variable as the levels measured among strains of different species, which does not indicate a
species-related effect. Of all strains tested, 46 % induced IL-10 levels above the expression
level induced by the anti-inflammatory control strain L. salivarius Ls-33 (1306 ±774 pg ml-
1); only three strains (i.e. LM 311, LM 588 and LMG 21590) induced expression levels
lower than the pro-inflammatory control strain Lc. lactis MG1363 (472 ±134 pg ml-1). An
overall low induction of IL-12 production was witnessed when PBMCs were cultured with
bifidobacteria (50 ±0 to 692 ±325 pg ml-1). For none of the tested strains, the expression
level exceeded the one induced by Lc. lactis MG1363 (897 ±256 pg ml-1). Together with L.
salivarius Ls-33, 20 Bifidobacterium strains did not induce IL-12 production above a basal
level of 50 pg ml-1. None of the bifidobacteria induced IFN-γ expression levels above the
ones induced by Lc. lactis MG1363 (73364 ±20641 pg ml-1), while 58 % of the strains
induced less IFN-γ than L. salivarius Ls-33 (17771 ±8134 pg ml-1), of which 27,6 % was
significantly lower. Noteworthy, even small amounts of IL-12 were able to induce IFN-γ
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Table 1. Cytokine secretion by human PBMCs after exposure to Bifidobacterium strains
a
Species Strain No. Origin IL-10 (pg ml
-1
) IFN-g (pg ml
-1
) IL-12 (pg ml
-1
) TNF-a (pg ml
-1
)
B. adolescentis LMG 10502
T
Adult, intestine 1174 ± 322 21921 ± 11587 77 ± 17* 41727 ± 15198
LMG 18897 Human, faeces 1039 ± 254 10491 ± 5872* 59 ± 9* 14957 ± 4012
B. angulatum LMG 10503
T
Human, faeces 926 ± 199 3096 ± 1671* 54 ± 4* 19818 ± 16647
LMG 11568 Sewage 931 ± 198 713 ± 474*** 50 ± 0* 4171 ± 1232*
B. animalis subsp. lactis LMG 18314 Yoghurt 1608 ± 299* 21773 ± 11017 72 ± 17* 35926 ± 16880
LMG 11615 Infant, faeces 1292 ± 274* 33493 ± 12944 119 ± 37* 51177 ± 15138
LM 2 Probiotic product 1618 ± 230* 5927 ± 3248* 50 ± 0* 29229 ± 9371
LM 13 Probiotic product 1714 ± 572 4815 ± 2794* 50 ± 0* 15574 ± 5461
LM 118 Probiotic product 1288 ± 181* 38620 ± 15185 125 ± 42* 46153 ± 14623
LM 125 Probiotic product 1447± 334* 18061 ± 8260 98 ± 35* 30078 ± 10852
LM 135 Probiotic product 1064 ± 234 40933 ± 19393 101 ± 32* 35296 ± 14822
LM 165 Probiotic product 1700 ± 399* 9184 ± 4589* 51 ± 1* 37214 ± 16359
LM 198 Probiotic product 1686 ± 430 1824 ± 1220* 50 ± 0* 7638 ± 2109*
LM 216 Probiotic product 1911 ± 453* 12923 ± 6824* 50 ± 0* 34125 ± 9107
LM 232 Probiotic product 1837 ± 304* 17140 ± 8972* 65 ± 9* 37593 ± 9847
LM 241 Probiotic product 1909 ± 391* 19680 ± 10167 67 ± 17* 31891 ± 8234
LM 271 Probiotic product 1272 ± 194* 33815 ± 15891 345 ± 123** 51475 ± 18517
LM 350 Probiotic product 1713 ± 449* 15345 ± 9739 50 ± 0* 27516 ± 9154
LM 371 Probiotic product 1224 ± 144* 41876 ± 16121 132 ± 40* 45789 ± 13905
LM 391 Probiotic product 901 ± 191* 44556 ± 17780 173 ± 67*** 38366 ± 11281
LM 441 Probiotic product 1352 ± 335* 19981 ± 10773 64 ± 14* 21354 ± 4124
LM 586 Probiotic product 1233 ± 198* 28793 ± 16414 107 ± 32* 52055 ± 21176
LM 594 Probiotic product 1102 ± 118* 46889 ± 17821 142 ± 55* 37427 ± 11379
LM 624 Probiotic product 1387 ± 494 3112 ± 2100* 50 ± 0* 15022 ± 8307
LM 635 Probiotic product 1300 ± 236* 34517 ± 16272 82 ± 20* 44689 ± 16771
B. bifidum LMG 11041
T
Breast-fed infant, faeces 890 ± 263 627 ± 389*** 129 ± 70* 2881 ± 1118*
LMG 13200 Not known 1613 ± 449* 14776 ± 13114 172 ± 109* 9130 ± 3856
LM 311 Probiotic product 215 ± 70 50 ± 0*** 50 ± 0* 170 ± 120***
LM 381 Probiotic product 1072 ± 290 20610 ± 12347 150 ± 67* 26569 ± 11108
LM 588 Probiotic product 372 ± 143 71 ± 19*** 50 ± 0* 1506 ± 1194***
B. breve LMG 13208
T
Infant, intestine 2144 ± 265* 782 ± 408*** 50 ± 0* 21429 ± 8320
LMG 10645 Not known 783 ± 302 15345 ± 8273 125 ± 72* 15692 ± 4934
LM 646 Probiotic product 1218 ± 293 608 ± 393*** 50 ± 0* 2182 ± 953***
B. catenulatum LMG 11043
T
Adult, intestine or faeces 1709 ± 294* 20729 ± 6929* 70 ± 9* 45282 ± 14277
LMG 18894 Sewage 1257± 199* 55498 ± 15137 238 ± 67* 38505 ± 10611
B. dentium LMG 11045
T
Dental caries 1175 ± 272* 10487 ± 5444* 50 ± 0* 30728 ± 13659
B. gallicum LMG 11596
T
Adult, intestine 745 ± 132 3115 ± 1806* 119 ± 69* 27113 ± 14616
B. longum biotype infantis LMG 8811
T
Infant, intestine 982 ± 325 49762 ± 16546 692 ± 325 51933 ± 17890**
LMG 18902 Infant, faeces 1877 ± 369* 25181 ± 12223 160 ± 76* 22683 ± 6235
LM 418 Probiotic product 2075 ± 436* 5448 ± 3504* 50 ± 0* 19491 ± 6958
B. longum biotype longum LMG 13197
T
Adult, intestine 484 ± 75 2772 ± 1631* 50 ± 0* 1954 ± 1570***
LMG 18899 Adult, faeces 1341 ± 204* 3938 ± 1728* 50 ± 0* 19113 ± 10980
LM 257 Probiotic product 1526 ± 400* 4740 ± 1892* 50 ± 0* 16006 ± 6097
LM 614 Probiotic product 2118 ± 556* 2825 ± 1690* 50 ± 0* 12044 ± 3562
LM 669 Probiotic product 1672 ± 227* 3047 ± 1517* 50 ± 0* 17602 ± 3514
LM 676 Probiotic product 1409 ± 300* 9345 ± 3609* 72 ± 27* 18550 ± 6321
B. pseudocatenulatum LMG 10505
T
Infant, faeces 1185 ± 208* 1094 ± 630*** 50 ± 0* 6916 ± 2737*
LMG 18904 Human, faeces 1424 ± 455 316 ± 114*** 50 ± 0* 8019 ± 5569
B. scardovii LMG 21589
T
50-year-old woman, blood 602 ± 133 24261 ± 17731 169 ± 61* 34385 ± 12692
LMG 21590 44-year-old woman, hip 385 ± 161 21628 ± 14112 76 ± 24* 26396 ± 10292
Lactobacillus salivarius Ls-33 Human isolate 1306 ± 774 17771 ± 8134* 50 ± 0* 14756 ± 7313
Lactococcus lactis MG1363 Cheese starter 472 ± 134 73364 ± 20641** 897 ± 256** 26546 ± 8394
Non-stimulated control 50± 0 50± 0 50± 0 50± 0
a
Results are expressed as means of five independent experiments ± SEM; values below the detection limit were appointed a basic value of 50 pg ml
-1
* significantly different from Lactococcus lactis MG1363 (p< 0.05)
** significantly different from Lactobacillus salivarius LS33 (p <0.05)
*** significantly different from Lactococcus lactis MG1363 and Lactobacillus salivarius LS33 (p <0.05)
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production, which underlines its potent inducers function (Trinchieri, 2003). Finally, half of the
strains tested induced TNF-α expression levels above the ones induced by Lc. lactis MG1363
(26546 ±8394 pg ml-1), however none of these differences were significant. 22 % of the
strains induced less TNF-α production than L. salivarius Ls-33 (14756 ±7313 pg ml-1) of
which 36,4% was significantly lower. For all cytokines quantified, B. bifidum LM 311 induced
the lowest expression levels.
In order to evaluate the immunomodulatory properties of bifidobacteria, the IL-10 to
IL-12 and IL-10 to TNF-α ratios were used as a marker to differentiate bifidobacteria with
potential pro-inflammatory properties from those with anti-inflammatory properties (Figure
1). Of the 50 Bifidobacterium strains tested, 18 strains (i.e. 36 %) displayed IL-10/IL-12
ratios above the one calculated for L. salivarius Ls-33 (26.1 ±15.5), however, none were
significantly different. None of the strains tested had lower IL-10/IL-12 ratios than Lc. lactis
MG1363 (0.8 ±0.5) and only three strains (i.e. B. bifidum LM 588, B. longum biotype
infantis LMG 8811T, B. scardovii LMG 21589T) were not significantly different from the Lc.
lactis MG1363 control strain in this respect (p > 0,05). Thirty strains (i.e. 60 %) displayed
IL-10/TNF-α ratios above the one calculated for L. salivarius Ls-33, however, none of
these differences were significant (p > 0.05). None of the strains tested had lower IL-10/
TNF-α ratios than Lc. lactis MG1363. Moreover, for 42 strains (i.e. 84 %) this value was
significantly higher than the ratio of Lc. lactis MG1363 (p < 0.05). Except for some cases of
low absolute values, ranking of strains based on the IL-10/TNF-α ratio corresponded to the
ranking of strains based on the IL-10/IL-12 ratio.
Of all strains tested, B. breve LMG 13208T, B. longum biotype longum LM 614 and
biotype infantis LM 418, B. animalis subsp. lactis LM 13 and LM 198, exhibited the highest
IL-10/IL-12 and IL-10/TNF-α ratios in association with high absolute values of IL-10 and
low IFN-γ levels. Conversely, B. animalis subsp. lactis LM 391, B. breve LMG 10645, B.
scardovii LMG 21589T and LMG 21590 and B. longum biotype infantis LMG 8811T were
characterized by the lowest IL-10/IL-12 and IL-10/TNF-α ratios in association with low
absolute values of IL-10 and high IFN-γ levels (Figure 2).
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Discussion
The intestinal flora and its interaction with the host play an important role in maintaining
the homeostasis of the immune system. Imbalance of the intestinal microflora, resulting from a
reduced level of ‘protective’ bacteria, has been associated with intestinal inflammation (Fiocchi,
1998; Shanahan, 2000). In recent years, probiotic administration has been considered as a
rational option in IBD therapy. Although the underlying mechanisms are not fully understood,
some probiotics are believed to modulate the host defenses by influencing the intestinal immune
system. In the present study, an in vitro comparison of a taxonomically diverse set of
Bifidobacterium strains was performed in order to classify and select strains according to
their indigenous pro- and anti-inflammatory properties for subsequent in vivo investigation.
All bifidobacterial strains tested induced the production of detectable amounts of the
pro-inflammatory cytokines IFN-γ, TNF-α and of the anti-inflammatory cytokine IL-10
regardless of their respective species designation and in a strain-specific way. In contrast,
very low amounts of the pro-inflammatory cytokine IL-12 were observed. These cytokine
responses do not seem to be restricted to bifidobacteria, but have also been observed in
other lactic acid bacteria (Mercenier et al., 2004).
In an attempt to classify Bifidobacterium strains tested on the basis of pro- and anti-
inflammatory properties, the IL-10/IL-12 and IL-10/TNF-α ratios were determined and
compared with the anti-inflammatory L. salivarius Ls-33 and pro-inflammatory Lc. lactis
MG1363 control strains. The IL-10/IL-12 marker has proven to be useful to evaluate the in
vivo effect of probiotic administration to irritable bowel syndrome (IBS) patients (O’Mahony
et al., 2005). In the latter study, abnormal IL-10/IL-12 ratios resulting from low IL-10 and
high IL-12 release by PBMCs in patients with IBS were normalized and accompanied by an
alleviation of IBS symptoms after administration of a B. infantis strain. Likewise, the
administration of the probiotic strain Lactobacillus rhamnosus GG, which reduces the TNF-
α/IL-10 ratio, has been reported to exert intestinal anti-inflammatory effects both in human
(Schultz et al., 2004) and in experimental intestinal inflammation (Dieleman et al., 2003).
TNF-α plays a key role in the pathogenesis of IBD, as evidenced by the increased production
of TNF-α in the intestinal mucosa from IBD patients (Reinecker et al., 1993; Reimund et al.,
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1996), as well as by a number of clinical studies using anti-TNF-α mAb therapy (Rutgeerts et
al., 2004). Furthermore, correlation between the in vitro characteristics of Lactobacillus
strains determined using the PBMC model and their capability to modulate intestinal inflammation
in a mouse model of chemically (TNBS) induced colitis has been established in previous
studies (Mercenier et al., 2004; Foligné et al., in press; Foligné et al., submitted). Strains,
that induce high IL-10 levels including control strain L. salivarius Ls-33, as well as strains
like Lc. lactis MG1363 that induce substantially less IL-10 and higher TNF-α and IL-12
levels were introduced in the mouse colitis model. These experiments indicated that strains
with a high IL-10/IL-12 ratio were able to reduce intestinal inflammation compared to low
ratio strains that never improved the immunological status (Foligné et al., submitted).
Furthermore, given the fact that IFN-γ levels are elevated in all genetic models of IBD and
that monoclonal antibodies to IFN-γ have been successfully used in the treatment of Crohn’s
disease (Rutgeerts et al., 2002; Van Assche and Pearce, 2004), strains associated with low
induction levels of IFN-γ are preferred for therapeutic application in IBD treatment. From
our findings, it is to be expected that Bifidobacterium strains LMG 13208T (B. breve), LM
614 (B. longum biotype longum), LM 418 (B. longum biotype infantis), LM 13 and LM 198
(B. animalis subsp. lactis), which display a higher IL-10/IL-12 and IL-10/TNF-α ratio than
L. salivarius Ls-33 in addition to low induction of IFN-γ may reduce colitis in the in vivo
TNBS model. By comparing data on cytokine responses obtained in vitro with reference
strains having known in vivo probiotic effects, it is thus possible to obtain a rational indication
of the probiotic potential of candidate strains. Furthermore, it may be possible to define
Bifidobacterium-specific in vitro reference values, which can be used for the selection of
candidate strains for subsequent in vivo testing.
It is clear from the present study that bifidobacteria induce the PBMC-derived cytokine
production to a variable extent, as evidenced by the fact that the species B. breve, B. animalis
subsp. lactis and B. longum biotype infantis harbour strains which elicit opposite effects as
discussed above. This observation confirms earlier findings of strain-specificity of
immunomodulation (Mercenier et al., 2004; Foligné et al., 2005). Despite the fact that the
majority of the B. animalis subsp. lactis isolates as well as half of the B. longum biotype
longum isolates have highly similar if not identical macrorestriction patterns in Pulsed Field Gel
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Electrophoresis (PFGE) (data not shown), there was no correlation between cytokine induction
profile and strain type. This finding confirms earlier indications that a high level of genomic
relatedness among strains as determined by PFGE is not always sustained by phenotypic
(and hence immunomodulatory) characteristics (Masco et al., 2005). This reinforces our
opinion that, although PFGE is often considered as the gold standard of bacterial typing,
caution is needed in the interpretation of such results during probiotic selection. Likewise, we
were interested to see to what extent Bifidobacterium isolates from probiotic products would
score better in cytokine profiling compared to the other strains included in the study. However,
our results indicate that not all product isolates would be equally successful in IBD treatment.
Conversely, the in vitro screening method enabled the identification of potential anti-
inflammatory characteristics among the commensal bifidobacteria tested. However, in vivo
analysis with a mouse colitis model needs to be performed to sustain these observations. In
contrast to most other strains, the two B. scardovii strains isolated from clinical sites (Hoyles
et al., 2002) were potent inducers of the pro-inflammatory cytokines tested and only weak
inducers of IL-10. However, it is not clear whether this specific cytokine response is associated
with the pathology of the strains.
In vivo experiments (animal models) and clinical trials can provide the ultimate evidence
for the fact that specific probiotic strains may provide protective or therapeutic benefits in
inflammatory bowel disease (IBD) (Fedorak and Madsen, 2004). However, because in vivo
studies are time-consuming, laborious and for ethical reasons not adapted to perform large-
scale strain screening assays, the in vitro approach presented in the current study provides a
promising alternative to this end. Although the use of PBMCs for screening purposes does not
take into account the complexity of the intestinal barrier, it involves the use of human immune
cells that are easily collectable and allows high-throughput screening. The in vitro assay used
in this study revealed that bifidobacteria have a pronounced anti-inflammatory potential,
characterized by overall high IL-10 and low IL-12, TNF-α and IFN-γ induction levels
compared to a pro-inflammatory control strain. This approach thus enables a more rational
selection of promising therapeutic strains for further investigation in vivo.
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Summary
Next to health promoting effects, the functional aspect of probiotic strains also involves
their capacity to reach the colon as viable metabolically active cells. The present study aimed
to assess the potential of 24 probiotic product isolates and 42 human reference strains of
Bifidobacterium to survive gastrointestinal transit under in vitro conditions. The survival
capacity of exponential and stationary phase cultures upon exposure to gastric and small
intestinal juices was determined using a recently developed microplate-based assay in
combination with the LIVE/DEAD BacLight Bacterial Viability kit. All 66 strains tested
displayed a considerable loss in viability during exposure to an acidic pepsin containing solution
(pH 2.0) (p < 0.001). Among the 10 taxa tested, cultures of B. animalis subsp. lactis appeared
to be most capable to survive gastric transit. Although to a lesser extent, the presence of bile
salts in the small intestinal tract also affected the viability of most of the strains tested. Except
for three strains, all 66 strains were shown to express bile salt hydrolase activity using an agar-
based assay. In contrast, the bifidobacterial strains used in this study appeared to possess a
natural ability to survive the presence of pancreatin (pH 8.0). Although the effect was not
significant, a slightly enhanced tolerance to gastrointestinal transit was observed when cells
were in the stationary phase, especially when exposed to acid, compared to cells being in the
exponential phase. Survival of the gastrointestinal tract appeared to be largely strain-dependent
and hence implies that different strains will likely display a different behaviour in functionality.
The assay used in this study allows an initial assessment of strains for use as probiotic cultures
prior to selecting potential candidate strains for further investigation in vivo.
Keywords: Fluorescent dyes, microplate, Bifidobacterium, probiotics, gastrointestinal survival
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Introduction
Probiotics are defined as “live microorganisms which, when administered in adequate
amounts, confer a health benefit on the host” (http://www.who.int/foodsafety/publications/
fs_management/en/probiotics.pdf). A wide range of dairy-based and dried probiotic products
for human consumption are currently available on the market (Stanton et al., 2001; Agrawal,
2005). Although cellular or culture components of dead probiotic bacteria are also thought to
mediate beneficial effects in the host, it has been argued that most health benefits associated
with probiotics are exerted by viable metabolically active microorganisms (Ouwehand and
Salminen, 1998). Prior to inducing any effect, however, most living probiotic cultures are
orally administered upon which they need to survive gastrointestinal (GI) transit in sufficient
numbers.
During GI passage, cultures are required to tolerate the presence of pepsin and the
low pH of the stomach, the protease-rich conditions of the duodenum and the anti-microbial
activity of bile salts. Although the pH of the stomach may increase up to 6.0 or higher after
food intake (Johnson, 1977), it generally ranges from 2.5 to 3.5 (Holzapfel et al., 1998).
Fasting pH in the stomach may even be as low as 1.5 (Waterman and Small, 1998), which
implies that survival in extreme acidic conditions is one of the first major physiological challenges
faced by probiotic cultures upon oral administration. Following stomach passage, the small
intestine is a second major barrier in the GI tract. Although the pH of the small intestine (i.e.
7.0-8.5) is more favourable towards bacterial survival, the presence of pancreatin and bile
salts may have adverse effects.
Traditionally, the ability of a probiotic candidate to survive GI transit is assessed using
conventional plating techniques that provide information on the number of viable and
reproductive cells during incubation in simulated GI juices (Charteris et al., 1998, Huang and
Adams, 2004, Mättö et al., 2004). In the present study, a recently developed technique
based on the use of two fluorescent staining agents (Alakomi et al., 2005) was evaluated to
assess the GI survival of probiotic cultures and human reference strains of Bifidobacterium
under in vitro conditions. Together with several Lactobacillus species, bifidobacteria are
amongst the most commonly used bacterial organisms in commercial probiotic products. Using
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a microplate-based assay, the relative degree of tolerance towards gastric and pancreatic
juices and the ability to survive in presence of bile salts was assessed by differentiation between
viable and dead cells. In addition, an agar-based culture method was applied to determine the
potential of Bifidobacterium strains to deconjugate bile salts.
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Materials and Methods
Bacterial Strains
A total of 66 Bifidobacterium strains were investigated in this study including 42 type and
reference strains obtained from the BCCM™/LMG Bacteria Collection, Ghent University, Belgium (http:/
/bccm.belspo.be/index.php) and 24 isolates obtained from 23 commercial probiotic products (Masco et
al., 2005). The species identity of all strains was previously checked by BOX-PCR fingerprinting (Masco
et al., 2005). The selection encompassed the following Bifidobacterium (sub)species: B. adolescentis (n
= 6), B. angulatum (n = 2), B. animalis subsp. lactis (n = 19), B. bifidum (n = 8), B. breve (n = 7), B.
catenulatum (n = 2), B. gallicum (n = 1), B. longum biotype infantis (n = 7), B. longum biotype longum
(n = 9) and B. pseudocatenulatum (n = 5). All strains were subcultured in MRS broth (288130, BD, Le
Pont de Claix, France) supplemented with 0.5 g l-1 L-cystein-HCl (C-6852, Sigma, Bornem, Belgium) (MRS-
cystein broth) at 37 °C under anaerobic conditions (84 % N
2
, 8 % H
2
, 8 % CO
2
). Subsequently, overnight
subcultures were grown in MRS-cystein broth until they reached the early exponential or the stationary
growth phase, respectively.
Microplate assays
Survival rates in gastrointestinal juices (i.e. gastric, pancreatic and bile salt solutions) were
assessed using a microplate-based fluorochrome assay in combination with the LIVE/DEAD BacLight
Bacterial Viability (L/D) kit (L7012, Molecular Probes Inc., Leiden, The Netherlands) as previously
described (Alakomi et al. 2005). The L/D kit combines the nucleic acid dyes propidium iodide (PI), a red-
coloured agent that is excluded from intact cells and SYTO9, a green-coloured agent that is membrane-
permeant and stains both viable and non-viable cells. Because PI has a higher affinity for DNA than
SYTO9, it is able to displace SYTO9 from the DNA. Hence, intact viable cells will stain fluorescent green,
whereas dead cells will colour red.
Exponential and stationary phase cells were harvested by centrifugation, washed with 0.85 % (w/v) NaCl
and incubated with (challenged culture) or without (control culture) each of the gastrointestinal juices.
Gastric juice [0.3 % (w/v) pepsine (P-7000, Sigma, Bornem, Belgium), 0.5 % (w/v) NaCl, pH 2.0, adjusted
with HCl] or pancreatic juice [0.1 % (w/v) pancreatin (P-1500, Sigma), 0.5 % (w/v) NaCl, pH 8.0, adjusted
with NaOH] was added to the harvested cells and aliquots were taken after 1, 90 and 180 min. of incubation
under microaerobic (6 % O
2
) or anaerobic conditions, respectively. Cells were treated with bile salt
solution [0.3 % (w/v) bovine bile (B3883, Sigma), 0.5 % (w/v) NaCl, pH 8.0, adjusted with NaOH] during
60 min. in anaerobic conditions. After incubation, cells were harvested by centrifugation, washed and
resuspended in 0.85 % (w/v) NaCl solution. Of each bacterial cell suspension, 100 µl was pipetted in
triplicate into separate wells of a white 96-well fluorescence microplate (C8 white maxisorp 437591,
Nunc, Roskilde, Denmark). Staining solutions of PI and SYTO9 were prepared according to the
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manufacturer’s instructions. Aliquots of 100 µl staining solution were added to each well and mixed.
Subsequently, plates were incubated in the dark at room temperature for 15 min. Fluorescence
measurements were performed using a fluorescence microplate reader (HTS 7000 Bio Assay Reader,
Perkin-Elmer, Monza, Italy). Intensities of green (535 nm) and red (635 nm) emission were recorded after
excitation at 485 nm. Following fluorescence background substraction, the mean ratio of green to red
fluorescence emission (Ratio
G/R
), which is proportional to the relative numbers of live bacteria and hence
the survival rate, was calculated from three measurements. For every in vitro test, B. animalis subsp.
lactis LMG 18314T was included for reproducibility assessment.
Bile salt hydrolase (BSH) assay
Strains were tested for taurodeoxycholic acid (TDCA) hydrolase activity using MRS-cystein
agar plates to which 0.3 % TDCA sodium salt (86345, Fluka-Biochemica, Buchs, Switzerland) was added
(MRS-TDCA). Overnight grown MRS-cystein broth cultures were inoculated on MRS-TDCA and
incubated for 24 h at 37 °C under anaerobic conditions. Strains were scored positive for BSH activity
when a white precipitate of deoxycholic acid beneath and around the colonies was observed. Growth
performance was compared with cultures grown on MRS-cystein agar.
Statistical analysis
Statistical analysis comprised significance testing of the difference between means of trendline
slopes calculated from the logarithmic (% ratio
G/R
)
 
values using the nonparametric Kruskal-Wallis H and
Mann-Whitney U test.
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Results
Despite some exceptions, there was a general tendency indicating that gastrointestinal
survival under in vitro conditions as determined from RatioG/R values was strain-specific among
the selected Bifidobacterium strain set. The overall mean coefficient of variation of triplicate
measurements of the RatioG/R was ± 0.94% with a maximum variation of 3.63%. Although
most strains performed slightly better in presence of gastric juice when being in the stationary
phase (Mean slopeSTAT: -0.00302 ±0.00020) compared to exponential phase cells (Mean
slopeEXP: -0.00356 ±0.00016) (p > 0.05), all strains tested showed significant loss in viability
after incubation for 180 min (p < 0.001) (Table 1). Of all strains tested, reference strains and
probiotic isolates of B. animalis subsp. lactis displayed the highest survival rates during
simulated gastric transit compared to the other taxa (p < 0.05). Only single strains of B.
adolescentis (LMG 10502T), B. angulatum (LMG 10503T), B. bifidum (LM 588), B. breve
(LM 646), B. catenulatum (LMG 11043T), B. longum biotype longum (LMG 13196) and
B. pseudocatenulatum (LMG 10505T) exhibited survival rates comparable to those observed
for the B. animalis subsp. lactis strains. Remarkably, probiotic product isolates of B. bifidum
and B. breve LM 646, showed higher survival rates compared to the B. bifidum and B.
breve reference strains (p < 0.05) (Figure 1), respectively.
A subset of 30 strains, encompassing the 10 Bifidobacterium taxa that exhibited
variable survival rates during simulated gastric transit, was selected for in vitro analysis of the
small intestinal transit (Tables 2-3). For most strains tested, no loss in viability was witnessed
after 180 min of incubation in presence of pancreatin when being in the stationary phase
compared to exponential phase cells that were more susceptible (p < 0.05). Exponential
phase cells belonging to B. angulatum, B. animalis subsp. lactis and B. catenulatum as
well as B. bifidum probiotic product isolates and B. breve reference strains showed a significant
decrease in viability (p < 0.05). As was the case for gastric transit, the survival capacity in the
presence of pancreatin proved to be largely strain dependent. However, cultures of B. animalis
subsp. lactis now grouped among the least pancreatin tolerant strains. Differences in survival
rates were noted between probiotic product isolates and reference strains of the same species,
the latter showing higher survival rates (p < 0.05).
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During testing of conjugated bile salt tolerance, a general slight decrease in viability
was witnessed after 60 minutes of incubation (Mean slopeEXP: -0.0112 ±0.0065; Mean
slopeSTAT: -0.0110 ±0.0071) (p < 0.05) (Table 3). Of the 30 strains tested, only B. longum
biotype infantis strains LMG 18902 (Mean slopeSTAT: 0.0007 ±0.0004) and LM 418 (Mean
slopeSTAT: 0.0060 ±0.0001) and B. longum biotype longum LM 257 (Mean slopeEXP: 0.0016
±0.0001) were able to retain their metabolically active state during this incubation period.
Within the species B. bifidum, human reference strains performed better than the probiotic
product isolates, while the opposite was the case for the B. breve strains (p < 0.05). For the
other species tested, no pronounced differences in RatioG/R were witnessed between probiotic
product isolates and reference strains at a level of p = 0.05. Likewise, no significant differences
were noted between stationary phase cells and exponential phase cells.
Of the 66 strains tested, only three strains (B. gallicum LMG 11596T and B. longum
biotype infantis LMG 8811T and LMG 11588) did not express TDCA hydrolase activity in
the BSH assay. Noteworthy, a slight reduction in growth performance was witnessed in the
presence of TDCA compared to growth on the MRS control plates.
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Figure 1. Graph illustrating the survival behaviour of probiotic product isolate B. breve LM 646 compared
to B. breve reference strains (stationary phase cells) over a 180 min incubation period.  Trendlines were
calculated for each strain based on the log (% ratio
G/R
) values which are expressed as the mean ±
standard deviation (bars) of three measurements. Comparison and statistical analysis were based on the
slopes of these trendlines [slope range for B. breve reference strains: -0.0028 – -0.0074 and B. breve LM
646: -0.0001].
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Discussion
Together with safety and technological aspects, functionality screening plays a key
role in the selection of potential probiotic strains for human use. Next to health promoting
characteristics, the functional aspect of probiotic strains also involves their capacity to reach
the colon in a metabolically active state. In the present study, a number of in vitro tests were
used to screen a large number of Bifidobacterium strains of intestinal and food origin for their
ability to survive in the presence of pepsin, pancreatin and bile salts. Survival rates were
assessed using a recently described microplate scale fluorochrome assay (Alakomi et al.,
2005) following incubation in each of the gastrointestinal juices. This approach proved to be
highly reproducible and provides a rapid alternative to laborious plate count techniques. As a
general tendency, survival rates of the bifidobacterial strains tested proved to be largely strain-
dependent. As previously reported for bifidobacteria of human origin, most of the strains
were susceptible to low pH and bile salts, while an apparently intrinsic ability to survive the
presence of pancreatin was witnessed (Charteris et al., 1998).
Of all strains tested, representatives of B. animalis subsp. lactis appeared to be
most capable to survive gastric transit, which is probably due to their enhanced acid tolerance
compared to other Bifidobacterium species (Matsumoto et al., 2004; Mättö et al., 2004).
When exposed to acidic conditions, bacteria try to maintain a pH homeostasis by discharging
H+ from the cell by H+-ATPase (Booth, 1985). It has previously been shown that upon
incubation under acidic conditions, the H+-ATPase activity in B. animalis subsp. lactis increases
whereas that of other, non acid-tolerant bifidobacteria, such as B. adolescentis, B. bifidum,
B. breve, B. catenulatum, B. longum biotype infantis and longum and B. pseudocatenulatum,
diminishes and results in a general decrease or loss of viability (Matsumoto et al., 2004).
These results suggest that many B. animalis subsp. lactis cultures incorporated in probiotic
food products are sufficiently acid tolerant to reach the intestinal tract in a metabolically active
state after oral administration. For probiotic strains with limited acid tolerance, gastric passage
can be enhanced by the presence of milk proteins due to a buffering or protective effect,
suggesting that milk-based products constitute an important carrier of probiotic strains (Charteris
et al., 1998). Other studies have demonstrated that probiotic cultures can be significantly
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protected by the addition of (cryo)protectants during spray- and freeze-drying or via
encapsulation in milk proteins and complex (prebiotic) carbohydrates (Ross et al., 2005).
Furthermore, the up-regulation of genes involved in stress responses has been shown to enhance
acid tolerance of probiotic bacteria (Kullen and Klaenhammer, 1999). To some extent, this
type of adaptation to acidic stress conditions might explain why the relative decrease in viability
after 180 minutes of incubation was lower than after 1 minute for all strains tested in our study.
Finally, also food-grade genetic manipulation has been used to improve probiotic performance
(Desmond et al., 2004), which leaves the option to further exploit promising cultures that are
sensitive to gastric transit.
Despite considerable loss of viability during simulated gastric transit, most of the
bifidobacterial strains used in this study appeared to possess a natural ability to survive the
presence of pancreatin. The survival of lactobacilli (Charteris et al., 1998) and dairy
propionibacteria (Huang and Adams, 2004) also seems unaffected when incubated with a
simulated pancreatin containing solution. Consequently, the presence of pancreatin in the small
intestine does not appear to confer an insuperable barrier for probiotic cultures. In contrast,
our results indicate that the presence of bile salts slightly reduces the viability of most of the
strains tested. After synthesis from cholesterol and conjugation to either glycine or taurine in
the liver, conjugated bile salts are secreted into the small intestine and undergo extensive
chemical modifications upon arrival in the colon due to microbial activity. Bile salt hydrolase
(BSH) catalyses the hydrolysis of conjugated bile salts into the bile salt and the amino acid
residue. Although the functions of this enzyme and the physiological impact on its host are far
from understood, conjugated bile salt hydrolysis is a commonly observed phenomenon among
gastrointestinal bacteria, including the genera Bacteroides, Bifidobacterium, Clostridium,
Enterococcus, Fusobacterium, Lactobacillus, and Peptostreptococcus (Aries and Hill,
1970; Hylemon, 1985; Chateau et al., 1994). Deconjugation of bile salts is an important
metabolic reaction in the bile salt metabolism of mammals and has been associated with a
reduction of serum cholesterol (Anderson and Gilliland, 1999; Pereira and Gibson, 2002).
On the other hand, excessive bile salt deconjugation can also exert pathological effects.
Deconjugated bile salts are thought to be involved in the formation of gallstones (Thomas et
al., 2000) and the development of colorectal cancer (Singh et al., 1997). In line with this
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functional paradox, it has been suggested that the release of deconjugated bile salts seems to
have a higher anti-microbial effect than the unmodified bile salts (Grill et al., 1995; 2000).
Although most bifidobacterial strains tested in the present study exhibited BSH activity, we
observed a slight overall sensitivity towards bile salts, which confirms earlier findings
(Kociubinski et al., 1999). Since BSH activity is expressed constitutively within the genus
Bifidobacterium (Grill et al., 1995; 2000), the absence of BSH activity in two B. longum
biotype infantis strains and in the type strain of B. gallicum might indicate absence, inactivation
or mutation of the BSH gene. Although interest has been shown to use strains that produce
BSH to lower serum cholesterol levels (De Smet et al., 1994), the lack of BSH activity is one
of the criteria currently used in the selection of probiotic candidates. However, given the wide
distribution and high activity of BSH in bifidobacteria compared to other probiotic groups
(Grill et al., 1995, 2000; Tanaka et al., 1999), the lack of BSH as a selection criterion seems
controversial and might need revision.
Stress responses of bacterial cultures generally vary with the growth phase. Bacterial cells
that enter the stationary phase tend to develop a general stress resistance and are thus more
resistant to various types of stress factors (van de Guchte et al., 2002) including the ones
encountered during gastrointestinal transit. When exposed in vitro to gastro-intestinal juices,
the Bifidobacterium strains tested in our study exhibited a slightly more tolerant profile during
the stationary phase than during the exponential phase, however, these differences were not
significant.
In conclusion, the results obtained during this study indicate that tolerance towards
bile salts is potentially more important during probiotic selection compared to gastric and
pancreatic tolerance. With the development of new delivery systems and the use of specific
foods, acid-sensitive strains can be buffered through the stomach. In addition, bifidobacteria
seem to possess a natural tolerance towards pancreatin. Consequently, the potential of a
probiotic strain to survive passage through the gastrointestinal tract after ingestion may largely
depend on its ability to resist the antimicrobial action of bile salts. Furthermore, the strain-
dependent tendency observed for transit survival implies that different strains will likely display
a different behaviour in functionality. For this reason, preliminary characterization of strains for
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use as probiotic cultures through in vitro screening is of great value in selecting functional
candidate strains for further in vivo studies.
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Probiotic membership application form
NAME:
ORIGIN:
Bifidobacterium bifidum
Strain X
FUNCTION:
Human intestine
Prevention and
alleviation of symptoms associated with
Inflammatory Bowel Disease (IBD)
SPECIAL FEATURES:
The applicant is able to survive passage through
the gastro-intestinal tract and declares to be
free of acquired antibiotic resistance genes.
Signature,
Bifidobacterium bifidum
Strain X
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In order to successfully commercialise probiotic products, it is important to correctly
identify the incorporated strains and to document their safety and functionality properties.
The research performed in this Ph.D. study has delivered a set of optimised and/or new
methodologies to analyse these key aspects for potentially probiotic bifidobacteria. Provided
that they are subjected to in vivo validation, these standardized in vitro protocols can be
used in the polyphasic screening of new candidate cultures. Only by doing so,
Bifidobacterium-specific cut-off values can be defined, which will allow a reliable in vitro
comparison and subsequent selection of promising strains for probiotic use.
The past few years have witnessed the development and evaluation of a broad range
of techniques for the identification of bifidobacteria (Ventura et al., 2004; Ward and Roy,
2005). Although the identification of most Bifidobacterium taxa is relatively straightforward,
some techniques fail to differentiate closely related species. In this study a database based on
BOX-PCR fingerprints from well-characterized type and reference strains was constructed
for the identification of unknown bifidobacteria. This technique was very suitable for
unambiguous discrimination of all validly described (sub)species within the genus
Bifidobacterium, and to some extend also allowed strain differentiation. As a result, only
those isolates that display highly similar if not identical BOX-PCR banding patterns may need
further typing.  Despite the fact that this technique does not provide phylogenetic information,
it has contributed to an enhanced understanding of the classification of species with a
controversial taxonomic position. For instance, BOX-PCR clearly discriminates among the
recently proposed biotypes longum, infantis and suis in the species B. longum (Sakata et al.,
2002). Likewise, the results obtained with BOX-PCR fingerprinting formed the onset for
further investigation of the affiliation of B. lactis to the closely related species B. animalis
(Scardovi and Trovatelli, 1974), a matter that had been much debated since its original
description (Meile et al., 1997). Triggered by recent proposals to elucidate the taxonomic
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standing of B. lactis within the genus Bifidobacterium and given its importance in the probiotic
industry, a polyphasic study was carried out to clarify its taxonomic position. New DNA-
DNA hybridisation data and phenotypic results formed the taxonomic basis to unify B. animalis
and B. lactis. Results of protein profiling, genotypic analyses and growth evaluation in milk,
on the other hand, indicated that both former species constituted different taxa at the subspecies
level. These findings resulted in the proposal to create two subspecies in B. animalis, namely
B. animalis subsp. animalis and B. animalis subsp. lactis. Despite this reclassification,
representatives of the latter subspecies continue to be referred to as B. lactis. Because the
species epithet ‘animalis’ suggests that strains in probiotic products are from animal origin, the
use of the correct taxonomic name may not appeal to consumer and/or producer from the
commercial point of view.
The research performed in this Ph.D. work also included a post-production surveillance
study of worldwide collected commercial probiotic products claiming to contain bifidobacteria.
Both qualitative and quantitative microbial analysis was performed using culture-dependent
and culture-independent methods. Qualitative microbial analysis revealed that a rather
high percentage of probiotic products were incorrectly or inadequately labeled with respect
to the identity of the incorporated strains and that a substantial number of dried products
inadmissibly lack the presence of any viable microorganisms, which must raise questions about
their postulated probiotic effects. In all product types tested, B. animalis subsp. lactis was
most frequently found, which confirms the industrial importance of strains assigned to this
subspecies. The use of conventional isolation and subsequent identification of the implemented
bifidobacterial strains in combination with Denaturing Gradient Gel Electrophoresis (DGGE)
proved to be successful in the characterization of the taxonomic content of Bifidobacterium-
claiming probiotic products. However, while the complementary use of these strategies provided
reliable qualitative data, both approaches struggled with their limitations in terms of quantification.
This is partly due to the lack of suitable media for the selective isolation of bifidobacteria from
probiotic products, which compromises the reliability of many enumeration procedures.
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Triggered by these shortcomings, real-time PCR based on the non-specific SYBR
Green I chemistry was evaluated for the culture-independent quantification of bifidobacteria
in probiotic products. Although preliminary research performed during this Ph.D. has clearly
demonstrated the potential of real-time PCR in quantitative microbial analysis, the accuracy
and sensitivity of the method has to be further evaluated. Such an evaluation should include
further optimization of the sample processing and DNA extraction protocol, which are essential
in the interpretation of real-time PCR data. Likewise, a reliable estimate of the detection limit
needs to be obtained e.g. based on spiking experiments. Additionally, implementation of Reverse
Transcriptase real-time PCR will allow differentiation between live and dead bifidobacteria.
Future developments including the use of species-specific or even strain-specific primers and
probes will certainly broaden the potential of real-time PCR and make it applicable for the
complete microbial analysis of probiotic products. However, when there is little or no information
on the bacterial content of a probiotic sample, a separate probe or primer is needed for each
possible probiotic species, resulting in a significant increase in cost and workload. Alternatively,
the combined use of real-time PCR based on the SYBR Green I chemistry and
Bifidobacterium-specific primers and DGGE analysis may also allow accurate quantitative
and qualitative analysis of probiotic products.
Culture-dependent analysis is still indispensable in the investigation of safety and
functionality related properties of individual probiotic candidates. The first step in this respect
is the identification of a probiotic organism at the strain level, which is of paramount
importance when attributing specific features to a specific strain. Results obtained from Pulsed-
Field Gel Electrophoresis (PFGE) typing performed during this Ph.D. study clearly indicated
a relatively high degree of genomic homogeneity among the Bifidobacterium strains currently
used in the probiotic industry, which is in contrast with the high diversity of Bifidobacterium
products available on the market. Although PFGE is considered as the ‘gold standard’ for
strain typing, phenotypic data obtained during this study occasionally revealed subtle differences
among certain strains, which were not reflected by PFGE data. These findings indicate that
probiotic cultures with indistinguishable PFGE profiles can still show phenotypic variation.
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Recent years have witnessed a growing concern about the risk related to the potential
transfer of antimicrobial resistances from probiotic strains to intestinal pathogens, especially
after reports on the presence of antibiotic resistance genes and transfer of plasmids and
transposons in Enterococcus and Lactobacillus species (Teuber et al., 1999).  Due to the
fact that bifidobacteria are considered as safe organisms, antimicrobial susceptibility of
Bifidobacterium strains has rarely been investigated. Furthermore, interpretive reading of
bifidobacterial resistance phenotypes has been significantly hampered by the lack of a validated
method tested on a taxonomically diverse set of strains. The use of the recently developed
LSM + cysteine medium formulation (Klare et al., 2005) allowed us to discriminate between
intrinsic and atypical resistance properties of bifidobacteria. Although the presence of non-
transmissible antibiotic resistances does not usually confer a safety concern and even might be
useful in the treatment of antibiotic associated diarrhoea (Charteris et al., 1998), the finding of
atypical antimicrobial resistances in some Bifidobacterium strains urges for a continuous
vigilance in the selection of strains for probiotic use. In this Ph.D. work, atypical tetracycline
resistance could be linked to the presence of an acquired tet(W) gene. Although this implies
the presence of a mobile genetic support, the tet(W) gene was not associated with a plasmid
nor with transposon TnB1230 (Melville et al., 2004). Further investigation, including up- and
downstream sequencing, as well as extended conjugation experiments should enhance our
understanding on the dissemination of the tet(W) gene. The fact that several probiotic product
isolates, including B. animalis subsp. lactis and B. bifidum strains were shown to possess an
acquired tet(W) gene stresses the need for a minimal safety evaluation during the selection of
Bifidobacterium strains for probiotic use.
An increasing number of clinical and experimental studies demonstrate that the resident
microbiota may steer the inflammatory responses in allergic and inflammatory bowel diseases
(Guarner and Malagelada, 2003). If this concept proves right, unbalanced indigenous
microbiota may be modulated by the administration of probiotics. An important part of the
beneficial effects of probiotics are related to their immunomodulatory effects including
immune-enhancing as well as anti-inflammatory activities. In this Ph.D. work, the potential of
selected Bifidobacterium strains to induce cytokine production by human peripheral blood
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mononuclear cells was investigated. For this purpose, an existing in vitro method was further
validated for high-throughput screening and subsequent selection of promising candidate strains
for possible biotherapeutic applications. Although the objective of the screening was focussed
on selecting strains for future application in IBD treatment, this technique also allows a more
rational selection of promising strains for probiotic therapy of other immune disorders such as
allergy.
Although cellular or culture components of dead probiotic bacteria are also thought
to mediate beneficial effects in the host, it has been argued that most health benefits associated
with probiotics are exerted by viable metabolically active microorganisms (Ouwehand and
Salminen, 1998). Prior to inducing any effect, however, most living probiotic cultures are
orally administered upon which they need to survive gastrointestinal (GI) transit in sufficient
numbers. In this Ph.D. study, a recently developed in vitro technique (Alakomi et al., 2005)
combining the use of fluorescent stains, which allow the differentiation between viable and
dead bacterial cells, with detection of fluorescence using a microplate reader was optimised
and used to screen human and probiotic Bifidobacterium isolates for their potential to survive
gastric and small intestinal transit. Although these functional properties appeared to be largely
strain-dependent, most of the strains were found to be susceptible to low pH and bile salts,
while an apparently intrinsic ability to survive the presence of pancreatin was witnessed. With
the development of new delivery systems and the use of specific foods, acid-sensitive strains
can be buffered through the stomach. Consequently, the potential of a probiotic strain to
survive passage through the gastrointestinal tract after ingestion may largely depend on its
ability to resist the antimicrobial action of bile salts and hence might be more important during
probiotic selection compared to gastric and pancreatic tolerance.
Except for three strains, all Bifidobacterium strains tested were shown to express bile salt
hydrolase (BSH) activity using an agar-based assay. Although interest has been shown to use
strains that produce BSH to lower serum cholesterol levels (De Smet et al., 1994), the lack
of BSH activity is one of the criteria currently used in the selection of probiotic candidates.
However, given the wide distribution and high activity of BSH in bifidobacteria compared to
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other probiotic groups (Grill et al., 1995, 2000; Tanaka et al., 1999), the lack of BSH as a
selection criterion seems controversial and might need revision.
It is clear from the results obtained in this study that several important probiotic
properties are strain-specific, which again highlights the need for accurate strain identification
and for characterization of probiotic attributes on an individual strain basis rather than designating
an entire species as probiotic. Of all Bifidobacterium taxa that have been associated with
probiotic use (Holzapfel et al., 1998), B. adolescentis was never found in any of the commercial
probiotic products analyzed. On the other hand, the scientific data gathered in this study
indicates that we might need to broaden our perspectives and consider the admission of
strains belonging to the species B. angulatum, B. catenulatum, B. gallicum and B.
pseudocatenulatum to the probiotic consortium. Several promising strains of these taxa
definitely merit further investigation. Conversely, given the involvement of B. dentium in
cariogenic processes and the clinical source of isolation of B. scardovii, it is evident that
strains belonging to these species should not be considered for use as probiotics.
In the light of the current genomics era, it is beyond doubt that future large-scale
comparative genomics studies will contribute to a better understanding of the evolutionary
relationships, the ability of horizontal gene transfer, and the unravelling of mechanisms linked
to probiotic effects. These new developments will also form the platform for microarray and
proteomic technologies for real-time analysis of RNA and protein expression by probiotic
Bifidobacterium strains. Investigation of probiotic organisms with these new and potentially
powerful tools will facilitate the selection of bacteria as therapeutic agents.
Several of the methods described in this Ph.D. thesis may contribute to a better
characterization of candidate probiotic strains with respect to their identity, safety and
functionality (Figure 1).
235
Conclusions and perspectives
Figure 1. Positioning of the methods described in this Ph.D. study in the general scheme of proposed
guidelines for the selection of potential probiotic strains for human use (based on Reid et al., 2002 and
Reid, 2005).
Safety
- Strain identification
=> BOX-PCR fingerprinting
=> Pulsed-Field Gel Electrophoresis
- Antibiotic resistance
=> Disc Diffusion and MIC determination
using the LSM + cysteine medium
- Human origin
- History of safe use
Functionality
- Gastric survival
- Resistance to bile acids
=> Microplate-based assay using the
LIVE/DEAD Light
Bacterial viability kit
- Immunomodulatory potential
=> ELISA detection of cytokine induction
profiles using human PBMCs
- Adhesion properties
Bac
TM
Technological properties
- Survival potential during processing
=> Microplate-based assay using the
LIVE/DEAD Light
Bacterial Viability kit
- Shelf-life stability
- Organoleptic properties
Bac
TM
Effectiveness trial (phase III)
- Compare probiotics with standard treatment of a specific condition
- Verify possible side-effects
Labeling
- Contents - genus, species, strain designation
=> Nested-PCR/Denaturing Gradient Gel Electrophoresis,
BOX-PCR fingerprinting and PFGE
- Minimum numbers of (viable) bacteria at end of shelf life
=> Real-time PCR using 16S rRNA and A gene
targeting primers
- Proper storage conditions
- Corporate contact details for consumer information
rec
Health benefits (DBPC studies)
Double blind, randomized, placebo-controlled phase II human studies
PROBIOTIC PRODUCT
236
Part 4 - Conclusions and perspectives
Although the research performed in this Ph.D. study did not aim at putting the current
definition of a ‘probiotic’ to the test, some considerations might set the scene for further
discussion. In contrast to the growing concern about the safety of human probiotics and
growing efforts to provide a qualified generic approval system to their safety assessment (von
Wright, 2005), this issue is not reflected in the definition. Although there is no question that
probiotics intended for human use should be safe, the appendage of “a live ‘QPS status’
microorganism...” would ascertain that the organism in question has been subjected to an
individually relevant safety review, as recommended by the EFSA. In addition to the importance
of careful strain selection evidenced in this Ph.D. work, there is also the emerging need for a
more profound description of the term ‘host’ to which carefully selected strains are
administered. A possible way forward would be to make a primary distinction between organisms
applied to maintain the healthy status of a healthy individual, in which case the current
definition might subsist, and those applied as biotherapeutics to individuals suffering from
a specific clinical disorder. In the latter case, probiotic candidates may need to be subjected
to profound analyses currently applicable to standard drug therapy. These studies would
eventually lead to specifications of the health benefit as well as the route of administration, the
active compound and hence whether or not viability is required, and the dosage needed to
achieve this benefit. These are merely some reflections on a definition that attempts to harmonize
the knowledge on a circumstantially complex, though increasingly important matter.
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Summary
In order to introduce probiotic products on the market on a scientific basis, it is
important that the organisms incorporated in such products are correctly identified and
subjected to profound analyses documenting their safety and functionality before conducting
clinical trials and entering a marketing strategy. Only in this way, successful probiotic products
can be delivered with long-term marketing potential. The goal of this Ph.D. work was to
evaluate and optimise new and existing methodologies to examine the microbial
aspects of probiotic product quality control and to provide scientific documentation
related to safety and functionality on commercially applied strains as well as on human
reference strains of the genus Bifidobacterium. Essentially, a post-production surveillance
study covering both qualitative and quantitative microbial analysis of worldwide collected
commercial probiotic products claiming to contain bifidobacteria was performed using culture-
dependent and culture-independent methods. Based on the results obtained with these
methods, a subset of probiotic product isolates was selected which was supplemented with
human reference strains of Bifidobacterium to assess the presence of atypical antibiotic
resistances, to investigate their immunomodulatory properties and to determine their
potential to survive gastrointestinal transit.
The aim of the first part of this study was to evaluate the use of repetitive DNA
element PCR fingerprinting (rep-PCR) for the taxonomic discrimination among the majority
of validly described species within the genus Bifidobacterium. After comparing several primer
sets targeting the repetitive DNA elements BOX, ERIC, (GTG)5 and REP, the BOXA1R
primer was found to be the most optimal choice for the establishment of a taxonomic framework
of Bifidobacterium type and reference strains. The BOX-PCR fingerprinting technique is
a rapid, easy-to-perform and reproducible tool for the unambiguous identification of a
wide range of bifidobacteria at the species, subspecies and potentially up to the strain level
(see Chapter 3.1.). The results obtained with BOX-PCR fingerprinting formed the onset for
a polyphasic study of the taxonomic affiliation between B. lactis (Meile et al., 1997) and
the closely related species B. animalis (Scardovi and Trovatelli, 1974). DNA-DNA
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hybridisation data and phenotypic results reinforced previous suggestions to consider B. lactis
as a later synonym of B. animalis. Despite their unification at the species level, however,
results of protein profiling, genotypic analyses and growth evaluation in milk indicated that the
two former species clearly belonged to different subtaxa. Therefore, we proposed to create
two subspecies in B. animalis, namely B. animalis subsp. animalis and B. animalis
subsp. lactis (see Chapter 3.2.). As a consequence, probiotic products previously shown to
contain B. lactis need to be relabelled with the new taxon name B. animalis subsp. lactis.
In a second part, a set of 58 commercially available, worldwide collected probiotic
products claiming to contain bifidobacteria including 22 yoghurts, 5 dairy fruit drinks, 28 food
supplements and 3 pharmaceutical preparations, were subjected to qualitative microbial
analysis by means of culture-dependent as well as culture-independent methods (see
Chapter 4.1.). Using two selective culture media, a total of 434 confirmed bifidobacterial
isolates were recovered of which 154 isolates, mainly corresponding to three isolates/product/
culture medium, were identified to the species level by BOX-PCR fingerprinting. Members of
Bifidobacterium animalis subsp. lactis were most frequently found, although also isolates
belonging to Bifidobacterium longum biotypes longum and infantis, Bifidobacterium bifidum
and Bifidobacterium breve were recovered. In parallel, all products were also subjected to
culture-independent analysis which involved a nested-PCR step on total bacterial DNA
extracted directly from the product, followed by separation of the amplicons by Denaturing
Gradient Gel Electrophoresis (DGGE) and subsequent species identification by band position
analysis and database comparison. By conventional cultivation, 70.7 % of the products analysed
were found to contain culturable bifidobacteria whereas by culture-independent DGGE analysis,
members of the genus Bifidobacterium could be detected in 96.5 % of the analysed products.
Qualitative microbial analysis revealed that a rather high percentage of probiotic products
were incorrectly or inadequately labeled with respect to the identity of the incorporated strains
and that a substantial number of dried products (51,6 %) inadmissibly lack the presence of
any viable microorganisms, which raised questions about their postulated probiotic effects.
From our data, it can be concluded that conventional isolation and subsequent identification
of the implemented bifidobacterial strains in combination with DGGE is a successful integrated
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strategy in the characterization of the taxonomic content of Bifidobacterium-claiming probiotic
products. However, while the complementary use of these strategies provided reliable qualitative
data, both approaches struggled with their limitations in terms of quantification. This is partly
due to the lack of suitable media for the selective isolation of bifidobacteria from probiotic
products, which compromises the reliability of many enumeration procedures. Therefore, to
complete microbial analysis, real-time PCR targeting the multicopy 16S rRNA gene and the
single copy recA gene was evaluated for the culture-independent quantification of bifidobacteria
in 29 probiotic products. Both assays relied on the use of genus-specific primers and non-
specific SYBR Green I detection. Based on the preliminary results obtained in this study and
the common assumption that products need to contain a minimum of 106 CFU/ml of probiotic
bacteria to exert any health effect, only 10 products (35 %) in the study fulfilled this criterion
for bifidobacteria. Independent from the gene target used for real-time PCR quantification, a
very broad distribution of bifidobacterial concentrations ranging from 0 – 108 CFU g-1 or ml-
1 was observed among the products tested. The preliminary research performed in this study
clearly demonstrates the potential of real-time PCR as alternative for the culture-based
approach in quantitative microbial analysis of probiotic products (see Chapter 4.2.).
Genotypic characterization of a number of bifidobacterial isolates at the strain level by
means of Pulsed-Field Gel Electrophoresis (PFGE) revealed a relatively high degree of genomic
homogeneity among the Bifidobacterium strains currently used in the probiotic industry (see
Chapter 4.1.). Furthermore, this approach allowed to compose a set of well-typed probiotic
product isolates encompassing the (sub)species B. animalis subsp. lactis, B. longum biotypes
longum and infantis, B. bifidum and B. breve. Supplemented with a set of unique type- and
reference strains encompassing all human Bifidobacterium (sub)species, this collection of
strains was subsequently characterised with respect to the presence of atypical antimicrobial
resistances, immunomodulatory properties and gastrointestinal transit tolerance.
The susceptibility of 100 strains encompassing 11 bifidobacterial species to 15
antimicrobial agents was tested by the agar overlay disc diffusion and broth microdilution
method using the Lactic acid bacteria Susceptibility test Medium (LSM) supplemented with
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cysteine. Based on the distribution of inhibition zone diameters and MIC values, all strains
tested were susceptible to amoxicillin, chloramphenicol, erythromycin, quinupristin-dalfopristin,
rifampicin and vancomycin. Our data also indicated that bifidobacteria are intrinsically resistant
to gentamicin, sulphamethoxazole and polymyxin B. Susceptibility to trimethoprim,
trimethoprim/sulphamethoxazole, ciprofloxacin, clindamycin, tetracycline and minocycline was
variable. The genotypic basis of atypical tetracycline resistance was further characterized
using PCR, Southern blotting and partial sequencing. The tet(W) gene was found to be
responsible for tetracycline resistance in 15 strains including 7 probiotic isolates belonging to
the taxa B. animalis subsp. lactis and B. bifidum. This gene was present in a single copy on
the chromosome and did not appear to be associated with the conjugative transposon TnB1230
previously found in tet(W)-containing Butyrivibrio fibrisolvens. The use of the LSM +
cysteine medium allowed us to discriminate between intrinsic and atypical resistance properties
of bifidobacteria, and sets the scene for future definition of epidemiological cut-off values for
all important Bifidobacterium species. Although the presence of specific antibiotic resistance
traits among probiotic strains may be desirable in certain applications, the detection of an
acquired tet(W) gene in several probiotic product isolates stresses the need for a minimal
safety evaluation during the selection of Bifidobacterium strains for probiotic use (see Chapter
5.1.).
Subsequently, we investigated the immunomodulatory capacity of a subset of 50
Bifidobacterium strains with respect to their potential to induce the production of the cytokines
IL-10, IL-12, TNF−α and IFN-γ by peripheral blood mononuclear cells isolated from healthy
donors. The results of this in vitro analysis confirmed that cytokine stimulation profiles are
strain-specific and revealed that bifidobacteria are potent inducers of the anti-inflammatory
IL-10, while induction of IL-12, TNF−α and IFN-γ were low compared to a pro-inflammatory
control strain. Given the key role of TNF−α in inflammatory bowel disease (IBD) pathogenesis
and the fact that intestinal inflammation is associated with low IL-10 and high pro-inflammatory
IL-12 and IFN-γ levels, our results suggest that administration of Bifidobacterium strains
that promote high IL-10/IL-12 and IL-10/TNF−α ratios in combination with a low induction
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of IFN-γ production may induce a shift towards a more anti-inflammatory state, resulting in
alleviation of IBD symptoms (see Chapter 6.1.).
In addition to these immunomodulating properties, which constitute a part of the
underlying mechanisms of health-promoting effects, the ability of probiotic bacteria to survive
passage through the GI-tract in order to reach the large intestine is an important issue of basic
functionality. A recently developed in vitro technique combining the use of fluorescent stains,
which allow the differentiation between viable and dead bacterial cells, with detection of
fluorescence using a microplate reader was optimised and used to screen human and probiotic
Bifidobacterium isolates for their degree of resistance against gastric and pancreatic juices
and their ability to survive in presence of bile salts. Although these properties were highly
strain-dependent, most strains were susceptible to low pH and bile salts, while an apparently
intrinsic resistance was witnessed against pancreatin. Furthermore, almost all strains possessed
bile salt hydrolase activity (see Chapter 6.2.).
The development of a successful Bifidobacterium-containing probiotic product
includes many aspects of safety, functionality as well as technological and labelling issues.
Overall, our results demonstrate the need for a profound microbial analysis of probiotic
products, in which a combined approach of culture-dependent and culture-independent methods
has proven its high competence. Furthermore, the in vitro approaches used in this study
provide high-throughput means for the correct identification and screening of Bifidobacterium
strains for the presence of atypical antibiotic resistances, gastrointestinal transit survival capacity
and immunomodulatory properties. In this way basic information documenting safety and
functionality is generated which permits a wilfully selection of potential candidate strains for
further investigation in vivo. The results obtained in the course of this work indicate that
besides the strains already implicated in functional food production, also other Bifidobacterium
strains of human origin may function as potential alternative sources for future probiotic
development.
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Om een wetenschappelijk verantwoord probiotisch product op de markt te
introduceren is het van uitermate groot belang dat de gebruikte probiotische stammen correct
geïdentificeerd zijn en onderworpen worden aan grondig onderzoek naar hun veiligheid en
functionaliteit vooraleer klinische studies worden aangevat en voor eigenlijke
commercialisering van het product. Enkel op die manier kunnen probiotische producten met
lange-termijn perspectieven succesvol geïntroduceerd worden. Dit doctoraat had tot doel
nieuwe en bestaande technieken te evalueren en optimaliseren voor microbiële
kwaliteitscontrole van probiotische producten evenals voor het verschaffen van
wetenschappelijke informatie gerelateerd aan de veiligheid en functionaliteit van
commercieel gebruikte en humane referentie stammen van het genus
Bifidobacterium. Dit omvatte de kwalitatieve en kwantitatieve microbiële analyse
van wereldwijd verzamelde probiotische producten die beweerden bifidobacteriën te bevatten,
gebruik makende van zowel kweekahankelijke als kweekonafhankelijke methoden.
Op basis van deze resultaten werd een subset probiotische product isolaten geselecteerd die
samen met humane referentie stammen van het genus Bifidobacterium onderzocht werden
naar de aanwezigheid van atypische antibiotica resistenties, naar hun immuunmodulerende
eigenschappen en hun capaciteit om transit doorheen het gastrointestinaal stelsel te
overleven.
Een eerste deel van de studie omvatte de evaluatie van repetitief DNA element PCR
fingerprinting (rep-PCR) voor de taxonomische discriminatie van de overgrote meerderheid
van valide beschreven species binnen het genus Bifidobacterium. Na vergelijking van
verschillende primer sets die respectievelijk de repetitieve elementen BOX, ERIC, (GTG)5
en REP herkennen, werd de BOXA1R primer gekozen voor de constructie van een
taxonomisch kader van Bifidobacterium type en referentie stammen. De BOX-PCR
fingerprinting techniek is een snelle, gemakkelijk uit te voeren en reproduceerbare methode
die toelaat een brede variëteit aan bifidobacteriën op een éénduidige manier te identificeren
tot op species, subspecies en soms zelfs tot op stamniveau (zie Hoofdstuk 3.1.). De resultaten
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bekomen met BOX-PCR fingerprinting gaven vervolgens aanleiding tot het aanvatten van een
polyfasische studie die de taxonomische verwantschap tussen B. lactis (Meile et al.,
1997) en het nauwverwante species B. animalis (Scardovi and Trovatelli, 1974) diende
op te helderen. DNA-DNA hybridisatie gegevens en fenotypische data bevestigden eerdere
suggesties om B. lactis te beschouwen als een recenter synonym van B. animalis.
Niettegenstaande, ondanks hun vereniging op species niveau, bewezen de resultaten bekomen
met eiwitprofilering, genotypische analyzes en groeitesten in melk dat de twee origineel
beschreven species duidelijk behoren tot verschillende subtaxa. Bijgevolg stelden we voor
twee subspecies te creëren binnen B. animalis, namelijk B. animalis subsp. animalis
en B. animalis subsp. lactis (zie Hoofdstuk 3.2.). Zodoende zouden probiotische producten
waarvan eerder werd aangetoond dat ze B. lactis bevatten opnieuw geëtiketteerd moeten
worden met de nieuwe taxon naam B. animalis subsp. lactis.
In een tweede deel werd een set van 58 wereldwijd commercieel verkrijgbare
probiotische producten die claimden bifidobacteriën te bevatten, verzameld. Deze selectie
omvatte 22 yoghurts, 5 zuivel fruitdranken, 28 voedingssupplementen en 3 farmaceutische
preparaten die onderworpen werden aan kwalitatieve microbiële analyze met behulp
van zowel een cultuur-afhankelijke als cultuur-onafhankelijke methode (see Chapter
4.1.). In totaal werden 434 bifidobacteriën geïsoleerd op twee selectieve media. Hiervan
werden drie isolaten/product/medium, in totaal 154 isolaten, geïdentificeerd tot op speciesniveau
met behulp van BOX-PCR fingerprinting. Representatieven van het species Bifidobacterium
animalis subsp. lactis werden het meeste teruggevonden, maar ook isolaten behorende tot
Bifidobacterium longum biotypes longum en infantis, Bifidobacterium bifidum en
Bifidobacterium breve werden teruggevonden. In parallel werden alle producten ook
onderworpen aan een cultuur-onafhankelijke analyse. Dit omvatte een nested-PCR stap
op totaal bacterieel DNA geëxtraheerd rechtstreeks uit het product, gevolgd door scheiding
van de amplicons door Denaturing Gradient Gel Electrophoresis (DGGE) en vergelijking van
de bandposities met deze van een voordien opgebouwde identificatiedatabank van
Bifidobacterium referentiestammen. Na analyse gebruik makend van de traditionele
kweekmethode bleek 70.7 % van de producten levensvatbare bifidobacteriën te bevatten
249
Summary - samenvatting
terwijl met kweek-onafhankelijke DGGE analyse het genus Bifidobacterium in 96.5 % van
de geanalyseerde producten kon worden gedetecteerd. Kwalitatieve microbiële analyze
onthulde voor een relatief hoog percentage aan probiotische producten een foutieve of
onvolledige vermelding van de identiteit van de stammen aanwezig in het product. Tevens
werd aangetoond dat 51.6 % van de gedroogde producten geen levende microorganismen
bevatten, wat hun geclaimde probiotische effecten in twijfel doet trekken. Uit onze resultaten
blijkt dat conventionele isolatie en daaropvolgende identificatie van de gebruikte
Bifidobacterium stammen in combinatie met DGGE een succesvolle strategie is voor de
analyze van de taxonomische inhoud van Bifidobacterium-claimende probiotische producten.
Niettegenstaande de combinatie van deze strategieën betrouwbare kwalitatieve data opleverde,
bleken beide methoden beperkt in hun mogelijkheid om kwantificatieve data te genereren. Dit
is deels te wijten aan het gebrek aan geschikte media voor de selectieve isolatie van
bifidobacteriën uit probiotische producten waardoor betrouwbare plaattellingen niet mogelijk
zijn. Bijgevolg werd real-time PCR gericht tegen het multicopy 16S rRNA gen en het single
copy recA gen geëvalueerd voor de cultuur-onafhankelijke kwantificatie van bifidobacteriën
in 29 probiotische producten teneinde deze producten volledig te kunnen onderwerpen aan
microbiële analyze. Beide methoden berustten op het gebruik van genus-specifieke primers
en niet-specifieke SYBR Green I detectie. Op basis van de resultaten bekomen in deze studie
en de algemene veronderstelling dat producten minstens 106 probiotische bacteriën per ml
dienen te bevatten om een gezondheidseffect teweeg te brengen, bleken slechts 10 producten
(35 %) te voldoen aan dit criterium. In de geteste producten werden, onafhankelijk van het
target gen, een zeer brede spreiding aan bifidobacteriële concentraties vastgesteld gaande
van 0 – 108 CFU g-1 of ml-1. De preliminaire resultaten bekomen in deze studie bewijzen
zeker het potentieel van real-time PCR als alternatief voor de kweek-gebaseerde aanpak in
de kwantitatieve microbiële analyze van probiotische producten (zie Hoofdstuk 4.2.).
Genotypische stamtypering van een aantal Bifidobacterium isolaten met behulp van
Pulsed-Field Gel Electrophoresis (PFGE) toonde aan dat de Bifidobacterium stammen die
momenteel gebruikt worden in de probiotische industrie een relatief hoge graad van genomische
gelijkenissen vertonen (zie Hoofdstuk 4.1.). Deze methode liet tevens toe een verzameling
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van correct-getypeerde probiotische product isolaten samen te stellen behorende tot de taxa
B. animalis subsp. lactis, B. longum biotypes longum en infantis, B. bifidum en B. breve.
Deze stammencollectie werd samen met een set unieke type- en referentie stammen die alle
humane Bifidobacterium (sub)species vertegenwoordigen vervolgens onderzocht op de
aanwezigheid van atypische antimicrobiële resistenties, hun immuunmodulerende eigenschappen
en gastrointestinale transit tolerantie.
De gevoeligheid van 100 stammen behorende tot 11 bifidobacteriële species voor 15
antimicrobiële agentia werd getest door middel van de agar overlay disk diffusie en broth
microdilutie methode gebruik makende van het Lactic acid bacteria Susceptibility test Medium
(LSM) gesupplementeerd met cysteine. Op basis van de spreiding van de inhibitie zone
diameters en MIC waarden bleken alle geteste stammen gevoelig te zijn voor amoxicilline,
chloramphenicol, erythromycine, quinupristin-dalfopristin, rifampicine en vancomycine. Uit
onze data blijkt tevens dat bifidobacteriën een inherente resistentie vertonen voor gentamicine,
sulphamethoxazole en polymyxin B. Gevoeligheid voor trimethoprim, trimethoprim/
sulphamethoxazole, ciprofloxacine, clindamycine, tetracycline en minocycline was variabel.
De genotypische achtergrond van de atypische tetracycline resistentie werd verder onderzocht
met behulp van PCR, Southern blotting en partiële sequenering. Het tet(W) gen bleek
verantwoordelijk te zijn voor de tetracycline resistentie die werd aangetoond in 15 stammen
waarvan 7 probiotische isolaten behorendende tot de taxa B. animalis subsp. lactis en B.
bifidum. Dit gen was aanwezig in één enkele copij op het chromosoom en bleek niet
geassocieerd te zijn met het conjugatieve transposon TnB1230 eerder gevonden in tet(W)-
positieve Butyrivibrio fibrisolvens isolaten. Het gebruik van het LSM + cysteine medium liet
ons toe onderscheid te maken tussen intrinsieke en atypische resistenties binnen het genus
Bifidobacterium en vormt de basis voor het definiëren van epidemiologische grenswaarden
voor alle belangrijke Bifidobacterium species. Niettegenstaande de aanwezigheid van
specifieke antibioticum resistenties bij probiotische stammen voordelig kan zijn in een aantal
toepassingen, benadrukt het vinden van een verworven tet(W) gen in verschillende probiotische
product isolaten de nood aan een minimale veiligheidsevaluatie in de selectie van
Bifidobacterium stammen voor probiotisch gebruik (zie Hoofdstuk 5.1.).
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Vervolgens onderzochten we de immuunmodulerende eigenschappen van een selectie
van 50 Bifidobacterium stammen. Hun capaciteit om de productie van de cytokines IL-10,
IL-12, TNF-α en IFN-γ door peripheral blood mononuclear cells geïsoleerd uit gezonde
donoren te induceren werd nagegaan. De resultaten bekomen met deze in vitro methode
bevestigden dat cytokine inductie profielen stam-specifiek zijn en dat bifidobacteriën sterke
induceerders zijn van het anti-inflammatoire IL-10, terwijl de inductie van IL-12, TNF-α en
IFN-γ beperkt bleek in vergelijking met een pro-inflammatoire controle stam. Gezien de
belangrijke rol van TNF-α bij intestinale ontsteking welke tevens geassocieerd is met lage
IL-10 en hoge pro-inflammatoire IL-12 en IFN-γ niveaus, suggereren onze resultaten dat
Bifidobacterium stammen die hoge IL-10/IL-12 en IL-10/TNF-α ratios teweeg brengen in
combinatie met lage IFN-γ inductiewaarden mogelijks een positief effect zullen teweegbrengen
wanneer zij worden toegediend aan patiënten die lijden aan chronische intestinale ontsteking
(zie Hoofdstuk 6.1.).
Naast deze immuunmodulerende eigenschappen die de basis vormen van verschillende
gezondheidsbevorderende effecten, maakt de mogelijkheid van probiotische stammen om de
transit naar de dikke darm te overleven een belangrijk onderdeel van hun functionaliteit. Een
recent ontwikkelde in vitro techniek die het gebruik van fluorescentie kleurstoffen, welke
onderscheid maken tussen levende en dode bacteriële cellen, combineert met detectie van die
fluorescentie op microplaat schaal werd geoptimaliseerd en vervolgens gebruikt voor het
nagaan van de tolerantie van humane en probiotische Bifidobacterium isolaten tegen maag-
en pancreassap en hun mogelijkheid te overleven in aanwezigheid van galzouten. Alhoewel
deze eigenschappen sterk stam-afhankelijk zijn, bleken de meeste stammen toch gevoelig te
zijn voor een lage pH en galzouten, terwijl een inherente resistentie werd vastgesteld voor
pancreatine. Bijna alle stammen vertoonden galzout hydrolase activiteit (zie Hoofdstuk 6.2.).
De succesvolle commercialisering van een Bifidobacterium-bevattend probiotisch
product vereist grondig voorafgaand onderzoek naar aspecten zoals veiligheid en functionaliteit
van de gebruikte stammen, alsook naar de technologie en etikettering van het product zelf. De
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resultaten bekomen in het kader van dit doctoraatswerk benadrukken de nood aan een grondige
microbiële analyze van probiotische producten, waarbij een gecombineerde aanpak van cultuur-
afhankelijke en cultuur-onafhankelijke methoden zeer geschikt bleek. Bovendien laten de in
vitro technieken geoptimaliseerd in deze studie toe om op een snelle en adequate manier
Bifidobacterium stammen correct te identificeren en te screenen naar de aanwezigheid van
atypische antibioticum resistenties, hun gastrointestinale transit tolerantie en immuunmodulerende
eigenschappen. Op die manier wordt fundamentele informatie bekomen die hun veiligheid en
functionaliteit toelichten en een weloverwogen keuze toelaten van potentiële kandidaten voor
verder in vivo onderzoek. De bekomen resultaten tonen tevens aan dat naast de stammen die
reeds gebruikt worden in de functionele voedingsindustrie ook andere Bifidobacterium
stammen van humane oorsprong zouden kunnen aangewend worden in de productie van
probiotische producten voor humane consumptie.
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Appendix
Species Original Strain No. Tetracycline Minocycline tet gene
B. adolescentis LMG 10502
T
 0.5 ND NF
LMG 10733  0.5 ND ND
LMG 10734  0.5 ND ND
LMG 11579 32 32 tet (W)
LMG 18897  0.5 ND ND
LMG 18898  0.5 ND ND
B. angulatum LMG 10503
T
 0.5 ND ND
LMG 11568  0.5 ND ND
B. animalis subsp. animalis LMG 10508
T
1 2 NF
LMG 18900 1 ND NF
B. animalis subsp. lactis LMG 18314
T
16 8 tet (W)
LMG 11580 4 4 tet (W)
LMG 18906 4 4 tet (W)
LMG 11615 16 4 tet (W)
LM 2 ND ND ND
LM 33 ND ND ND
LM 13 8 4 tet (W)
LM 21 16 16 tet (W)
LM 155 ND ND ND
LM 41 ND ND ND
LM 79 ND ND ND
LM 90 ND ND ND
LM 104 ND ND ND
LM 198 32 16 tet (W)
LM 118 ND ND ND
LM 146 ND ND ND
LM 165 ND ND ND
LM 175 ND ND ND
LM 441 16 8 tet (W)
LM 185 ND ND ND
LM 209 ND ND ND
LM 216 ND ND ND
LM 232 ND ND ND
LM 241 ND ND ND
LM 252 ND ND ND
LM 281 32 4 tet (W)
LM 286 ND ND ND
LM 298 32 4 tet (W)
LM 334 ND ND ND
LM 635 ND ND ND
LM 350 16 8 tet (W)
LM 391 ND ND ND
LM 400 ND ND ND
LM 430 ND ND ND
LM 450 ND ND ND
LM 574 ND ND ND
LM 586 ND ND ND
LM 594 ND ND ND
LM 624 8 16 tet (W)
LM 135 ND ND ND
LM 125 16 8 tet (W)
LM 271 16 8 tet (W)
LM 371 8 4 tet (W)
Table B: Tetracycline resistance properties of Bifidobacterium strains tested in this study
a
MIC (µg ml
-1
)
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Species Original Strain No. Tetracycline Minocycline tet gene
B. bifidum LMG 11041
T
ND ND ND
LMG 11582 ND ND ND
LMG 11583 ND ND ND
LMG 13195 ND ND ND
LMG 13200  0.5 ND NF
LM 311 1  0.5 NF
LM 381 4 2 tet (W)
LM 588 4 4 tet (W)
B. breve LMG 13208
T
ND ND ND
LMG 10645 ND ND ND
LMG 11040 ND ND ND
LMG 11084  0.5 ND NF
LMG 11613  0.5 ND ND
LMG 13194  0.5  0.5 NF
LM 646 ND ND ND
B. catenulatum LMG 11043
T
 0.5 ND ND
LMG 18894  0.5 ND ND
B. dentium LMG 11045T  0.5 ND NF
LMG 11585  0.5 ND NF
LMG 10507  0.5 ND ND
B. gallicum LMG 11596
T
 0.5 ND NF
B. longum (biotype infantis) LMG 8811
T
2 1 NF
LMG 11570 ND ND ND
LMG 11588 ND ND ND
LMG 13204 ND ND ND
LMG 18901 ND ND ND
LMG 18902 ND ND ND
LM 418 1 ND NF
B. longum (biotype longum) LMG 13197
T
ND ND ND
LMG 11047 ND ND ND
LMG 11589 ND ND ND
LMG 13196 ND ND ND
LMG 18899  0.5 ND ND
LM 257 ND ND ND
LM 613  0.5 ND ND
LM 614 ND ND ND
LM 655 ND ND ND
LM 669 ND ND ND
LM 676 ND ND ND
B. pseudocatenulatum LMG 10505
T
32 1 tet (W)
LMG 11593 32 1 tet (W)
LMG 18903 1 ND NF
LMG 18904 1 ND NF
LMG 18910 32 2 tet (W)
B. scardovii LMG 21589
T
 0.5 ND NF
LMG 21590  0.5 ND NF
ND: Not Determined
NF: None of the tested tet genes were Found
quinupristin/dalfopristin and vancomycin
was variable and strain-specific.
a
All bifidobacteria tested possessed a natural resistance to gentamicin, polymyxin B and sulphamethoxazole.
They were uniformely susceptible to amoxicillin, chloramphenicol, clindamycin, erythromycin, rifampicin,
Susceptibility to ciprofloxacin, minocycline, tetracycline, trimethoprim and trimethoprim/sulphamethoxazole
Table B (continued)
MIC (µg ml
-1
)
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Species Original Strain No. IL-10/IL-12 IL-10/TNF- Tests performed Bile Salt Hydrolase
B. adolescentis LMG 10502
T
19,0 ± 7,59 0,065 ± 0,030 GJ, P, CBS +
LMG 10733 ND ND GJ, P, CBS +
LMG 10734 ND ND GJ +
LMG 11579 ND ND GJ, P, CBS +
LMG 18897 17,7 ± 4,04 0,173 ± 0,115 GJ +
LMG 18898 ND ND GJ +
B. angulatum LMG 10503
T
18,0 ± 4,32 0,946 ± 0,577 GJ, P, CBS +
LMG 11568 18,6 ± 3,97 0,401 ± 0,164 GJ, P, CBS +
B. animalis subsp. animalis LMG 10508
T
ND ND ND ND
LMG 18900 ND ND ND ND
B. animalis subsp. lactis LMG 18314
T
26,6 ± 7,65 0,084 ± 0,028 GJ, P, CBS +
LMG 11580 ND ND GJ +
LMG 18906 ND ND GJ +
LMG 11615 13,5 ± 3,01 0,039 ± 0,012 GJ, P, CBS +
LM 2 32,4 ± 4,60 0,092 ± 0,031 GJ, P, CBS +
LM 33 ND ND ND ND
LM 13 34,3 ± 11,44 0,305 ± 0,176 GJ +
LM 21 ND ND ND ND
LM 155 ND ND ND ND
LM 41 ND ND ND ND
LM 79 ND ND ND ND
LM 90 ND ND ND ND
LM 104 ND ND ND ND
LM 198 33,7 ± 8,59 0,380 ± 0,156 GJ +
LM 118 15,2 ± 3,78 0,045 ± 0,015 GJ +
LM 146 ND ND ND ND
LM 165 33,3 ± 8,02 0,084 ± 0,028 GJ, P, CBS +
LM 175 ND ND ND ND
LM 441 24,1 ± 7,47 0,080 ± 0,030 GJ +
LM 185 ND ND ND ND
LM 209 ND ND ND ND
LM 216 38,2 ± 9,06 0,075 ± 0,023 GJ +
LM 232 30,9 ± 7,10 0,066 ± 0,016 GJ +
LM 241 30,4 ± 5,61 0,077 ± 0,021 GJ +
LM 252 ND ND ND ND
LM 281 ND ND ND ND
LM 286 ND ND ND ND
LM 298 ND ND ND ND
LM 334 ND ND ND ND
LM 635 21,4 ± 6,79 0,056 ± 0,022 ND ND
LM 350 34,3 ± 8,99 0,091 ± 0,029 GJ +
LM 391 9,6 ± 4,06 0,040 ± 0,017 ND ND
LM 400 ND ND ND ND
LM 430 ND ND ND ND
LM 450 ND ND ND ND
LM 574 ND ND ND ND
Table C: Immunological and survival properties of Bifidobacterium strains tested in this study
Immunological properties Survival properties
a
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Table C: Continued
Species Original Strain No. IL-10/IL-12 IL-10/TNF- Tests performed Bile Salt Hydrolase
LM 586 17,5 ± 6,07 0,053 ± 0,020 ND ND
LM 594 13,2 ± 3,61 0,042 ± 0,011 ND ND
LM 624 27,7 ± 9,88 0,326 ± 0,172 GJ, P, CBS +
LM 135 17,1 ± 6,45 0,058 ± 0,026 GJ +
LM 125 24,2 ± 8,84 0,089 ± 0,032 GJ +
LM 271 8,2 ± 3,43 0,045 ± 0,016 GJ +
LM 371 13,3 ± 3,36 0,044 ± 0,015 GJ +
B. bifidum LMG 11041
T
12,5 ± 5,54 0,414 ± 0,077 GJ, P, CBS +
LMG 11582 ND ND GJ +
LMG 11583 ND ND GJ +
LMG 13195 ND ND GJ +
LMG 13200 26,6 ± 11,33 2,531 ± 1,994 GJ +
LM 311 4,3 ± 1,39 3,270 ± 1,526 GJ +
LM 381 11,5 ± 4,81 0,049 ± 0,010 GJ, P, CBS +
LM 588 7,4 ± 2,85 1,358 ± 0,521 GJ, P, CBS +
B. breve LMG 13208
T
42,9 ± 5,30 0,177 ± 0,061 GJ, P, CBS +
LMG 10645 10,1 ± 4,88 0,247 ± 0,189 GJ +
LMG 11040 ND ND GJ, P, CBS +
LMG 11084 ND ND GJ +
LMG 11613 ND ND GJ +
LMG 13194 ND ND GJ +
LM 646 24,4 ± 5,86 2,808 ± 2,005 GJ, P, CBS +
B. catenulatum LMG 11043
T
24,5 ± 2,75 0,062 ± 0,020 GJ, P, CBS +
LMG 18894 12,1 ± 7,51 0,052 ± 0,016 GJ, P, CBS +
B. dentium LMG 11045T 23,5 ± 5,44 0,061 ± 0,019 ND ND
LMG 11585 ND ND ND ND
LMG 10507 ND ND ND ND
B. gallicum LMG 11596
T
13,5 ± 3,71 5,031 ± 4,689 GJ, P, CBS -
B. longum (biotype infantis) LMG 8811
T
5,2 ± 3,05 0,030 ± 0,011 GJ, P, CBS -
LMG 11570 ND ND GJ, P, CBS +
LMG 11588 ND ND GJ -
LMG 13204 ND ND GJ +
LMG 18901 ND ND GJ +
LMG 18902 25,1± 10,50 0,107 ± 0,027 GJ, P, CBS +
LM 418 41,5 ± 8,71 0,304 ± 0,178 GJ, P, CBS +
B. longum (biotype longum) LMG 13197
T
9,7 ± 1,50 5,347 ± 2,506 GJ, P, CBS +
LMG 11047 ND ND GJ +
LMG 11589 ND ND GJ +
LMG 13196 ND ND GJ, P, CBS +
LMG 18899 26,8 ± 4,09 0,259 ± 0,113 GJ +
LM 257 30,5 ± 8,00 0,161 ± 0,067 GJ, P, CBS +
LM 613 ND ND ND ND
LM 614 42,4 ± 11,12 0,258 ± 0,098 GJ +
LM 655 ND ND ND ND
LM 669 33,4 ± 4,53 0,134 ± 0,052 GJ +
LM 676 25,2 ± 7,32 0,128 ± 0,058 GJ, P, CBS +
Survival properties
a
Immunological properties
Table C: Continued
Species Original Strain No. IL-10/IL-12 IL-10/TNF- Tests performed Bile Salt Hydrolase
B. pseudocatenulatum LMG 10505
T
23,7 ± 4,16 0,349 ± 0,132 GJ, P, CBS +
LMG 11593 ND ND GJ +
LMG 18903 ND ND GJ, P, CBS +
LMG 18904 28,5 ± 9,09 0,341 ± 0,116 GJ +
LMG 18910 ND ND GJ, P, CBS +
B. scardovii LMG 21589
T
5,2 ± 1,32 0,029 ± 0,010 ND ND
LMG 21590 6,4 ± 3,41 0,083 ± 0,073 ND ND
Lactobacillus salivarius LS 33 26,1 ± 15,48 0,082 ± 0,019 X X
Lactococcus lactis MG1363 0,8 ± 0,45 0,019 ± 0,005 X X
ND: Not Determined
a
All strains tested showed good survival capacity in presence of pancreatin (P). Survival in presence of
gastric juice (GJ) and conjugated bile salts (CBS) was variable and strain-specific.
Survival properties
a
Immunological properties
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